study_name,sitegroupname_countryname_,sitenumber,subjectname,overall_subject_status,visit_level_subject_status,foldername,visit_date,form_type__summary_or_visit_,formname,no___days_page_missing,_source_study,form_1_subject_status
Study 15,USA,Site 2,Subject 2,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 2,Screening,,Screening,2025-10-14,Visit Level,Form 2,31.0,Study 15,
Study 15,USA,Site 2,Subject 2,Screening,,Screening,2025-10-14,Visit Level,Form 3,31.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Baseline,,Visit Level,Form 4,,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Baseline,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Baseline,,Visit Level,Form 6,,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 7,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 8,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 9,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 10,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 11,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 12,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 13,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 14,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 15,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 16,1.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,,Day 2,,Visit Level,Form 17,,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 4,29.0,Study 15,
Study 15,USA,Site 2,Subject 3,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 19,29.0,Study 15,
Study 15,USA,Site 2,Subject 4,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 4,Screening,,Screening,2025-10-16,Visit Level,Form 2,29.0,Study 15,
Study 15,USA,Site 2,Subject 4,Screening,,Screening,2025-10-16,Visit Level,Form 3,29.0,Study 15,
Study 15,USA,Site 2,Subject 5,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 5,Screening,,Screening,2025-10-16,Visit Level,Form 2,29.0,Study 15,
Study 15,USA,Site 2,Subject 5,Screening,,Screening,2025-10-16,Visit Level,Form 3,29.0,Study 15,
Study 15,USA,Site 2,Subject 99,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 99,Screening,,Screening,2025-10-16,Visit Level,Form 2,29.0,Study 15,
Study 15,USA,Site 2,Subject 99,Screening,,Screening,2025-10-16,Visit Level,Form 3,29.0,Study 15,
Study 15,USA,Site 2,Subject 100,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 100,Screening,,Screening,2025-10-22,Visit Level,Form 2,23.0,Study 15,
Study 15,USA,Site 2,Subject 100,Screening,,Screening,2025-10-22,Visit Level,Form 3,23.0,Study 15,
Study 15,USA,Site 2,Subject 3399,Screening,Subject continuing,Baseline,2025-11-12,Visit Level,Form 4,2.0,Study 15,
Study 15,USA,Site 2,Subject 3399,Screening,Subject continuing,Baseline,2025-11-12,Visit Level,Form 6,2.0,Study 15,
Study 15,USA,Site 2,Subject 3399,Screening,,Day 1,,Visit Level,Form 20,,Study 15,
Study 15,USA,Site 2,Subject 3399,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 3399,Screening,Subject continuing,Screening,2025-10-24,Visit Level,Form 4,21.0,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject continuing,Baseline,2025-11-12,Visit Level,Form 4,2.0,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject continuing,Baseline,2025-11-12,Visit Level,Form 6,2.0,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,,Concomitant Medication,,Summary Page,Form 21,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 7,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 22,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 9,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 10,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 11,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 12,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 13,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 14,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject discontinued from study at this visit,Day 1,,Visit Level,Form 16,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,,Medical History,,Summary Page,Form 23,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,,Non-drug therapies,,Summary Page,Form 24,,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject continuing,Screening,2025-10-24,Visit Level,Form 4,21.0,Study 15,
Study 15,USA,Site 2,Subject 3400,Completed,Subject continuing,Screening,2025-10-24,Visit Level,Form 19,21.0,Study 15,
Study 15,USA,Site 2,Subject 3403,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 3403,Screening,,Screening,2025-10-27,Visit Level,Form 2,18.0,Study 15,
Study 15,USA,Site 2,Subject 3403,Screening,,Screening,2025-10-27,Visit Level,Form 3,18.0,Study 15,
Study 15,USA,Site 2,Subject 3405,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 3405,Screening,,Screening,2025-10-29,Visit Level,Form 2,16.0,Study 15,
Study 15,USA,Site 2,Subject 3405,Screening,,Screening,2025-10-29,Visit Level,Form 3,16.0,Study 15,
Study 15,USA,Site 2,Subject 3409,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 3409,Screening,,Screening,2025-11-03,Visit Level,Form 2,11.0,Study 15,
Study 15,USA,Site 2,Subject 3409,Screening,,Screening,2025-11-03,Visit Level,Form 3,11.0,Study 15,
Study 15,USA,Site 2,Subject 3410,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 3410,Screening,,Screening,2025-11-03,Visit Level,Form 2,11.0,Study 15,
Study 15,USA,Site 2,Subject 3410,Screening,,Screening,2025-11-03,Visit Level,Form 3,11.0,Study 15,
Study 15,USA,Site 2,Subject 3411,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 3411,Screening,,Screening,2025-11-03,Visit Level,Form 2,11.0,Study 15,
Study 15,USA,Site 2,Subject 3411,Screening,,Screening,2025-11-03,Visit Level,Form 3,11.0,Study 15,
Study 15,USA,Site 2,Subject 4023,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 4023,Screening,,Screening,2025-11-07,Visit Level,Form 2,7.0,Study 15,
Study 15,USA,Site 2,Subject 4023,Screening,,Screening,2025-11-07,Visit Level,Form 3,7.0,Study 15,
Study 15,USA,Site 2,Subject 4024,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 2,Subject 4024,Screening,,Screening,2025-11-07,Visit Level,Form 2,7.0,Study 15,
Study 15,USA,Site 2,Subject 4024,Screening,,Screening,2025-11-07,Visit Level,Form 3,7.0,Study 15,
Study 15,USA,Site 3,Subject 8,Screening,,Baseline,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 8,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 104,On Trial,Subject continuing,Day 1,2025-11-11,Visit Level,Form 7,3.0,Study 15,
Study 15,USA,Site 3,Subject 104,On Trial,Subject continuing,Day 1,2025-11-11,Visit Level,Form 12,3.0,Study 15,
Study 15,USA,Site 3,Subject 104,On Trial,Subject continuing,Day 2,2025-11-12,Visit Level,Form 4,2.0,Study 15,
Study 15,USA,Site 3,Subject 104,On Trial,Subject continuing,Day 2,2025-11-12,Visit Level,Form 9,2.0,Study 15,
Study 15,USA,Site 3,Subject 104,On Trial,Subject continuing,Day 2,2025-11-12,Visit Level,Form 12,2.0,Study 15,
Study 15,USA,Site 3,Subject 104,On Trial,Subject continuing,Day 3,2025-11-13,Visit Level,Form 9,1.0,Study 15,
Study 15,USA,Site 3,Subject 104,On Trial,Subject continuing,Day 3,2025-11-13,Visit Level,Form 12,1.0,Study 15,
Study 15,USA,Site 3,Subject 104,On Trial,,Day 4,,Visit Level,Form 17,,Study 15,
Study 15,USA,Site 3,Subject 104,On Trial,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,Subject continuing,Day 1,2025-11-11,Visit Level,Form 7,3.0,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,Subject continuing,Day 1,2025-11-11,Visit Level,Form 12,3.0,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,Subject continuing,Day 2,2025-11-12,Visit Level,Form 4,2.0,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,Subject continuing,Day 2,2025-11-12,Visit Level,Form 9,2.0,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,Subject continuing,Day 2,2025-11-12,Visit Level,Form 12,2.0,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,Subject continuing,Day 3,2025-11-13,Visit Level,Form 4,1.0,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,Subject continuing,Day 3,2025-11-13,Visit Level,Form 9,1.0,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,Subject continuing,Day 3,2025-11-13,Visit Level,Form 12,1.0,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,,Day 4,,Visit Level,Form 17,,Study 15,
Study 15,USA,Site 3,Subject 776,On Trial,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 777,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 777,Screening,,Screening,2025-10-14,Visit Level,Form 2,31.0,Study 15,
Study 15,USA,Site 3,Subject 777,Screening,,Screening,2025-10-14,Visit Level,Form 3,31.0,Study 15,
Study 15,USA,Site 3,Subject 781,Screening,,Baseline,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 781,Screening,,Baseline,,Visit Level,Form 25,,Study 15,
Study 15,USA,Site 3,Subject 781,Screening,,Baseline,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 781,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 781,Screening,Subject continuing,Screening,2025-10-14,Visit Level,Form 4,31.0,Study 15,
Study 15,USA,Site 3,Subject 781,Screening,Subject continuing,Screening,2025-10-14,Visit Level,Form 19,31.0,Study 15,
Study 15,USA,Site 3,Subject 4028,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 7,1.0,Study 15,
Study 15,USA,Site 3,Subject 4028,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 9,1.0,Study 15,
Study 15,USA,Site 3,Subject 4028,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 11,1.0,Study 15,
Study 15,USA,Site 3,Subject 4028,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 12,1.0,Study 15,
Study 15,USA,Site 3,Subject 4028,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 16,1.0,Study 15,
Study 15,USA,Site 3,Subject 4028,On Trial,,Day 2,,Visit Level,Form 17,,Study 15,
Study 15,USA,Site 3,Subject 4028,On Trial,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4033,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4033,Screening,,Screening,2025-10-16,Visit Level,Form 2,29.0,Study 15,
Study 15,USA,Site 3,Subject 4033,Screening,,Screening,2025-10-16,Visit Level,Form 3,29.0,Study 15,
Study 15,USA,Site 3,Subject 4034,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 7,1.0,Study 15,
Study 15,USA,Site 3,Subject 4034,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 9,1.0,Study 15,
Study 15,USA,Site 3,Subject 4034,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 11,1.0,Study 15,
Study 15,USA,Site 3,Subject 4034,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 12,1.0,Study 15,
Study 15,USA,Site 3,Subject 4034,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 16,1.0,Study 15,
Study 15,USA,Site 3,Subject 4034,On Trial,,Day 2,,Visit Level,Form 17,,Study 15,
Study 15,USA,Site 3,Subject 4034,On Trial,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4035,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 7,1.0,Study 15,
Study 15,USA,Site 3,Subject 4035,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 9,1.0,Study 15,
Study 15,USA,Site 3,Subject 4035,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 11,1.0,Study 15,
Study 15,USA,Site 3,Subject 4035,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 12,1.0,Study 15,
Study 15,USA,Site 3,Subject 4035,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 16,1.0,Study 15,
Study 15,USA,Site 3,Subject 4035,On Trial,,Day 2,,Visit Level,Form 17,,Study 15,
Study 15,USA,Site 3,Subject 4035,On Trial,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4038,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 7,1.0,Study 15,
Study 15,USA,Site 3,Subject 4038,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 9,1.0,Study 15,
Study 15,USA,Site 3,Subject 4038,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 11,1.0,Study 15,
Study 15,USA,Site 3,Subject 4038,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 12,1.0,Study 15,
Study 15,USA,Site 3,Subject 4038,On Trial,Subject continuing,Day 1,2025-11-13,Visit Level,Form 16,1.0,Study 15,
Study 15,USA,Site 3,Subject 4038,On Trial,,Day 2,,Visit Level,Form 17,,Study 15,
Study 15,USA,Site 3,Subject 4038,On Trial,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4038,On Trial,Subject continuing,Screening,2025-10-17,Visit Level,Form 4,28.0,Study 15,
Study 15,USA,Site 3,Subject 4046,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4046,Screening,,Screening,2025-10-21,Visit Level,Form 2,24.0,Study 15,
Study 15,USA,Site 3,Subject 4046,Screening,,Screening,2025-10-21,Visit Level,Form 3,24.0,Study 15,
Study 15,USA,Site 3,Subject 4047,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4047,Screening,,Screening,2025-10-21,Visit Level,Form 3,24.0,Study 15,
Study 15,USA,Site 3,Subject 4052,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4053,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4053,Screening,,Screening,2025-10-22,Visit Level,Form 2,23.0,Study 15,
Study 15,USA,Site 3,Subject 4053,Screening,,Screening,2025-10-22,Visit Level,Form 3,23.0,Study 15,
Study 15,USA,Site 3,Subject 4055,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-22,Visit Level,Form 2,23.0,Study 15,
Study 15,USA,Site 3,Subject 4057,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4057,Screening,,Screening,2025-10-22,Visit Level,Form 2,23.0,Study 15,
Study 15,USA,Site 3,Subject 4057,Screening,,Screening,2025-10-22,Visit Level,Form 3,23.0,Study 15,
Study 15,USA,Site 3,Subject 4058,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4058,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4058,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4058,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4058,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4058,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4059,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4059,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4059,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4059,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4059,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4059,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4060,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4060,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4060,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4060,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4060,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4060,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4061,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4061,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4061,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4061,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4061,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4061,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4063,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4063,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4063,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4063,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4063,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4063,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4064,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4064,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4064,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4064,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4064,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4064,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4065,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4065,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4065,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4065,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4065,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4065,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4066,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4066,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4066,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4066,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4066,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4066,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4067,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4067,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4067,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4067,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4067,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4067,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4068,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4068,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4068,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4068,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4068,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4068,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4069,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4069,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4069,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4069,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4069,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4069,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4070,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4070,Screening,,Screening,,Visit Level,Form 26,,Study 15,
Study 15,USA,Site 3,Subject 4070,Screening,,Screening,,Visit Level,Form 2,,Study 15,
Study 15,USA,Site 3,Subject 4070,Screening,,Screening,,Visit Level,Form 27,,Study 15,
Study 15,USA,Site 3,Subject 4070,Screening,,Screening,,Visit Level,Form 3,,Study 15,
Study 15,USA,Site 3,Subject 4070,Screening,,Screening,,Visit Level,Form 5,,Study 15,
Study 15,USA,Site 3,Subject 4071,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4071,Screening,,Screening,2025-11-07,Visit Level,Form 3,7.0,Study 15,
Study 15,USA,Site 3,Subject 4072,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4072,Screening,,Screening,2025-11-07,Visit Level,Form 3,7.0,Study 15,
Study 15,USA,Site 3,Subject 4073,Screening,,Disposition,,Summary Page,Form 1,,Study 15,
Study 15,USA,Site 3,Subject 4073,Screening,,Screening,2025-11-07,Visit Level,Form 3,7.0,Study 15,
Study 19,AUS,Site 109,Subject 836,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,AUS,Site 109,Subject 837,On Trial,Subject continuing,,2025-10-21,Visit Level,Form 2,24.0,Study 19,
Study 19,AUS,Site 109,Subject 837,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,AUS,Site 109,Subject 837,On Trial,Subject continuing,,2025-09-04,Visit Level,Form 4,71.0,Study 19,
Study 19,AUS,Site 109,Subject 837,On Trial,,,,Summary Page,Form 5,,Study 19,
Study 19,AUS,Site 109,Subject 838,On Trial,Subject continuing,,2025-10-28,Visit Level,Form 6,17.0,Study 19,
Study 19,AUS,Site 109,Subject 838,On Trial,Subject continuing,,2025-10-28,Visit Level,Form 7,17.0,Study 19,
Study 19,AUS,Site 109,Subject 838,On Trial,Subject continuing,,2025-10-28,Visit Level,Form 8,17.0,Study 19,
Study 19,AUS,Site 109,Subject 838,On Trial,Subject continuing,,2025-10-28,Visit Level,Form 9,17.0,Study 19,
Study 19,AUS,Site 109,Subject 838,On Trial,Subject continuing,,2025-10-28,Visit Level,Form 10,17.0,Study 19,
Study 19,AUS,Site 109,Subject 838,On Trial,Subject continuing,,2025-10-28,Visit Level,Form 11,17.0,Study 19,
Study 19,AUS,Site 109,Subject 838,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,AUS,Site 109,Subject 838,On Trial,,,,Summary Page,Form 5,,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,,,,Visit Level,Form 13,,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 14,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 15,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 16,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 6,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 7,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 8,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 17,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 9,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 18,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 4,25.0,Study 19,
Study 19,AUS,Site 109,Subject 839,Screening,Subject continuing,,2025-10-20,Visit Level,Form 19,25.0,Study 19,
Study 19,AUS,Site 467,Subject 3553,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,AUS,Site 467,Subject 3553,Screening,Subject continuing,,2025-11-06,Visit Level,Form 20,8.0,Study 19,
Study 19,AUS,Site 468,Subject 3560,On Trial,Subject continuing,,2025-11-04,Visit Level,Form 9,10.0,Study 19,
Study 19,AUS,Site 468,Subject 3560,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,AUS,Site 468,Subject 3561,On Trial,Subject continuing,,2025-10-14,Visit Level,Form 10,31.0,Study 19,
Study 19,AUS,Site 468,Subject 3561,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,AUS,Site 468,Subject 3561,On Trial,Subject continuing,,2025-10-02,Visit Level,Form 9,43.0,Study 19,
Study 19,AUS,Site 468,Subject 3562,On Trial,,,,Summary Page,Form 12,,Study 19,
Study 19,AUS,Site 468,Subject 3562,On Trial,,,,Visit Level,Form 21,,Study 19,
Study 19,AUS,Site 468,Subject 3563,On Trial,Subject continuing,,2025-11-04,Visit Level,Form 9,10.0,Study 19,
Study 19,AUS,Site 468,Subject 3563,On Trial,Subject continuing,,2025-11-04,Visit Level,Form 10,10.0,Study 19,
Study 19,AUS,Site 468,Subject 3563,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,AUS,Site 468,Subject 3563,On Trial,,,,Summary Page,Form 12,,Study 19,
Study 19,AUS,Site 468,Subject 3563,On Trial,Subject continuing,,2025-09-23,Visit Level,Form 9,52.0,Study 19,
Study 19,AUS,Site 468,Subject 3563,On Trial,Subject continuing,,2025-09-23,Visit Level,Form 19,52.0,Study 19,
Study 19,AUS,Site 468,Subject 3563,On Trial,,,,Summary Page,Form 5,,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,Subject continuing,,2025-10-28,Visit Level,Form 9,17.0,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,Subject continuing,,2025-10-28,Visit Level,Form 10,17.0,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,Subject continuing,,2025-11-12,Visit Level,Form 9,2.0,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,Subject continuing,,2025-11-12,Visit Level,Form 2,2.0,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,,,,Summary Page,Form 12,,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,,,,Summary Page,Form 22,,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,,,,Summary Page,Form 23,,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,,,,Summary Page,Form 24,,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,,,,Summary Page,Form 25,,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,,,,Summary Page,Form 26,,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,,,,Summary Page,Form 27,,Study 19,
Study 19,AUS,Site 468,Subject 3564,On Trial,,,,Summary Page,Form 28,,Study 19,
Study 19,AUS,Site 468,Subject 4880,Screening,,,,Summary Page,Form 29,,Study 19,
Study 19,AUS,Site 468,Subject 4880,Screening,,,,Summary Page,Form 30,,Study 19,
Study 19,DEU,Site 777,Subject 4881,Screening,,,,Visit Level,Form 31,,Study 19,
Study 19,DEU,Site 777,Subject 4881,Screening,,,,Visit Level,Form 20,,Study 19,
Study 19,DEU,Site 777,Subject 4881,Screening,,,,Visit Level,Form 32,,Study 19,
Study 19,DEU,Site 777,Subject 4881,Screening,,,,Visit Level,Form 33,,Study 19,
Study 19,DEU,Site 777,Subject 4881,Screening,,,,Visit Level,Form 34,,Study 19,
Study 19,DEU,Site 777,Subject 4882,Screening,,,,Visit Level,Form 31,,Study 19,
Study 19,DEU,Site 777,Subject 4882,Screening,,,,Visit Level,Form 20,,Study 19,
Study 19,DEU,Site 777,Subject 4882,Screening,,,,Visit Level,Form 32,,Study 19,
Study 19,DEU,Site 777,Subject 4882,Screening,,,,Visit Level,Form 33,,Study 19,
Study 19,DEU,Site 777,Subject 4882,Screening,,,,Visit Level,Form 34,,Study 19,
Study 19,DEU,Site 777,Subject 4883,Screening,,,,Visit Level,Form 31,,Study 19,
Study 19,DEU,Site 777,Subject 4883,Screening,,,,Visit Level,Form 20,,Study 19,
Study 19,DEU,Site 777,Subject 4883,Screening,,,,Visit Level,Form 32,,Study 19,
Study 19,DEU,Site 777,Subject 4883,Screening,,,,Visit Level,Form 33,,Study 19,
Study 19,DEU,Site 777,Subject 4883,Screening,,,,Visit Level,Form 34,,Study 19,
Study 19,FRA,Site 9,Subject 16,Screening,,,,Visit Level,Form 31,,Study 19,
Study 19,FRA,Site 9,Subject 16,Screening,,,,Visit Level,Form 20,,Study 19,
Study 19,FRA,Site 9,Subject 16,Screening,,,,Visit Level,Form 32,,Study 19,
Study 19,FRA,Site 9,Subject 16,Screening,,,,Visit Level,Form 33,,Study 19,
Study 19,FRA,Site 9,Subject 16,Screening,,,,Visit Level,Form 34,,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,,,,Visit Level,Form 35,,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,,,,Summary Page,Form 12,,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,Subject continuing,,2025-11-05,Visit Level,Form 36,9.0,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,Subject continuing,,2025-11-05,Visit Level,Form 10,9.0,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,Subject continuing,,2025-10-23,Visit Level,Form 17,22.0,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,Subject continuing,,2025-10-23,Visit Level,Form 37,22.0,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,Subject continuing,,2025-10-23,Visit Level,Form 4,22.0,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,Subject continuing,,2025-10-23,Visit Level,Form 38,22.0,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,Subject continuing,,2025-10-23,Visit Level,Form 39,22.0,Study 19,
Study 19,FRA,Site 9,Subject 3512,On Trial,,,,Summary Page,Form 5,,Study 19,
Study 19,ISR,Site 778,Subject 4884,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,,,,Summary Page,Form 12,,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 15,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 16,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 6,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 7,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 8,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 17,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 31,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 37,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 9,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 18,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 4,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 38,50.0,Study 19,
Study 19,ISR,Site 778,Subject 4886,On Trial,Subject continuing,,2025-09-25,Visit Level,Form 39,50.0,Study 19,
Study 19,ISR,Site 779,Subject 4887,Screening,,,2025-10-26,Visit Level,Form 20,19.0,Study 19,
Study 19,ISR,Site 779,Subject 4887,Screening,,,2025-10-26,Visit Level,Form 33,19.0,Study 19,
Study 19,ISR,Site 493,Subject 3670,Screening,,,2025-08-19,Visit Level,Form 33,87.0,Study 19,
Study 19,ISR,Site 493,Subject 3671,Screening,,,2025-08-28,Visit Level,Form 33,78.0,Study 19,
Study 19,KOR,Site 417,Subject 3227,On Trial,,,,Visit Level,Form 35,,Study 19,
Study 19,KOR,Site 417,Subject 3227,On Trial,,,,Summary Page,Form 12,,Study 19,
Study 19,KOR,Site 417,Subject 3227,On Trial,,,,Summary Page,Form 5,,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,,,,Visit Level,Form 13,,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 14,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 15,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 16,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 6,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 7,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 8,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 17,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 37,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 9,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 18,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 4,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 38,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 39,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3228,Screening,Subject continuing,,2025-11-04,Visit Level,Form 19,10.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,,,,Visit Level,Form 13,,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 14,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 40,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 41,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 6,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 7,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 8,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 17,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 37,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 9,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 4,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 38,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 39,4.0,Study 19,
Study 19,KOR,Site 417,Subject 3229,Screening,Subject continuing,,2025-11-10,Visit Level,Form 19,4.0,Study 19,
Study 19,PRK,Site 113,Subject 911,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,PRK,Site 113,Subject 912,On Trial,,,,Visit Level,Form 35,,Study 19,
Study 19,PRK,Site 113,Subject 913,On Trial,,,,Visit Level,Form 35,,Study 19,
Study 19,PRK,Site 113,Subject 914,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,PRK,Site 113,Subject 914,Screening,,,,Visit Level,Form 13,,Study 19,
Study 19,PRK,Site 113,Subject 914,Screening,Subject continuing,,2025-11-07,Visit Level,Form 40,7.0,Study 19,
Study 19,PRK,Site 113,Subject 914,Screening,Subject continuing,,2025-11-07,Visit Level,Form 41,7.0,Study 19,
Study 19,SGP,Site 780,Subject 4890,On Trial,Subject continuing,,2025-10-09,Visit Level,Form 42,36.0,Study 19,
Study 19,SGP,Site 780,Subject 4890,On Trial,Subject continuing,,2025-10-09,Visit Level,Form 43,36.0,Study 19,
Study 19,SGP,Site 780,Subject 4890,On Trial,Subject continuing,,2025-10-09,Visit Level,Form 44,36.0,Study 19,
Study 19,SGP,Site 780,Subject 4890,On Trial,Subject continuing,,2025-10-27,Visit Level,Form 45,18.0,Study 19,
Study 19,SGP,Site 780,Subject 4890,On Trial,Subject continuing,,2025-11-11,Visit Level,Form 8,3.0,Study 19,
Study 19,SGP,Site 780,Subject 4890,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,,,,Visit Level,Form 46,,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,,,,Summary Page,Form 47,,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,,,,Summary Page,Form 48,,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,,,,Summary Page,Form 49,,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,,,,Summary Page,Form 50,,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,,,,Summary Page,Form 51,,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,Subject continuing,,2025-10-21,Visit Level,Form 52,24.0,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,Subject continuing,,2025-10-21,Visit Level,Form 44,24.0,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,Subject discontinued from treatment at this visit,,,Visit Level,Form 53,,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,Subject moving to post treatment follow up,,2025-11-10,Visit Level,Form 8,4.0,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,Subject moving to post treatment follow up,,2025-11-10,Visit Level,Form 9,4.0,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,Subject moving to post treatment follow up,,2025-11-10,Visit Level,Form 18,4.0,Study 19,
Study 19,SGP,Site 780,Subject 4891,On Trial,,,,Summary Page,Form 54,,Study 19,
Study 19,SGP,Site 780,Subject 4892,On Trial,Subject continuing,,2025-10-28,Visit Level,Form 44,17.0,Study 19,
Study 19,SGP,Site 780,Subject 4892,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,SGP,Site 780,Subject 4892,On Trial,,,,Summary Page,Form 23,,Study 19,
Study 19,SGP,Site 780,Subject 4892,On Trial,,,,Summary Page,Form 25,,Study 19,
Study 19,SGP,Site 780,Subject 4892,On Trial,,,,Summary Page,Form 26,,Study 19,
Study 19,SGP,Site 780,Subject 4892,On Trial,,,,Summary Page,Form 27,,Study 19,
Study 19,SGP,Site 780,Subject 4893,On Trial,Subject continuing,,2025-10-29,Visit Level,Form 55,16.0,Study 19,
Study 19,SGP,Site 780,Subject 4893,On Trial,Subject continuing,,2025-10-29,Visit Level,Form 56,16.0,Study 19,
Study 19,SGP,Site 780,Subject 4893,On Trial,Subject continuing,,2025-10-29,Visit Level,Form 44,16.0,Study 19,
Study 19,SGP,Site 780,Subject 4893,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Visit Level,Form 46,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Summary Page,Form 47,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Summary Page,Form 48,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Summary Page,Form 49,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Summary Page,Form 50,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Summary Page,Form 51,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,Subject moving to post treatment follow up,,2025-11-04,Visit Level,Form 7,10.0,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,Subject moving to post treatment follow up,,2025-11-04,Visit Level,Form 8,10.0,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,Subject moving to post treatment follow up,,2025-11-04,Visit Level,Form 57,10.0,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,Subject moving to post treatment follow up,,2025-11-04,Visit Level,Form 18,10.0,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Summary Page,Form 23,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Summary Page,Form 24,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Summary Page,Form 26,,Study 19,
Study 19,SGP,Site 780,Subject 4895,On Trial,,,,Summary Page,Form 58,,Study 19,
Study 19,SGP,Site 780,Subject 4896,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,SGP,Site 780,Subject 4896,Screening,Subject continuing,,2025-10-28,Visit Level,Form 20,17.0,Study 19,
Study 19,SGP,Site 780,Subject 4897,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,SGP,Site 780,Subject 4897,Screening,Subject continuing,,2025-10-28,Visit Level,Form 20,17.0,Study 19,
Study 19,TWN,Site 155,Subject 1427,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,TWN,Site 155,Subject 1427,Screening,Subject continuing,,2025-11-10,Visit Level,Form 20,4.0,Study 19,
Study 19,TWN,Site 155,Subject 1428,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,TWN,Site 155,Subject 1428,Screening,Subject continuing,,2025-11-13,Visit Level,Form 20,1.0,Study 19,
Study 19,USA,Site 781,Subject 4898,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,USA,Site 781,Subject 4898,Screening,Subject continuing,,2025-10-31,Visit Level,Form 31,14.0,Study 19,
Study 19,USA,Site 781,Subject 4898,Screening,Subject continuing,,2025-10-31,Visit Level,Form 20,14.0,Study 19,
Study 19,USA,Site 782,Subject 4899,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,USA,Site 782,Subject 4901,On Trial,,,,Visit Level,Form 1,,Study 19,
Study 19,USA,Site 782,Subject 4901,On Trial,,,2025-10-14,Visit Level,Form 2,31.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,,,,Summary Page,Form 12,,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,,,,Visit Level,Form 13,,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 14,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 15,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 16,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 6,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 7,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 8,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 17,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 9,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 18,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 4,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 38,9.0,Study 19,
Study 19,USA,Site 782,Subject 4902,Screening,Subject continuing,,2025-11-05,Visit Level,Form 19,9.0,Study 19,
Study 20,AUS,Site 47,Subject 190,Screening,,Disposition,,Summary Page,Form 1,,Study 20,
Study 20,AUS,Site 47,Subject 190,Screening,Subject continuing,Screening,2025-10-29,Visit Level,Form 2,15.0,Study 20,
Study 20,AUS,Site 466,Subject 3544,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-24,Visit Level,Form 3,50.0,Study 20,
Study 20,AUS,Site 466,Subject 3544,On Trial,,Cycle 3 Day 1,,Visit Level,Form 4,,Study 20,
Study 20,AUS,Site 466,Subject 3544,On Trial,Subject continuing,Screening,2025-08-27,Visit Level,Form 5,78.0,Study 20,
Study 20,CZE,Site 8,Subject 15,Screening,,Screening,,Visit Level,Form 6,,Study 20,
Study 20,CZE,Site 8,Subject 15,Screening,,Screening,,Visit Level,Form 2,,Study 20,
Study 20,CZE,Site 8,Subject 15,Screening,,Screening,,Visit Level,Form 7,,Study 20,
Study 20,CZE,Site 8,Subject 15,Screening,,Screening,,Visit Level,Form 8,,Study 20,
Study 20,CZE,Site 8,Subject 15,Screening,,Screening,,Visit Level,Form 9,,Study 20,
Study 20,FRA,Site 9,Subject 16,On Trial,,Cycle 1 Day 15,,Visit Level,Form 4,,Study 20,
Study 20,FRA,Site 9,Subject 16,On Trial,,Disposition,,Summary Page,Form 1,,Study 20,
Study 20,FRA,Site 9,Subject 16,On Trial,,Study Drug Administration,,Summary Page,Form 11,,Study 20,
Study 20,FRA,Site 9,Subject 16,On Trial,,Study Drug Administration,,Summary Page,Form 12,,Study 20,
Study 20,FRA,Site 9,Subject 3512,Screening,,Cycle 1 Day 1,,Visit Level,Form 13,,Study 20,
Study 20,FRA,Site 9,Subject 3512,Screening,,Disposition,,Summary Page,Form 1,,Study 20,
Study 20,FRA,Site 9,Subject 3512,Screening,Subject continuing,Screening,2025-11-10,Visit Level,Form 14,3.0,Study 20,
Study 20,ITA,Site 87,Subject 627,On Trial,,Cycle 2 Day 1,,Visit Level,Form 4,,Study 20,
Study 20,ITA,Site 87,Subject 627,On Trial,,Unplanned Visit,2025-10-20,Visit Level,Form 15,24.0,Study 20,
Study 20,ITA,Site 87,Subject 627,On Trial,,Unplanned Visit,2025-10-28,Visit Level,Form 16,16.0,Study 20,
Study 20,ITA,Site 87,Subject 627,On Trial,,Unplanned Visit,2025-11-12,Visit Level,Form 16,1.0,Study 20,
Study 20,ITA,Site 87,Subject 627,On Trial,,Unplanned Visit,2025-11-12,Visit Level,Form 17,1.0,Study 20,
Study 20,KOR,Site 417,Subject 3227,Screening,,Cycle 1 Day 1,,Visit Level,Form 13,,Study 20,
Study 20,KOR,Site 417,Subject 3227,Screening,,Disposition,,Summary Page,Form 1,,Study 20,
Study 20,KOR,Site 417,Subject 3227,Screening,Subject continuing,Screening,2025-11-03,Visit Level,Form 18,10.0,Study 20,
Study 20,KOR,Site 417,Subject 3227,Screening,Subject continuing,Screening,2025-11-03,Visit Level,Form 19,10.0,Study 20,
Study 20,NLD,Site 124,Subject 1067,On Trial,,Cycle 1 Day 15,,Visit Level,Form 4,,Study 20,
Study 20,NLD,Site 124,Subject 1067,On Trial,,Disposition,,Summary Page,Form 1,,Study 20,
Study 20,NLD,Site 124,Subject 1067,On Trial,Subject continuing,Screening,2025-10-15,Visit Level,Form 20,29.0,Study 20,
Study 20,NLD,Site 124,Subject 1067,On Trial,,Study Drug Administration,,Summary Page,Form 11,,Study 20,
Study 20,NLD,Site 124,Subject 1067,On Trial,,Study Drug Administration,,Summary Page,Form 12,,Study 20,
Study 20,SGP,Site 353,Subject 2844,On Trial,,Cycle 5 Day 1,,Visit Level,Form 4,,Study 20,
Study 20,SGP,Site 353,Subject 2844,On Trial,,Unplanned Visit,2025-09-10,Visit Level,Form 21,64.0,Study 20,
Study 20,SGP,Site 353,Subject 2844,On Trial,,Unplanned Visit,2025-09-17,Visit Level,Form 21,57.0,Study 20,
Study 20,SGP,Site 353,Subject 2844,On Trial,,Unplanned Visit,2025-09-30,Visit Level,Form 21,44.0,Study 20,
Study 20,SGP,Site 353,Subject 2844,On Trial,,Unplanned Visit,2025-10-21,Visit Level,Form 22,23.0,Study 20,
Study 20,SGP,Site 353,Subject 2845,On Trial,Subject continuing,Cycle 4 Day 1,2025-10-29,Visit Level,Form 23,15.0,Study 20,
Study 20,SGP,Site 353,Subject 2845,On Trial,,Cycle 5 Day 1,,Visit Level,Form 4,,Study 20,
Study 20,SGP,Site 353,Subject 2845,On Trial,,SAE/ADR,,Summary Page,Form 24,,Study 20,
Study 20,SGP,Site 353,Subject 2845,On Trial,,SAE/ADR,,Summary Page,Form 25,,Study 20,
Study 20,SGP,Site 353,Subject 2845,On Trial,,SAE/ADR,,Summary Page,Form 26,,Study 20,
Study 20,SGP,Site 353,Subject 2845,On Trial,,SAE/ADR,,Summary Page,Form 27,,Study 20,
Study 20,SGP,Site 353,Subject 2845,On Trial,,SAE/ADR,,Summary Page,Form 28,,Study 20,
Study 20,SGP,Site 353,Subject 2845,On Trial,,SAE/ADR,,Summary Page,Form 29,,Study 20,
Study 20,SGP,Site 353,Subject 3737,On Trial,,Cycle 1 Day 15,,Visit Level,Form 4,,Study 20,
Study 20,SGP,Site 353,Subject 3737,On Trial,Subject continuing,Screening,2025-10-01,Visit Level,Form 14,43.0,Study 20,
Study 20,SGP,Site 353,Subject 3737,On Trial,Subject continuing,Screening,2025-10-01,Visit Level,Form 30,43.0,Study 20,
Study 20,SGP,Site 353,Subject 3737,On Trial,Subject continuing,Screening,2025-10-01,Visit Level,Form 23,43.0,Study 20,
Study 20,USA,Site 783,Subject 4904,On Trial,Subject continuing,Cycle 2 Day 1,2025-09-30,Visit Level,Form 31,44.0,Study 20,
Study 20,USA,Site 783,Subject 4904,On Trial,Subject continuing,Cycle 2 Day 1,2025-09-30,Visit Level,Form 32,44.0,Study 20,
Study 20,USA,Site 783,Subject 4904,On Trial,Subject continuing,Cycle 2 Day 1,2025-09-30,Visit Level,Form 33,44.0,Study 20,
Study 20,USA,Site 783,Subject 4904,On Trial,Subject continuing,Cycle 2 Day 1,2025-09-30,Visit Level,Form 34,44.0,Study 20,
Study 20,USA,Site 783,Subject 4904,On Trial,,Cycle 4 Day 1,,Visit Level,Form 4,,Study 20,
Study 20,USA,Site 784,Subject 4905,Screening,,Screening,2025-10-30,Visit Level,Form 2,14.0,Study 20,
Study 20,USA,Site 784,Subject 4905,Screening,,Screening,2025-10-30,Visit Level,Form 7,14.0,Study 20,
Study 20,USA,Site 784,Subject 4905,Screening,,Screening,2025-10-30,Visit Level,Form 8,14.0,Study 20,
Study 20,USA,Site 784,Subject 4906,Screening,,Screening,2025-10-30,Visit Level,Form 2,14.0,Study 20,
Study 20,USA,Site 784,Subject 4906,Screening,,Screening,2025-10-30,Visit Level,Form 8,14.0,Study 20,
Study 20,USA,Site 785,Subject 4907,Screening,,Disposition,,Summary Page,Form 1,,Study 20,
Study 20,USA,Site 785,Subject 4907,Screening,Subject continuing,Screening,2025-10-01,Visit Level,Form 2,43.0,Study 20,
Study 20,USA,Site 575,Subject 3947,Screening,,Disposition,,Summary Page,Form 1,,Study 20,
Study 20,USA,Site 575,Subject 3949,On Trial,,Cycle 2 Day 1,,Visit Level,Form 4,,Study 20,
Study 20,USA,Site 575,Subject 3949,On Trial,,Study Drug Administration,,Summary Page,Form 11,,Study 20,
Study 20,USA,Site 575,Subject 3949,On Trial,,Study Drug Administration,,Summary Page,Form 12,,Study 20,
Study 21,,Site 456,Subject 5701,Subject continuing,Subject continuing,Month33,,Visit Level,Form 1,,Study 21,
Study 21,,Site 456,Subject 5701,Subject continuing,Subject continuing,Month33,,Visit Level,Form 2,,Study 21,
Study 21,,Site 456,Subject 5701,Subject continuing,Subject continuing,Month33,,Visit Level,Form 3,,Study 21,
Study 21,,Site 456,Subject 5721,Subject continuing,Subject continuing,Month27,2025-09-26,Visit Level,Form 1,40.0,Study 21,
Study 21,,Site 789,Subject 5844,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 789,Subject 5844,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 789,Subject 5844,,,EOS,,Visit Level,Form 5,,Study 21,
Study 21,,Site 789,Subject 5856,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 789,Subject 5856,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 789,Subject 5856,,,EOS,,Visit Level,Form 5,,Study 21,
Study 21,,Site 59,Subject 6065,Subject continuing,Subject continuing,Month21,,Visit Level,Form 1,,Study 21,
Study 21,,Site 59,Subject 6065,Subject continuing,Subject continuing,Month21,,Visit Level,Form 2,,Study 21,
Study 21,,Site 59,Subject 6065,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month27,,Visit Level,Form 1,,Study 21,
Study 21,,Site 59,Subject 6065,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month27,,Visit Level,Form 2,,Study 21,
Study 21,,Site 502,Subject 6302,Subject continuing,Subject continuing,Month27,,Visit Level,Form 6,,Study 21,
Study 21,,Site 422,Subject 6475,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 825,Subject 6905,Subject continuing,Subject continuing,Month33,2025-09-17,Visit Level,Form 1,49.0,Study 21,
Study 21,,Site 464,Subject 3523,Missed visit - subject unavailable,Missed visit - subject unavailable,Month39,,Visit Level,Form 3,,Study 21,
Study 21,,Site 835,Subject 7038,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 842,Subject 7159,Subject continuing,Subject continuing,Month39,2025-08-25,Visit Level,Form 1,72.0,Study 21,
Study 21,,Site 842,Subject 7162,Subject continuing,Subject continuing,Month39,2025-09-01,Visit Level,Form 1,65.0,Study 21,
Study 21,,Site 155,Subject 7303,Subject continuing,Subject continuing,Month33,2025-10-08,Visit Level,Form 1,28.0,Study 21,
Study 21,,Site 156,Subject 7326,Subject continuing,Subject continuing,Month33,2025-08-21,Visit Level,Form 1,76.0,Study 21,
Study 21,,Site 156,Subject 7326,Subject continuing,Subject continuing,Month33,2025-08-21,Visit Level,Form 2,76.0,Study 21,
Study 21,,Site 848,Subject 7570,Subject continuing,Subject continuing,Month45,,Visit Level,Form 1,,Study 21,
Study 21,,Site 848,Subject 7570,Subject continuing,Subject continuing,Month45,,Visit Level,Form 3,,Study 21,
Study 21,,Site 848,Subject 7570,Subject continuing,Subject continuing,Month45,,Visit Level,Form 6,,Study 21,
Study 21,,Site 848,Subject 7595,,,eSAE - Study 21_2609048_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 160,Subject 7732,,,eSAE - Study 21_2614024_0001,,Summary Page,Form 9,,Study 21,
Study 21,,Site 160,Subject 7732,,,eSAE - Study 21_2614024_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 160,Subject 7732,Subject continuing,Subject continuing,Month33,2025-10-27,Visit Level,Form 1,9.0,Study 21,
Study 21,,Site 160,Subject 7736,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 160,Subject 7736,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 160,Subject 7736,,,EOS,,Visit Level,Form 5,,Study 21,
Study 21,,Site 160,Subject 7736,,,EOS,,Visit Level,Form 6,,Study 21,
Study 21,,Site 855,Subject 7835,,,Unplanned Visit (1),,Visit Level,Form 10,,Study 21,
Study 21,,Site 855,Subject 7835,,,Unplanned Visit (1),,Visit Level,Form 11,,Study 21,
Study 21,,Site 855,Subject 7844,Subject continuing,Subject continuing,Month27,,Visit Level,Form 1,,Study 21,
Study 21,,Site 855,Subject 7844,Subject continuing,Subject continuing,Month27,,Visit Level,Form 2,,Study 21,
Study 21,,Site 857,Subject 7874,,,eSAE - Study 21_2619006_0003,,Summary Page,Form 8,,Study 21,
Study 21,,Site 575,Subject 8243,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 1,,Study 21,
Study 21,,Site 575,Subject 8243,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 2,,Study 21,
Study 21,,Site 575,Subject 8243,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 3,,Study 21,
Study 21,,Site 575,Subject 8243,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 6,,Study 21,
Study 21,,Site 781,Subject 8263,Subject continuing,Subject continuing,Month27,2025-09-22,Visit Level,Form 2,44.0,Study 21,
Study 21,,Site 522,Subject 8933,,,Unplanned Visit (1),2024-02-28,Visit Level,Form 2,616.0,Study 21,
Study 21,,Site 522,Subject 8951,,,Survival,,Summary Page,Form 12,,Study 21,
Study 21,,Site 875,Subject 8976,Subject continuing,Subject continuing,Month33,2025-10-27,Visit Level,Form 3,9.0,Study 21,
Study 21,,Site 878,Subject 9101,Subject continuing,Subject continuing,Month33,2025-10-14,Visit Level,Form 1,22.0,Study 21,
Study 21,,Site 890,Subject 9347,Subject continuing,Subject continuing,Month39,,Visit Level,Form 1,,Study 21,
Study 21,,Site 890,Subject 9363,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month27,2025-09-17,Visit Level,Form 1,49.0,Study 21,
Study 21,,Site 283,Subject 9441,,,eSAE - Study 21_3131013_0002,,Summary Page,Form 8,,Study 21,
Study 21,,Site 895,Subject 9459,Subject continuing,Subject continuing,Month39,2025-09-17,Visit Level,Form 1,49.0,Study 21,
Study 21,,Site 895,Subject 9459,Subject continuing,Subject continuing,Month39,2025-09-17,Visit Level,Form 2,49.0,Study 21,
Study 21,,Site 895,Subject 9459,Subject continuing,Subject continuing,Month39,2025-09-17,Visit Level,Form 3,49.0,Study 21,
Study 21,,Site 897,Subject 9496,Subject continuing,Subject continuing,Month33,2025-09-11,Visit Level,Form 1,55.0,Study 21,
Study 21,,Site 356,Subject 10281,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 356,Subject 10281,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 356,Subject 10281,,,EOS,,Visit Level,Form 5,,Study 21,
Study 21,,Site 356,Subject 10281,,,EOS,,Visit Level,Form 6,,Study 21,
Study 21,,Site 169,Subject 10368,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 436,Subject 10541,Subject continuing,Subject continuing,Month33,,Visit Level,Form 1,,Study 21,
Study 21,,Site 436,Subject 10541,Subject continuing,Subject continuing,Month33,,Visit Level,Form 2,,Study 21,
Study 21,,Site 436,Subject 10541,Subject continuing,Subject continuing,Month33,,Visit Level,Form 3,,Study 21,
Study 21,,Site 436,Subject 10541,Subject continuing,Subject continuing,Month33,,Visit Level,Form 6,,Study 21,
Study 21,,Site 174,Subject 10676,Subject continuing,Subject continuing,Month39,2025-09-10,Visit Level,Form 1,56.0,Study 21,
Study 21,,Site 174,Subject 10676,Subject continuing,Subject continuing,Month39,2025-09-10,Visit Level,Form 2,56.0,Study 21,
Study 21,,Site 175,Subject 10761,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 913,Subject 10991,Subject continuing,Subject continuing,Month39,,Visit Level,Form 1,,Study 21,
Study 21,,Site 913,Subject 10991,Subject continuing,Subject continuing,Month39,,Visit Level,Form 2,,Study 21,
Study 21,,Site 913,Subject 10991,Subject continuing,Subject continuing,Month39,,Visit Level,Form 3,,Study 21,
Study 21,,Site 913,Subject 10991,Subject continuing,Subject continuing,Month39,,Visit Level,Form 6,,Study 21,
Study 21,,Site 913,Subject 10993,Subject continuing,Subject continuing,Month39,2025-10-22,Visit Level,Form 1,14.0,Study 21,
Study 21,,Site 913,Subject 10993,Subject continuing,Subject continuing,Month39,2025-10-22,Visit Level,Form 2,14.0,Study 21,
Study 21,,Site 913,Subject 10993,Subject continuing,Subject continuing,Month39,2025-10-22,Visit Level,Form 3,14.0,Study 21,
Study 21,,Site 923,Subject 11839,Subject continuing,Subject continuing,Month33,2025-09-05,Visit Level,Form 1,61.0,Study 21,
Study 21,,Site 924,Subject 11904,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 924,Subject 11904,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 924,Subject 11904,,,EOS,,Visit Level,Form 5,,Study 21,
Study 21,,Site 924,Subject 11904,,,EOS,,Visit Level,Form 6,,Study 21,
Study 21,,Site 927,Subject 12317,Subject continuing,Subject continuing,Month27,2025-10-02,Visit Level,Form 1,34.0,Study 21,
Study 21,,Site 928,Subject 12326,Subject continuing,Subject continuing,Month39,2025-10-20,Visit Level,Form 1,16.0,Study 21,
Study 21,,Site 930,Subject 12464,Subject continuing,Subject continuing,Month39,2025-10-29,Visit Level,Form 1,7.0,Study 21,
Study 21,,Site 933,Subject 12858,Subject continuing,Subject continuing,Screening,2023-05-31,Visit Level,Form 13,889.0,Study 21,
Study 21,,Site 940,Subject 13137,Subject continuing,Subject continuing,Month39,2025-09-15,Visit Level,Form 1,51.0,Study 21,
Study 21,,Site 941,Subject 13181,Subject continuing,Subject continuing,Month39,2025-09-15,Visit Level,Form 1,51.0,Study 21,
Study 21,,Site 979,Subject 14033,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 981,Subject 14137,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 984,Subject 14164,Subject continuing,Subject continuing,Month39,2025-09-03,Visit Level,Form 2,63.0,Study 21,
Study 21,,Site 994,Subject 14541,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month27,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1008,Subject 14794,Missed visit - subject unavailable,Missed visit - subject unavailable,Month33,,Visit Level,Form 3,,Study 21,
Study 21,,Site 325,Subject 14967,,,eSAE - Study 21_5005013_0001,,Summary Page,Form 9,,Study 21,
Study 21,,Site 325,Subject 14967,,,eSAE - Study 21_5005013_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 330,Subject 15412,,,eSAE - Study 21_5028016_0001,,Summary Page,Form 9,,Study 21,
Study 21,,Site 330,Subject 15412,,,eSAE - Study 21_5028016_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 330,Subject 15412,,,eSAE - Study 21_5028016_0002,,Summary Page,Form 9,,Study 21,
Study 21,,Site 330,Subject 15412,,,eSAE - Study 21_5028016_0002,,Summary Page,Form 8,,Study 21,
Study 21,,Site 330,Subject 15418,Subject continuing,Subject continuing,Month33,2025-10-13,Visit Level,Form 3,23.0,Study 21,
Study 21,,Site 330,Subject 15428,Subject continuing,Subject continuing,Month33,2025-10-31,Visit Level,Form 3,5.0,Study 21,
Study 21,,Site 538,Subject 3827,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 538,Subject 3827,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 538,Subject 3827,,,EOS,,Visit Level,Form 5,,Study 21,
Study 21,,Site 538,Subject 3827,,,EOS,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1031,Subject 15602,,,eSAE - Study 21_5055001_0005,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1031,Subject 15602,,,eSAE - Study 21_5055001_0006,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1038,Subject 15734,,,eSAE - Study 21_5077003_0001,,Summary Page,Form 9,,Study 21,
Study 21,,Site 1038,Subject 15734,,,eSAE - Study 21_5077003_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1038,Subject 15737,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1038,Subject 15737,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1061,Subject 16180,Subject continuing,Subject continuing,Month33,2025-10-01,Visit Level,Form 1,35.0,Study 21,
Study 21,,Site 1062,Subject 16218,,,eSAE - Study 21_5124021_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1067,Subject 16262,,,Unplanned Visit (1),,Visit Level,Form 10,,Study 21,
Study 21,,Site 1067,Subject 16262,,,Unplanned Visit (1),,Visit Level,Form 11,,Study 21,
Study 21,,Site 1084,Subject 16508,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1084,Subject 16508,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1084,Subject 16508,,,EOS,,Visit Level,Form 5,,Study 21,
Study 21,,Site 1089,Subject 16588,Subject continuing,Subject continuing,Month39,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1089,Subject 16588,Subject continuing,Subject continuing,Month39,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1089,Subject 16588,Subject continuing,Subject continuing,Month39,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1089,Subject 16588,Subject continuing,Subject continuing,Month39,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1090,Subject 16633,Subject continuing,Subject continuing,Month27,2025-10-24,Visit Level,Form 2,12.0,Study 21,
Study 21,,Site 1093,Subject 16684,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1093,Subject 16684,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1099,Subject 16753,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1099,Subject 16753,,,eSAE - Study 21_5205005_0004,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1099,Subject 16753,,,eSAE - Study 21_5205005_0008,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1099,Subject 16753,,,eSAE - Study 21_5205005_0010,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1099,Subject 16753,,,eSAE - Study 21_5205005_0011,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1099,Subject 16753,,,eSAE - Study 21_5205005_0013,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1099,Subject 16753,,,eSAE - Study 21_5205005_0014,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1105,Subject 16818,,,eSAE - Study 21_5211015_0002,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1110,Subject 16879,Subject continuing,Subject continuing,Month45,2025-11-05,Visit Level,Form 1,0.0,Study 21,
Study 21,,Site 1114,Subject 17058,,,eSAE - Study 21_5229006_0002,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1025,Subject 17140,Subject continuing,Subject continuing,Month27,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1025,Subject 17140,Subject continuing,Subject continuing,Month27,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1138,Subject 17401,Subject continuing,Subject continuing,Month21,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1026,Subject 17594,Missed visit - subject unavailable,Missed visit - subject unavailable,Month27,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1026,Subject 17594,Missed visit - subject unavailable,Missed visit - subject unavailable,Month33,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1026,Subject 17594,Missed visit - subject unavailable,Missed visit - subject unavailable,Month33,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1159,Subject 17639,,,eSAE - Study 21_5342023_0004,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1161,Subject 17722,Missed visit - subject unavailable,Missed visit - subject unavailable,Month21,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1161,Subject 17722,Missed visit - subject unavailable,Missed visit - subject unavailable,Month21,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1168,Subject 17789,,,Unplanned Visit (1),,Visit Level,Form 10,,Study 21,
Study 21,,Site 1168,Subject 17789,,,Unplanned Visit (1),,Visit Level,Form 11,,Study 21,
Study 21,,Site 1178,Subject 17833,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month39,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1178,Subject 17833,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month39,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1178,Subject 17836,Subject discontinued from study at this visit,Subject discontinued from study at this visit,Month39,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1181,Subject 17872,,,eSAE - Study 21_5420007_0001,,Summary Page,Form 9,,Study 21,
Study 21,,Site 1182,Subject 17896,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1182,Subject 17896,Subject discontinued from study at this visit,Subject discontinued from study at this visit,Month21,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1182,Subject 17896,Subject discontinued from study at this visit,Subject discontinued from study at this visit,Month21,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1184,Subject 17931,,,eSAE - Study 21_5425004_0002,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1210,Subject 18389,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1211,Subject 18402,,,eSAE - Study 21_5532008_0009,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1216,Subject 18462,,,eSAE - Study 21_5536002_0006,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1227,Subject 18647,Subject continuing,Subject continuing,Month27,2025-10-15,Visit Level,Form 1,21.0,Study 21,
Study 21,,Site 1230,Subject 18683,Subject continuing,Subject continuing,Month27,2025-09-03,Visit Level,Form 1,63.0,Study 21,
Study 21,,Site 1245,Subject 19024,,,eSAE - Study 21_5617017_0001,,Summary Page,Form 9,,Study 21,
Study 21,,Site 1245,Subject 19024,,,eSAE - Study 21_5617017_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1261,Subject 19209,Missed visit - subject unavailable,Missed visit - subject unavailable,Month33,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1264,Subject 19252,,,eSAE - Study 21_5653002_0005,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1264,Subject 19252,,,eSAE - Study 21_5653002_0007,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1264,Subject 19255,Subject continuing,Subject continuing,Month27,2025-10-13,Visit Level,Form 1,23.0,Study 21,
Study 21,,Site 1264,Subject 19255,Subject continuing,Subject continuing,Month27,2025-10-13,Visit Level,Form 2,23.0,Study 21,
Study 21,,Site 1267,Subject 19283,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month21,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1267,Subject 19283,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month21,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1267,Subject 19286,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month9,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1267,Subject 19286,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month9,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1270,Subject 19298,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1270,Subject 19298,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1270,Subject 19298,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1270,Subject 19298,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month33,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1133,Subject 19349,,,eSAE - Study 21_5674006_0001,,Summary Page,Form 9,,Study 21,
Study 21,,Site 1133,Subject 19349,,,eSAE - Study 21_5674006_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1275,Subject 19410,Subject discontinued from study at this visit,Subject discontinued from study at this visit,Month27,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1279,Subject 19438,Subject continuing,Subject continuing,Month27,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1279,Subject 19438,Subject continuing,Subject continuing,Month27,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1279,Subject 19438,Subject continuing,Subject continuing,Month27,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1279,Subject 19438,Subject continuing,Subject continuing,Month27,,Visit Level,Form 6,,Study 21,
Study 21,,Site 191,Subject 1683,Subject continuing,Subject continuing,Month27,2025-10-23,Visit Level,Form 1,13.0,Study 21,
Study 21,,Site 195,Subject 19906,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month9,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1313,Subject 20223,Subject continuing,Subject continuing,Month27,2025-10-29,Visit Level,Form 1,7.0,Study 21,
Study 21,,Site 1313,Subject 20223,Subject continuing,Subject continuing,Month27,2025-10-29,Visit Level,Form 2,7.0,Study 21,
Study 21,,Site 1318,Subject 20252,Subject continuing,Subject continuing,Month27,2025-10-23,Visit Level,Form 1,13.0,Study 21,
Study 21,,Site 1318,Subject 20252,Subject continuing,Subject continuing,Month27,2025-10-23,Visit Level,Form 2,13.0,Study 21,
Study 21,,Site 1318,Subject 20252,Subject continuing,Subject continuing,Month27,2025-10-23,Visit Level,Form 3,13.0,Study 21,
Study 21,,Site 1334,Subject 20346,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1335,Subject 20372,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1335,Subject 20372,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month27,2025-09-01,Visit Level,Form 3,65.0,Study 21,
Study 21,,Site 1336,Subject 20377,,,eSAE - Study 21_7011002_0004,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1355,Subject 20693,Subject continuing,Subject continuing,Month33,2025-09-19,Visit Level,Form 1,47.0,Study 21,
Study 21,,Site 1369,Subject 21120,Subject continuing,Subject continuing,Month39,2025-09-29,Visit Level,Form 1,37.0,Study 21,
Study 21,,Site 546,Subject 21877,Subject continuing,Subject continuing,Month27,2025-08-27,Visit Level,Form 1,70.0,Study 21,
Study 21,,Site 546,Subject 21877,Subject continuing,Subject continuing,Month27,2025-08-27,Visit Level,Form 2,70.0,Study 21,
Study 21,,Site 548,Subject 22082,Subject continuing,Subject continuing,Month27,2025-10-20,Visit Level,Form 1,16.0,Study 21,
Study 21,,Site 548,Subject 22082,Subject continuing,Subject continuing,Month27,2025-10-20,Visit Level,Form 2,16.0,Study 21,
Study 21,,Site 548,Subject 22084,Subject continuing,Subject continuing,Month27,2025-10-20,Visit Level,Form 1,16.0,Study 21,
Study 21,,Site 548,Subject 22084,Subject continuing,Subject continuing,Month27,2025-10-20,Visit Level,Form 2,16.0,Study 21,
Study 21,,Site 548,Subject 22086,Subject continuing,Subject continuing,Month27,2025-10-21,Visit Level,Form 1,15.0,Study 21,
Study 21,,Site 548,Subject 22086,Subject continuing,Subject continuing,Month27,2025-10-21,Visit Level,Form 2,15.0,Study 21,
Study 21,,Site 1400,Subject 22516,,,eSAE - Study 21_7508056_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1404,Subject 22604,,,eSAE - Study 21_7512010_0002,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1405,Subject 22639,,,Unplanned Visit (2),,Visit Level,Form 10,,Study 21,
Study 21,,Site 1405,Subject 22639,,,Unplanned Visit (2),,Visit Level,Form 11,,Study 21,
Study 21,,Site 1413,Subject 22874,Subject continuing,Subject continuing,Month27,2025-09-02,Visit Level,Form 1,64.0,Study 21,
Study 21,,Site 1415,Subject 22969,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1415,Subject 22969,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1415,Subject 22969,,,EOS,,Visit Level,Form 5,,Study 21,
Study 21,,Site 1415,Subject 22969,,,EOS,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1415,Subject 22984,Subject continuing,Subject continuing,Month27,2025-09-04,Visit Level,Form 1,62.0,Study 21,
Study 21,,Site 1415,Subject 22984,Subject continuing,Subject continuing,Month27,2025-09-04,Visit Level,Form 2,62.0,Study 21,
Study 21,,Site 1415,Subject 22984,Subject continuing,Subject continuing,Month27,2025-09-04,Visit Level,Form 3,62.0,Study 21,
Study 21,,Site 1426,Subject 23261,Subject continuing,Subject continuing,Month27,2025-09-30,Visit Level,Form 3,36.0,Study 21,
Study 21,,Site 1426,Subject 23261,Subject continuing,Subject continuing,Month33,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1432,Subject 23392,,,Unplanned Visit (1),2022-05-18,Visit Level,Form 10,1267.0,Study 21,
Study 21,,Site 1433,Subject 23444,Subject continuing,Subject continuing,Month33,2025-09-08,Visit Level,Form 1,58.0,Study 21,
Study 21,,Site 1433,Subject 23444,Subject continuing,Subject continuing,Month33,2025-09-08,Visit Level,Form 2,58.0,Study 21,
Study 21,,Site 1433,Subject 23444,Subject continuing,Subject continuing,Month33,2025-09-08,Visit Level,Form 3,58.0,Study 21,
Study 21,,Site 1444,Subject 23758,,,eSAE - Study 21_7815006_0002,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1456,Subject 24066,Subject continuing,Subject continuing,Month27,2025-09-18,Visit Level,Form 1,48.0,Study 21,
Study 21,,Site 1458,Subject 24105,Subject continuing,Subject continuing,Month33,2025-11-02,Visit Level,Form 1,3.0,Study 21,
Study 21,,Site 1458,Subject 24147,Subject continuing,Subject continuing,Month27,2025-10-27,Visit Level,Form 1,9.0,Study 21,
Study 21,,Site 1458,Subject 24173,Subject continuing,Subject continuing,Month27,2025-10-26,Visit Level,Form 1,10.0,Study 21,
Study 21,,Site 1464,Subject 24283,Subject continuing,Subject continuing,Month27,2025-09-18,Visit Level,Form 2,48.0,Study 21,
Study 21,,Site 1471,Subject 24644,Subject continuing,Subject continuing,Month33,2025-10-07,Visit Level,Form 1,29.0,Study 21,
Study 21,,Site 1488,Subject 25044,Subject continuing,Subject continuing,Month33,2025-10-15,Visit Level,Form 1,21.0,Study 21,
Study 21,,Site 1488,Subject 25044,Subject continuing,Subject continuing,Month33,2025-10-15,Visit Level,Form 2,21.0,Study 21,
Study 21,,Site 1492,Subject 25119,,,Unplanned Visit (1),2024-06-24,Visit Level,Form 2,499.0,Study 21,
Study 21,,Site 1494,Subject 25161,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1509,Subject 25531,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month9,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1509,Subject 25531,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month9,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1509,Subject 25538,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month15,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month15,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month15,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month15,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month21,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month21,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month21,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month21,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month27,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month27,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month27,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1509,Subject 25538,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month27,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1510,Subject 25553,,,Unplanned Visit (1),2023-03-02,Visit Level,Form 10,979.0,Study 21,
Study 21,,Site 1510,Subject 25553,,,Unplanned Visit (2),2023-03-09,Visit Level,Form 10,972.0,Study 21,
Study 21,,Site 1510,Subject 25553,,,Unplanned Visit (3),2023-03-21,Visit Level,Form 10,960.0,Study 21,
Study 21,,Site 1510,Subject 25553,,,Unplanned Visit (4),2023-04-14,Visit Level,Form 10,936.0,Study 21,
Study 21,,Site 1510,Subject 25553,,,Unplanned Visit (5),2023-05-17,Visit Level,Form 10,903.0,Study 21,
Study 21,,Site 1516,Subject 26027,,,eSAE - Study 21_8512083_0003,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1519,Subject 26170,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1519,Subject 26220,,,eSAE - Study 21_8516148_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1526,Subject 26453,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1526,Subject 26455,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1527,Subject 26526,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month15,2024-02-21,Visit Level,Form 1,623.0,Study 21,
Study 21,,Site 1527,Subject 26526,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month15,2024-02-21,Visit Level,Form 2,623.0,Study 21,
Study 21,,Site 1542,Subject 27024,,,eSAE - Study 21_8610011_0002,,Summary Page,Form 9,,Study 21,
Study 21,,Site 1542,Subject 27024,,,eSAE - Study 21_8610011_0002,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1542,Subject 27024,,,eSAE - Study 21_8610011_0003,,Summary Page,Form 9,,Study 21,
Study 21,,Site 1542,Subject 27024,,,eSAE - Study 21_8610011_0003,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1559,Subject 27402,,,Unplanned Visit (7),,Visit Level,Form 10,,Study 21,
Study 21,,Site 1559,Subject 27402,,,Unplanned Visit (7),,Visit Level,Form 11,,Study 21,
Study 21,,Site 1572,Subject 27715,,,EOS,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1572,Subject 27715,,,EOS,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1572,Subject 27715,,,EOS,,Visit Level,Form 5,,Study 21,
Study 21,,Site 1572,Subject 27715,,,EOS,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1572,Subject 27715,,,eSAE - Study 21_8814001_0001,,Summary Page,Form 8,,Study 21,
Study 21,,Site 1580,Subject 27937,Subject continuing,Subject continuing,Month33,2025-10-16,Visit Level,Form 1,20.0,Study 21,
Study 21,,Site 1609,Subject 28565,Subject continuing,Subject continuing,Month33,2025-10-15,Visit Level,Form 1,21.0,Study 21,
Study 21,,Site 1623,Subject 28893,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month21,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1623,Subject 28893,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month21,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1624,Subject 28967,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month9,,Visit Level,Form 1,,Study 21,
Study 21,,Site 1624,Subject 28967,Subject discontinued from treatment at this visit,Subject discontinued from treatment at this visit,Month9,,Visit Level,Form 2,,Study 21,
Study 21,,Site 1625,Subject 29031,Missed visit - subject unavailable,Missed visit - subject unavailable,Month15,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1625,Subject 29034,Subject continuing,Subject continuing,Month27,2025-10-10,Visit Level,Form 3,26.0,Study 21,
Study 21,,Site 1627,Subject 29229,Subject continuing,Subject continuing,Month27,2025-09-02,Visit Level,Form 1,64.0,Study 21,
Study 21,,Site 1627,Subject 29229,Subject continuing,Subject continuing,Month27,2025-09-02,Visit Level,Form 2,64.0,Study 21,
Study 21,,Site 1627,Subject 29229,Subject continuing,Subject continuing,Month27,2025-09-02,Visit Level,Form 3,64.0,Study 21,
Study 21,,Site 1627,Subject 29250,Subject continuing,Subject continuing,Month27,2025-10-01,Visit Level,Form 1,35.0,Study 21,
Study 21,,Site 1640,Subject 29670,,,Adverse Events,,Summary Page,Form 14,,Study 21,
Study 21,,Site 1640,Subject 29670,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1640,Subject 29670,Subject discontinued from study at this visit,Subject discontinued from study at this visit,Month27,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1640,Subject 29670,Subject discontinued from study at this visit,Subject discontinued from study at this visit,Month27,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1640,Subject 29693,,,Adverse Events,,Summary Page,Form 14,,Study 21,
Study 21,,Site 1640,Subject 29693,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1640,Subject 29693,Subject discontinued from study at this visit,Subject discontinued from study at this visit,Month27,,Visit Level,Form 3,,Study 21,
Study 21,,Site 1640,Subject 29693,Subject discontinued from study at this visit,Subject discontinued from study at this visit,Month27,,Visit Level,Form 6,,Study 21,
Study 21,,Site 1640,Subject 29694,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1640,Subject 29745,,,Adverse Events,,Summary Page,Form 14,,Study 21,
Study 21,,Site 1640,Subject 29745,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 21,,Site 1640,Subject 29830,,,Disposition,,Summary Page,Form 7,,Study 21,
Study 22,ARG,Site 435,Subject 9825,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 435,Subject 9825,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 315,Subject 9959,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 315,Subject 9959,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 166,Subject 37812,On Trial,Subject continuing,Visit 4 (Month 15),2025-08-27,Visit Level,Form 4,75.0,Study 22,
Study 22,ARG,Site 316,Subject 2595,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 316,Subject 2595,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 316,Subject 2596,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 316,Subject 2596,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 316,Subject 2597,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 316,Subject 2597,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 910,Subject 10083,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 910,Subject 10083,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 910,Subject 10084,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 910,Subject 10084,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 910,Subject 10085,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 910,Subject 10085,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 910,Subject 10087,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,ARG,Site 168,Subject 1536,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 168,Subject 1536,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 168,Subject 37817,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-28,Visit Level,Form 4,13.0,Study 22,
Study 22,ARG,Site 168,Subject 37832,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-28,Visit Level,Form 6,13.0,Study 22,
Study 22,ARG,Site 168,Subject 37834,On Trial,,Disposition,,Summary Page,Form 7,,Study 22,
Study 22,ARG,Site 168,Subject 37835,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 168,Subject 37835,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 356,Subject 10166,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 356,Subject 10166,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 169,Subject 10353,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 169,Subject 10353,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 170,Subject 1545,On Trial,,Unplanned visit,2025-02-07,Visit Level,Form 8,276.0,Study 22,
Study 22,ARG,Site 436,Subject 3315,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 436,Subject 3315,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 436,Subject 3318,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 436,Subject 3318,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 174,Subject 1580,On Trial,Subject continuing,Visit 6 (Month 27),2025-11-04,Visit Level,Form 9,6.0,Study 22,
Study 22,ARG,Site 174,Subject 10678,On Trial,Subject continuing,Visit 4 (Month 15),2025-09-30,Visit Level,Form 4,41.0,Study 22,
Study 22,ARG,Site 438,Subject 10890,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 438,Subject 10890,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 438,Subject 10891,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 438,Subject 10891,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 438,Subject 10892,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 438,Subject 10892,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 911,Subject 10908,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 911,Subject 10908,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 912,Subject 10987,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-14,Visit Level,Form 10,27.0,Study 22,
Study 22,ARG,Site 912,Subject 10987,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-14,Visit Level,Form 9,27.0,Study 22,
Study 22,ARG,Site 913,Subject 10992,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 913,Subject 10992,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 913,Subject 10994,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 913,Subject 10994,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 913,Subject 37866,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 913,Subject 37866,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 913,Subject 37867,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-06,Visit Level,Form 4,35.0,Study 22,
Study 22,ARG,Site 913,Subject 37875,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 913,Subject 37875,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 913,Subject 37877,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-27,Visit Level,Form 4,14.0,Study 22,
Study 22,ARG,Site 913,Subject 37879,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-05,Visit Level,Form 10,5.0,Study 22,
Study 22,ARG,Site 914,Subject 37927,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 914,Subject 37927,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 914,Subject 37933,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 914,Subject 37933,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 914,Subject 37967,On Trial,Subject continuing,Visit 3 (Month 9),2025-05-14,Visit Level,Form 9,180.0,Study 22,
Study 22,ARG,Site 441,Subject 37993,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 441,Subject 37993,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 916,Subject 11073,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 916,Subject 11073,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 917,Subject 11282,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 917,Subject 11282,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 917,Subject 11285,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 917,Subject 11285,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 917,Subject 11288,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 917,Subject 11288,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 917,Subject 38032,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 917,Subject 38032,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 917,Subject 38033,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 917,Subject 38033,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 917,Subject 38034,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 917,Subject 38034,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 919,Subject 11341,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 919,Subject 11341,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 919,Subject 11346,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 919,Subject 11346,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 919,Subject 11355,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,ARG,Site 919,Subject 11355,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,ARG,Site 919,Subject 11355,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,ARG,Site 919,Subject 11355,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,ARG,Site 919,Subject 11355,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,ARG,Site 919,Subject 11355,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,ARG,Site 919,Subject 11355,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,ARG,Site 919,Subject 11355,Discontinued,,Non-drug therapies,,Summary Page,Form 18,,Study 22,
Study 22,ARG,Site 317,Subject 38083,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 317,Subject 38083,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 317,Subject 38084,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 317,Subject 38084,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 318,Subject 11410,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 318,Subject 11410,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 318,Subject 11434,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 318,Subject 11434,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 321,Subject 38103,On Trial,,Unplanned visit,2025-10-31,Visit Level,Form 19,10.0,Study 22,
Study 22,ARG,Site 321,Subject 38106,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-27,Visit Level,Form 4,14.0,Study 22,
Study 22,ARG,Site 442,Subject 3355,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 442,Subject 3355,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 442,Subject 3359,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 442,Subject 3359,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 442,Subject 38124,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 442,Subject 38124,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 442,Subject 38156,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 442,Subject 38156,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 442,Subject 38168,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 442,Subject 38168,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 442,Subject 38174,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-24,Visit Level,Form 9,17.0,Study 22,
Study 22,ARG,Site 442,Subject 38175,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 442,Subject 38175,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 442,Subject 38177,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 442,Subject 38177,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 442,Subject 38179,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 442,Subject 38179,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 442,Subject 38181,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 442,Subject 38181,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1951,Subject 38239,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,ARG,Site 1951,Subject 38239,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,ARG,Site 1951,Subject 38239,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,ARG,Site 1951,Subject 38239,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,ARG,Site 1951,Subject 38239,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,ARG,Site 1951,Subject 38239,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,ARG,Site 1951,Subject 38244,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 1951,Subject 38244,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1951,Subject 38248,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 1951,Subject 38248,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1951,Subject 38250,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 1951,Subject 38250,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1951,Subject 38294,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 1951,Subject 38294,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1951,Subject 38295,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-22,Visit Level,Form 4,19.0,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,,End of Study (EOS),,Visit Level,Form 10,,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,,End of Study (EOS),,Visit Level,Form 6,,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,,End of Study (EOS),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,,Unplanned visit,2025-08-12,Visit Level,Form 4,90.0,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,Subject discontinued from study at this visit,Visit 5 (Month 21),,Visit Level,Form 20,,Study 22,
Study 22,ARG,Site 1952,Subject 38307,Discontinued,Subject discontinued from study at this visit,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1952,Subject 38319,On Trial,Subject continuing,Visit 4 (Month 15),2025-06-18,Visit Level,Form 4,145.0,Study 22,
Study 22,ARG,Site 443,Subject 38332,On Trial,,Unplanned visit,2024-01-29,Visit Level,Form 19,651.0,Study 22,
Study 22,ARG,Site 443,Subject 38350,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-13,Visit Level,Form 10,28.0,Study 22,
Study 22,ARG,Site 443,Subject 38350,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-13,Visit Level,Form 4,28.0,Study 22,
Study 22,ARG,Site 443,Subject 38371,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 443,Subject 38371,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 443,Subject 38375,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 443,Subject 38375,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 444,Subject 38388,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 444,Subject 38388,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 444,Subject 38392,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 444,Subject 38392,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 445,Subject 38398,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 445,Subject 38398,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 445,Subject 38401,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 445,Subject 38401,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 445,Subject 38404,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 445,Subject 38404,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 176,Subject 3370,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 176,Subject 3370,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 446,Subject 38496,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 446,Subject 38496,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 446,Subject 38500,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 446,Subject 38500,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 446,Subject 38502,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 446,Subject 38502,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 446,Subject 38503,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 446,Subject 38503,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 446,Subject 38515,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 446,Subject 38515,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 446,Subject 38516,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 446,Subject 38516,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1956,Subject 38561,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 1956,Subject 38561,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1956,Subject 38562,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 1956,Subject 38562,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ARG,Site 1956,Subject 38563,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ARG,Site 1956,Subject 38563,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,AUS,Site 29,Subject 30098,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,AUS,Site 29,Subject 30098,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,AUS,Site 29,Subject 30107,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUS,Site 29,Subject 30107,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUS,Site 30,Subject 5018,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,AUS,Site 30,Subject 5018,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,AUS,Site 31,Subject 2856,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUS,Site 31,Subject 2856,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUS,Site 357,Subject 5144,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,AUS,Site 357,Subject 5144,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,AUS,Site 452,Subject 5340,On Trial,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,AUS,Site 452,Subject 5340,On Trial,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,AUS,Site 452,Subject 5340,On Trial,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,AUS,Site 452,Subject 5340,On Trial,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,AUS,Site 452,Subject 5340,On Trial,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,AUS,Site 452,Subject 5340,On Trial,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,AUS,Site 452,Subject 5340,On Trial,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,AUS,Site 452,Subject 5340,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUS,Site 452,Subject 5340,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUS,Site 452,Subject 5348,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,AUS,Site 452,Subject 5348,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,AUS,Site 452,Subject 5348,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,AUS,Site 452,Subject 5348,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,AUS,Site 452,Subject 5348,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,AUS,Site 452,Subject 5348,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,AUS,Site 452,Subject 5348,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,AUS,Site 452,Subject 5348,Discontinued,Subject discontinued from study at this visit,Visit 4 (Month 15),,Visit Level,Form 20,,Study 22,
Study 22,AUT,Site 10,Subject 851,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUT,Site 10,Subject 851,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUT,Site 87,Subject 627,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 10,,Study 22,
Study 22,AUT,Site 87,Subject 627,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 4,,Study 22,
Study 22,AUT,Site 87,Subject 627,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 6,,Study 22,
Study 22,AUT,Site 87,Subject 627,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 20,,Study 22,
Study 22,AUT,Site 87,Subject 627,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUT,Site 87,Subject 627,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 9,,Study 22,
Study 22,AUT,Site 359,Subject 31763,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUT,Site 359,Subject 31763,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUT,Site 359,Subject 31764,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUT,Site 359,Subject 31764,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUT,Site 359,Subject 31765,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUT,Site 359,Subject 31765,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUT,Site 359,Subject 31766,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUT,Site 359,Subject 31766,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUT,Site 359,Subject 31767,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUT,Site 359,Subject 31767,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,AUT,Site 1694,Subject 31788,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,AUT,Site 1694,Subject 31788,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BEL,Site 417,Subject 31799,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BEL,Site 417,Subject 31799,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 125,Subject 31817,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 125,Subject 31817,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 125,Subject 31832,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 125,Subject 31832,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 125,Subject 31833,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 125,Subject 31833,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 125,Subject 31834,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 125,Subject 31834,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 126,Subject 1116,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 126,Subject 1116,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 126,Subject 31870,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 126,Subject 31870,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1695,Subject 31881,On Trial,,Adverse Event,,Summary Page,Form 21,,Study 22,
Study 22,BGR,Site 1695,Subject 31881,On Trial,Subject discontinued from treatment at this visit,Visit 5 (Month 21),2025-08-18,Visit Level,Form 9,84.0,Study 22,
Study 22,BGR,Site 1695,Subject 31881,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1695,Subject 31881,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1695,Subject 31894,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1695,Subject 31894,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1695,Subject 31895,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-31,Visit Level,Form 9,10.0,Study 22,
Study 22,BGR,Site 803,Subject 31937,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-16,Visit Level,Form 6,25.0,Study 22,
Study 22,BGR,Site 803,Subject 31940,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 803,Subject 31940,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 803,Subject 31956,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 803,Subject 31956,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1696,Subject 31979,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-20,Visit Level,Form 10,21.0,Study 22,
Study 22,BGR,Site 1696,Subject 31996,On Trial,,eSAE,,Summary Page,Form 22,,Study 22,
Study 22,BGR,Site 1696,Subject 31998,On Trial,Subject continuing,Visit 1,2024-10-07,Visit Level,Form 23,399.0,Study 22,
Study 22,BGR,Site 1699,Subject 32047,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1699,Subject 32047,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1699,Subject 32048,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1699,Subject 32048,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1699,Subject 32050,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1699,Subject 32050,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1699,Subject 32055,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1699,Subject 32055,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1699,Subject 32056,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1699,Subject 32056,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1699,Subject 32057,Discontinued,,End of Study (EOS),,Visit Level,Form 24,,Study 22,
Study 22,BGR,Site 1699,Subject 32058,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1699,Subject 32058,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1699,Subject 32063,On Trial,,Disposition,,Summary Page,Form 7,,Study 22,
Study 22,BGR,Site 1700,Subject 32084,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1700,Subject 32084,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1703,Subject 32158,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1703,Subject 32158,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1705,Subject 32194,On Trial,Subject continuing,Visit 3 (Month 9),2025-06-01,Visit Level,Form 9,162.0,Study 22,
Study 22,BGR,Site 1706,Subject 32200,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1706,Subject 32200,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1706,Subject 32204,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,BGR,Site 1706,Subject 32204,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,BGR,Site 1706,Subject 32204,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,BGR,Site 1706,Subject 32204,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,BGR,Site 1706,Subject 32204,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,BGR,Site 1706,Subject 32204,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,BGR,Site 1706,Subject 32210,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1706,Subject 32210,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1706,Subject 32211,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1706,Subject 32211,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BGR,Site 1706,Subject 32212,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BGR,Site 1706,Subject 32212,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 923,Subject 11758,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-06,Visit Level,Form 4,4.0,Study 22,
Study 22,BRA,Site 931,Subject 12614,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 931,Subject 12614,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 931,Subject 12615,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 931,Subject 12615,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 931,Subject 12616,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 931,Subject 12616,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 931,Subject 12617,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 931,Subject 12617,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 931,Subject 12618,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 931,Subject 12618,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 932,Subject 12746,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 932,Subject 12746,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 933,Subject 12840,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 933,Subject 12840,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 934,Subject 12870,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 934,Subject 12870,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 935,Subject 38587,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 935,Subject 38587,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 935,Subject 38588,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 935,Subject 38588,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 936,Subject 12980,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 936,Subject 12980,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 937,Subject 13003,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 937,Subject 13003,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 937,Subject 13008,On Trial,Subject continuing,Visit 4 (Month 15),2025-06-30,Visit Level,Form 4,133.0,Study 22,
Study 22,BRA,Site 937,Subject 13018,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 937,Subject 13018,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 1957,Subject 38645,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 1957,Subject 38645,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 1957,Subject 38672,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 1957,Subject 38672,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 1957,Subject 38678,On Trial,Subject continuing,Visit 5 (Month 21),2025-09-18,Visit Level,Form 4,53.0,Study 22,
Study 22,BRA,Site 1957,Subject 38683,On Trial,Subject continuing,Visit 5 (Month 21),2025-09-23,Visit Level,Form 4,48.0,Study 22,
Study 22,BRA,Site 1957,Subject 38702,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 1957,Subject 38702,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 938,Subject 38744,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 938,Subject 38744,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 939,Subject 38778,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-20,Visit Level,Form 4,21.0,Study 22,
Study 22,BRA,Site 941,Subject 13177,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 941,Subject 13177,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 941,Subject 13181,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 941,Subject 13181,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 941,Subject 13182,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 941,Subject 13182,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 941,Subject 13189,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 941,Subject 13189,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 941,Subject 13199,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 941,Subject 13199,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 942,Subject 13237,On Trial,Subject continuing,Visit 5 (Month 21),2025-07-31,Visit Level,Form 4,102.0,Study 22,
Study 22,BRA,Site 942,Subject 13253,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),2024-10-15,Visit Level,Form 9,391.0,Study 22,
Study 22,BRA,Site 942,Subject 13258,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 942,Subject 13258,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 942,Subject 13259,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 942,Subject 13259,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 944,Subject 13338,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 944,Subject 13338,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 944,Subject 13339,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-24,Visit Level,Form 10,17.0,Study 22,
Study 22,BRA,Site 944,Subject 13340,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 944,Subject 13340,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 944,Subject 13342,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 944,Subject 13342,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 946,Subject 38834,On Trial,Subject continuing,Visit 5 (Month 21),2025-07-22,Visit Level,Form 4,111.0,Study 22,
Study 22,BRA,Site 1958,Subject 38881,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 1958,Subject 38881,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 949,Subject 13464,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,BRA,Site 950,Subject 13508,On Trial,,Disposition,,Summary Page,Form 7,,Study 22,
Study 22,BRA,Site 950,Subject 13521,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 950,Subject 13521,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 950,Subject 13522,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 950,Subject 13522,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,BRA,Site 1961,Subject 38906,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,BRA,Site 1961,Subject 38906,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 951,Subject 13634,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,CAN,Site 951,Subject 38914,On Trial,Subject continuing,Visit 5 (Month 21),2025-08-01,Visit Level,Form 4,101.0,Study 22,
Study 22,CAN,Site 952,Subject 13637,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 952,Subject 13637,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 952,Subject 13638,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 952,Subject 13638,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 952,Subject 13639,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 952,Subject 13639,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 952,Subject 13640,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 10,,Study 22,
Study 22,CAN,Site 952,Subject 13640,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 4,,Study 22,
Study 22,CAN,Site 952,Subject 13640,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 6,,Study 22,
Study 22,CAN,Site 952,Subject 13640,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 9,,Study 22,
Study 22,CAN,Site 958,Subject 13709,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 958,Subject 13709,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 958,Subject 13713,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 958,Subject 13713,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 958,Subject 13717,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 958,Subject 13717,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 958,Subject 13719,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 958,Subject 13719,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 958,Subject 13723,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 958,Subject 13723,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 958,Subject 13731,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 958,Subject 13731,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 1963,Subject 38975,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 1963,Subject 38975,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 1963,Subject 38977,On Trial,,Unplanned visit,2023-10-05,Visit Level,Form 8,767.0,Study 22,
Study 22,CAN,Site 1963,Subject 38986,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 1963,Subject 38986,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 959,Subject 13756,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 959,Subject 13756,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Disposition,,Summary Page,Form 7,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 960,Subject 13762,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 961,Subject 13798,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 961,Subject 13798,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 961,Subject 13807,On Trial,Subject continuing,Visit 6 (Month 27),,Visit Level,Form 10,,Study 22,
Study 22,CAN,Site 961,Subject 13807,On Trial,Subject continuing,Visit 6 (Month 27),,Visit Level,Form 4,,Study 22,
Study 22,CAN,Site 961,Subject 13807,On Trial,Subject continuing,Visit 6 (Month 27),,Visit Level,Form 6,,Study 22,
Study 22,CAN,Site 961,Subject 13807,On Trial,Subject continuing,Visit 6 (Month 27),,Visit Level,Form 20,,Study 22,
Study 22,CAN,Site 961,Subject 13807,On Trial,Subject continuing,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 961,Subject 13807,On Trial,Subject continuing,Visit 6 (Month 27),,Visit Level,Form 9,,Study 22,
Study 22,CAN,Site 961,Subject 39003,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 961,Subject 39003,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 961,Subject 39004,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 961,Subject 39004,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 963,Subject 39025,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 963,Subject 39025,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 963,Subject 39026,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 963,Subject 39026,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 967,Subject 39092,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 967,Subject 39092,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 967,Subject 39108,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 967,Subject 39108,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 967,Subject 39112,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 967,Subject 39112,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 967,Subject 39118,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 967,Subject 39118,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 967,Subject 39120,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 967,Subject 39120,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 970,Subject 13882,Discontinued,Subject discontinued from treatment at this visit,Visit 4 (Month 15),2024-12-20,Visit Level,Form 10,325.0,Study 22,
Study 22,CAN,Site 970,Subject 39136,Discontinued,,End of Study (EOS),,Visit Level,Form 9,,Study 22,
Study 22,CAN,Site 969,Subject 13884,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 969,Subject 13884,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 972,Subject 13926,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 972,Subject 13926,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 975,Subject 13983,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 975,Subject 13983,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 976,Subject 39210,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 976,Subject 39210,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 1967,Subject 39244,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 1967,Subject 39244,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 1967,Subject 39252,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 10,,Study 22,
Study 22,CAN,Site 1967,Subject 39252,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 4,,Study 22,
Study 22,CAN,Site 1967,Subject 39252,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 6,,Study 22,
Study 22,CAN,Site 1967,Subject 39252,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 20,,Study 22,
Study 22,CAN,Site 1967,Subject 39252,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 9,,Study 22,
Study 22,CAN,Site 1967,Subject 39253,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 1967,Subject 39253,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 1967,Subject 39258,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 1967,Subject 39258,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CAN,Site 1967,Subject 39259,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CAN,Site 1967,Subject 39259,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CHE,Site 587,Subject 36515,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CHE,Site 587,Subject 36515,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CHE,Site 587,Subject 36516,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CHE,Site 587,Subject 36516,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CHN,Site 192,Subject 1693,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CHN,Site 192,Subject 1693,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CHN,Site 193,Subject 2785,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-28,Visit Level,Form 4,13.0,Study 22,
Study 22,CHN,Site 345,Subject 19601,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CHN,Site 345,Subject 19601,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CHN,Site 345,Subject 19602,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CHN,Site 345,Subject 19602,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CHN,Site 198,Subject 1726,On Trial,Subject continuing,Visit 6 (Month 27),2025-11-06,Visit Level,Form 4,4.0,Study 22,
Study 22,CHN,Site 198,Subject 1729,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,CHN,Site 198,Subject 1729,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,CHN,Site 206,Subject 44171,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CHN,Site 206,Subject 44171,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CHN,Site 2139,Subject 44238,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CHN,Site 2139,Subject 44238,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CHN,Site 2139,Subject 44239,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-03,Visit Level,Form 10,7.0,Study 22,
Study 22,COL,Site 995,Subject 14555,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 995,Subject 14555,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 996,Subject 14571,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 996,Subject 14571,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 997,Subject 14592,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 997,Subject 14592,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1970,Subject 39403,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-27,Visit Level,Form 9,14.0,Study 22,
Study 22,COL,Site 1972,Subject 39472,On Trial,Subject continuing,Visit 4 (Month 15),2025-11-04,Visit Level,Form 9,6.0,Study 22,
Study 22,COL,Site 1974,Subject 39501,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1974,Subject 39501,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1974,Subject 39504,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1974,Subject 39504,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1974,Subject 39508,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1974,Subject 39508,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1974,Subject 39521,On Trial,,Rescreen,,Summary Page,Form 25,,Study 22,
Study 22,COL,Site 1976,Subject 39552,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1976,Subject 39552,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1976,Subject 39560,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1976,Subject 39560,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1978,Subject 39621,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1978,Subject 39621,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1978,Subject 39622,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1978,Subject 39622,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1978,Subject 39623,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1978,Subject 39623,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1978,Subject 39624,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1978,Subject 39624,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1978,Subject 39626,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,COL,Site 1978,Subject 39626,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,COL,Site 1980,Subject 39667,On Trial,,Unplanned visit,2025-09-30,Visit Level,Form 4,41.0,Study 22,
Study 22,CZE,Site 11,Subject 1133,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 11,Subject 1133,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 131,Subject 6648,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 131,Subject 6648,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 808,Subject 32266,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-20,Visit Level,Form 10,21.0,Study 22,
Study 22,CZE,Site 808,Subject 32266,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-20,Visit Level,Form 4,21.0,Study 22,
Study 22,CZE,Site 808,Subject 32267,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-06,Visit Level,Form 4,4.0,Study 22,
Study 22,CZE,Site 809,Subject 6728,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 809,Subject 6728,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 810,Subject 32284,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 810,Subject 32284,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 817,Subject 32409,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 817,Subject 32409,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 807,Subject 6823,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 807,Subject 6823,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 1712,Subject 32546,On Trial,,eSAE,,Summary Page,Form 22,,Study 22,
Study 22,CZE,Site 1712,Subject 32546,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,CZE,Site 1712,Subject 32547,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 1712,Subject 32547,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 1714,Subject 32564,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 1714,Subject 32564,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 824,Subject 6879,On Trial,,Unplanned visit,2025-04-16,Visit Level,Form 19,208.0,Study 22,
Study 22,CZE,Site 824,Subject 6883,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 824,Subject 6883,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 824,Subject 6884,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 824,Subject 6884,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,CZE,Site 824,Subject 6885,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,CZE,Site 824,Subject 6885,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,DNK,Site 1346,Subject 20557,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,DNK,Site 1346,Subject 20557,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,DNK,Site 1346,Subject 20558,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,DNK,Site 1346,Subject 20558,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,DNK,Site 1346,Subject 20559,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,DNK,Site 1346,Subject 20559,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,DNK,Site 1346,Subject 44697,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-13,Visit Level,Form 10,28.0,Study 22,
Study 22,DNK,Site 1350,Subject 44750,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,DNK,Site 1350,Subject 44750,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,DNK,Site 2150,Subject 44960,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,DNK,Site 2150,Subject 44960,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,DNK,Site 2150,Subject 44961,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,DNK,Site 2150,Subject 44961,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 349,Subject 35358,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 349,Subject 35358,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 349,Subject 35359,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 349,Subject 35359,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 350,Subject 35373,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 350,Subject 35373,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 350,Subject 35374,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 350,Subject 35374,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1846,Subject 35387,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1846,Subject 35387,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 529,Subject 35394,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 529,Subject 35394,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 529,Subject 35399,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,ESP,Site 529,Subject 35399,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 529,Subject 35399,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 529,Subject 35400,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 529,Subject 35400,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 530,Subject 35420,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 530,Subject 35420,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 530,Subject 35421,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 530,Subject 35421,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35452,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35452,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35453,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35453,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35454,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35454,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35456,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35456,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35457,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35457,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35460,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35460,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35461,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35461,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35462,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35462,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35463,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35463,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35464,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35464,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35467,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35467,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35470,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35470,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1848,Subject 35471,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1848,Subject 35471,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1849,Subject 35516,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1849,Subject 35516,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1850,Subject 35532,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1850,Subject 35532,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1851,Subject 35563,On Trial,Subject continuing,Visit 4 (Month 15),2025-02-21,Visit Level,Form 9,262.0,Study 22,
Study 22,ESP,Site 1851,Subject 35563,On Trial,Subject continuing,Visit 5 (Month 21),2025-08-19,Visit Level,Form 9,83.0,Study 22,
Study 22,ESP,Site 1851,Subject 35587,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1851,Subject 35587,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1853,Subject 35621,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1853,Subject 35621,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1854,Subject 35626,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1854,Subject 35626,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1854,Subject 35627,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1854,Subject 35627,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1856,Subject 35657,On Trial,Subject continuing,Visit 5 (Month 21),2025-09-02,Visit Level,Form 4,69.0,Study 22,
Study 22,ESP,Site 1859,Subject 35735,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1859,Subject 35735,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1860,Subject 35756,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1860,Subject 35756,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1860,Subject 35757,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1860,Subject 35757,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1866,Subject 35830,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1866,Subject 35830,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1866,Subject 35834,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1866,Subject 35834,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1866,Subject 35837,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1866,Subject 35837,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1867,Subject 35835,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1867,Subject 35835,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1870,Subject 35871,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1870,Subject 35871,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1871,Subject 35881,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1871,Subject 35881,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1872,Subject 35894,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1872,Subject 35894,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1878,Subject 35992,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1878,Subject 35992,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1878,Subject 35994,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1878,Subject 35994,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1878,Subject 35995,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1878,Subject 35995,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1878,Subject 35996,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1878,Subject 35996,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1879,Subject 36013,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1879,Subject 36013,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1880,Subject 36025,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1880,Subject 36025,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1883,Subject 36071,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1883,Subject 36071,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1884,Subject 36124,On Trial,,Disposition,,Summary Page,Form 7,,Study 22,
Study 22,ESP,Site 1886,Subject 36140,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1886,Subject 36140,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1886,Subject 36142,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1886,Subject 36142,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1887,Subject 36152,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1887,Subject 36152,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1887,Subject 36154,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1887,Subject 36154,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1888,Subject 36170,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1888,Subject 36170,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1890,Subject 36203,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1890,Subject 36203,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1891,Subject 36219,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1891,Subject 36219,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1894,Subject 36248,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1894,Subject 36248,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1894,Subject 36251,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1894,Subject 36251,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1895,Subject 36258,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1895,Subject 36258,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1895,Subject 36259,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1895,Subject 36259,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1896,Subject 36284,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1896,Subject 36284,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1897,Subject 36336,On Trial,,eSAE,,Summary Page,Form 22,,Study 22,
Study 22,ESP,Site 1897,Subject 36337,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1897,Subject 36337,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1897,Subject 36338,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1897,Subject 36338,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1897,Subject 36339,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1897,Subject 36339,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1867,Subject 36382,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1867,Subject 36382,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1867,Subject 36384,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1867,Subject 36384,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1867,Subject 36385,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1867,Subject 36385,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1900,Subject 36406,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1900,Subject 36406,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1902,Subject 36439,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1902,Subject 36439,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1903,Subject 36466,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1903,Subject 36466,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ESP,Site 1904,Subject 36485,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-06,Visit Level,Form 4,4.0,Study 22,
Study 22,ESP,Site 1905,Subject 36498,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ESP,Site 1905,Subject 36498,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,EST,Site 2151,Subject 45148,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,EST,Site 2151,Subject 45148,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,EST,Site 2151,Subject 45149,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,EST,Site 2151,Subject 45149,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,EST,Site 2152,Subject 45267,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,EST,Site 2152,Subject 45267,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,EST,Site 2153,Subject 45295,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,EST,Site 2153,Subject 45295,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,EST,Site 2153,Subject 45298,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,EST,Site 2153,Subject 45298,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,EST,Site 2153,Subject 45336,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,EST,Site 2153,Subject 45336,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,EST,Site 2155,Subject 45356,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,EST,Site 2155,Subject 45356,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,EST,Site 2155,Subject 45357,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,EST,Site 2155,Subject 45357,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,EST,Site 2155,Subject 45358,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,EST,Site 2155,Subject 45358,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 353,Subject 32594,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 353,Subject 32594,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 512,Subject 3738,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 512,Subject 3738,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 513,Subject 32605,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,FRA,Site 513,Subject 32605,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,FRA,Site 513,Subject 32605,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,FRA,Site 513,Subject 32605,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,FRA,Site 513,Subject 32605,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,FRA,Site 513,Subject 32605,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,FRA,Site 513,Subject 32605,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,FRA,Site 1717,Subject 32629,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1717,Subject 32629,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 516,Subject 32632,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 516,Subject 32632,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1718,Subject 32638,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1718,Subject 32638,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 572,Subject 32653,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),,Visit Level,Form 10,,Study 22,
Study 22,FRA,Site 572,Subject 32653,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),,Visit Level,Form 4,,Study 22,
Study 22,FRA,Site 572,Subject 32653,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),,Visit Level,Form 6,,Study 22,
Study 22,FRA,Site 572,Subject 32653,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),,Visit Level,Form 20,,Study 22,
Study 22,FRA,Site 572,Subject 32653,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),,Visit Level,Form 9,,Study 22,
Study 22,FRA,Site 572,Subject 32653,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 572,Subject 32653,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1719,Subject 32679,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-16,Visit Level,Form 10,25.0,Study 22,
Study 22,FRA,Site 1719,Subject 32680,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1719,Subject 32680,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1722,Subject 32700,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1722,Subject 32700,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1723,Subject 32740,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1723,Subject 32740,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1723,Subject 32765,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1723,Subject 32765,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1726,Subject 32781,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1726,Subject 32781,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1728,Subject 32803,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-03,Visit Level,Form 10,7.0,Study 22,
Study 22,FRA,Site 1728,Subject 32803,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-03,Visit Level,Form 4,7.0,Study 22,
Study 22,FRA,Site 1730,Subject 32861,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1730,Subject 32861,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1730,Subject 32862,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1730,Subject 32862,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1730,Subject 32863,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1730,Subject 32863,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,FRA,Site 1730,Subject 32864,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,FRA,Site 1730,Subject 32864,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1909,Subject 36604,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1909,Subject 36604,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1909,Subject 36608,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1909,Subject 36608,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1909,Subject 36612,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1909,Subject 36612,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1909,Subject 36641,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1909,Subject 36641,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1909,Subject 36646,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1909,Subject 36646,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 588,Subject 3983,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 10,,Study 22,
Study 22,GBR,Site 588,Subject 3983,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 4,,Study 22,
Study 22,GBR,Site 588,Subject 3983,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 6,,Study 22,
Study 22,GBR,Site 588,Subject 3983,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 20,,Study 22,
Study 22,GBR,Site 588,Subject 3983,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 588,Subject 3983,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 9,,Study 22,
Study 22,GBR,Site 588,Subject 3983,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 588,Subject 3983,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 588,Subject 36650,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 588,Subject 36650,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 589,Subject 36665,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 589,Subject 36665,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 589,Subject 36674,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 589,Subject 36674,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 589,Subject 36676,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 589,Subject 36676,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 589,Subject 36680,On Trial,Subject continuing,Visit 3 (Month 9),,Visit Level,Form 9,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,End of Study (EOS),,Visit Level,Form 10,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,End of Study (EOS),,Visit Level,Form 4,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,End of Study (EOS),,Visit Level,Form 6,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,End of Study (EOS),,Visit Level,Form 24,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,End of Study (EOS),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 589,Subject 36688,Discontinued,,Non-drug therapies,,Summary Page,Form 18,,Study 22,
Study 22,GBR,Site 589,Subject 36689,On Trial,,Visit 3 (Month 9),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 589,Subject 36689,On Trial,,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 590,Subject 3990,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 590,Subject 3990,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 590,Subject 36709,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 590,Subject 36709,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 590,Subject 36710,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-22,Visit Level,Form 4,19.0,Study 22,
Study 22,GBR,Site 592,Subject 36736,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-13,Visit Level,Form 10,28.0,Study 22,
Study 22,GBR,Site 592,Subject 36737,On Trial,Missed visit - subject unavailable,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 592,Subject 36737,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 592,Subject 36737,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 592,Subject 36738,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 592,Subject 36738,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1913,Subject 36810,Screen Failure,Subject discontinued from study at this visit,Screening,2024-06-11,Visit Level,Form 27,517.0,Study 22,
Study 22,GBR,Site 1914,Subject 36829,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,GBR,Site 1914,Subject 36833,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1914,Subject 36833,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1914,Subject 36847,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1914,Subject 36847,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1914,Subject 36850,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1914,Subject 36850,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1914,Subject 36852,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1914,Subject 36852,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1914,Subject 36856,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1914,Subject 36856,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1917,Subject 37027,On Trial,,Unplanned visit,2025-05-07,Visit Level,Form 8,187.0,Study 22,
Study 22,GBR,Site 1917,Subject 37041,On Trial,,Unplanned visit,2025-03-06,Visit Level,Form 8,249.0,Study 22,
Study 22,GBR,Site 1917,Subject 37082,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,GBR,Site 1917,Subject 37085,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1917,Subject 37085,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1917,Subject 37096,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1917,Subject 37096,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1918,Subject 37098,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1918,Subject 37098,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1918,Subject 37099,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1918,Subject 37099,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1924,Subject 37167,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1924,Subject 37167,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1925,Subject 37169,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1925,Subject 37169,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1925,Subject 37177,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1925,Subject 37177,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1925,Subject 37178,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1925,Subject 37178,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1925,Subject 37179,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1925,Subject 37179,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1925,Subject 37180,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1925,Subject 37180,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1925,Subject 37222,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-16,Visit Level,Form 9,25.0,Study 22,
Study 22,GBR,Site 1929,Subject 37244,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 6,,Study 22,
Study 22,GBR,Site 1929,Subject 37244,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 9,,Study 22,
Study 22,GBR,Site 1929,Subject 37244,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1929,Subject 37244,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1929,Subject 37250,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-27,Visit Level,Form 10,14.0,Study 22,
Study 22,GBR,Site 1929,Subject 37250,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-27,Visit Level,Form 6,14.0,Study 22,
Study 22,GBR,Site 1930,Subject 37263,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1930,Subject 37263,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1930,Subject 37266,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1930,Subject 37266,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1931,Subject 37277,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1931,Subject 37277,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1934,Subject 37341,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1934,Subject 37341,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1934,Subject 37344,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-04,Visit Level,Form 4,6.0,Study 22,
Study 22,GBR,Site 1934,Subject 37345,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1934,Subject 37345,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1935,Subject 37410,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1935,Subject 37410,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1935,Subject 37452,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1935,Subject 37452,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1935,Subject 37462,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1935,Subject 37462,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1936,Subject 37465,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1936,Subject 37465,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1938,Subject 37479,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1938,Subject 37479,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1942,Subject 37513,On Trial,Missed visit - subject unavailable,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1944,Subject 37545,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1944,Subject 37545,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1944,Subject 37561,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-16,Visit Level,Form 10,25.0,Study 22,
Study 22,GBR,Site 1944,Subject 37563,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-21,Visit Level,Form 10,20.0,Study 22,
Study 22,GBR,Site 1945,Subject 37566,On Trial,Subject continuing,Visit 5 (Month 21),2025-09-16,Visit Level,Form 4,55.0,Study 22,
Study 22,GBR,Site 1945,Subject 37578,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1945,Subject 37578,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1945,Subject 37580,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1945,Subject 37580,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1945,Subject 37581,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1945,Subject 37581,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1945,Subject 37582,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1945,Subject 37582,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1945,Subject 37583,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1945,Subject 37583,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1946,Subject 37605,On Trial,Subject discontinued from treatment at this visit,Visit 5 (Month 21),,Visit Level,Form 9,,Study 22,
Study 22,GBR,Site 1946,Subject 37606,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1946,Subject 37606,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1946,Subject 37607,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1946,Subject 37607,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1946,Subject 37643,On Trial,Subject continuing,Visit 1,2024-05-08,Visit Level,Form 23,551.0,Study 22,
Study 22,GBR,Site 1946,Subject 37656,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1946,Subject 37656,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1947,Subject 37674,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1947,Subject 37674,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1947,Subject 37676,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1947,Subject 37676,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1947,Subject 37678,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1947,Subject 37678,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1947,Subject 37699,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1947,Subject 37699,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1947,Subject 37700,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1947,Subject 37700,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1947,Subject 37701,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1947,Subject 37701,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1948,Subject 37702,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1948,Subject 37702,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1948,Subject 37703,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1948,Subject 37703,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1948,Subject 37747,On Trial,,Visit 3 (Month 9),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1948,Subject 37747,On Trial,,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1948,Subject 37752,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1948,Subject 37752,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GBR,Site 1949,Subject 37762,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GBR,Site 1949,Subject 37762,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GRC,Site 147,Subject 1391,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GRC,Site 147,Subject 1391,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GRC,Site 147,Subject 32883,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GRC,Site 147,Subject 32883,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GRC,Site 147,Subject 32892,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GRC,Site 147,Subject 32892,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GRC,Site 148,Subject 1395,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,GRC,Site 148,Subject 1395,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,GRC,Site 464,Subject 6982,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,GRC,Site 464,Subject 6982,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GRC,Site 464,Subject 32926,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 10,,Study 22,
Study 22,GRC,Site 464,Subject 32926,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 4,,Study 22,
Study 22,GRC,Site 464,Subject 32926,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 6,,Study 22,
Study 22,GRC,Site 464,Subject 32926,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 20,,Study 22,
Study 22,GRC,Site 464,Subject 32926,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,GRC,Site 464,Subject 32926,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 9,,Study 22,
Study 22,GRC,Site 464,Subject 32929,On Trial,Subject continuing,Visit 4 (Month 15),2025-08-20,Visit Level,Form 4,82.0,Study 22,
Study 22,HKG,Site 2141,Subject 44305,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,HKG,Site 2141,Subject 44305,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,HKG,Site 2143,Subject 44347,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,HKG,Site 2143,Subject 44347,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1333,Subject 20336,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1333,Subject 20336,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1336,Subject 44408,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1336,Subject 44408,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1336,Subject 44477,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1336,Subject 44477,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1336,Subject 44489,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-23,Visit Level,Form 9,18.0,Study 22,
Study 22,HRV,Site 1340,Subject 20496,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1340,Subject 20496,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1340,Subject 20497,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1340,Subject 20497,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44581,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44581,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44582,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44582,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44583,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44583,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44585,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44585,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44586,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44586,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44587,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44587,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44588,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44588,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44595,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44595,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44597,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44597,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1342,Subject 44599,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 1342,Subject 44599,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 1343,Subject 20508,On Trial,,Unplanned visit,2024-04-24,Visit Level,Form 19,565.0,Study 22,
Study 22,HRV,Site 2147,Subject 44644,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 2147,Subject 44644,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HRV,Site 2148,Subject 44665,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,HRV,Site 2148,Subject 44665,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,HUN,Site 153,Subject 7207,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HUN,Site 153,Subject 7207,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,HUN,Site 153,Subject 7208,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HUN,Site 153,Subject 7208,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,HUN,Site 153,Subject 7211,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HUN,Site 153,Subject 7211,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,HUN,Site 854,Subject 7763,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HUN,Site 854,Subject 7763,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,HUN,Site 1737,Subject 33000,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HUN,Site 1737,Subject 33000,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,HUN,Site 1734,Subject 33042,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HUN,Site 1734,Subject 33042,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,HUN,Site 1734,Subject 33045,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HUN,Site 1734,Subject 33045,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,HUN,Site 1741,Subject 33072,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,HUN,Site 1741,Subject 33072,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 47,Subject 30134,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 47,Subject 30134,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 47,Subject 30160,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 47,Subject 30160,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 47,Subject 30161,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 47,Subject 30161,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 109,Subject 847,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 109,Subject 847,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 109,Subject 848,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 109,Subject 848,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 466,Subject 3544,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 466,Subject 3544,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 466,Subject 3545,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 466,Subject 3545,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 466,Subject 30215,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 466,Subject 30215,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 467,Subject 30243,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 467,Subject 30243,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1645,Subject 30316,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1645,Subject 30316,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 597,Subject 30330,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 597,Subject 30330,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 597,Subject 30342,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 597,Subject 30342,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 597,Subject 30343,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 597,Subject 30343,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1650,Subject 30435,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1650,Subject 30435,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1655,Subject 30486,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),2025-03-24,Visit Level,Form 9,231.0,Study 22,
Study 22,IND,Site 1655,Subject 30493,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1655,Subject 30493,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1656,Subject 30501,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1656,Subject 30501,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1656,Subject 30502,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1656,Subject 30502,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1657,Subject 30515,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1657,Subject 30515,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1659,Subject 30545,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1659,Subject 30545,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1659,Subject 30552,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1659,Subject 30552,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1659,Subject 30553,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1659,Subject 30553,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1659,Subject 30554,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1659,Subject 30554,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1659,Subject 30555,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1659,Subject 30555,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1659,Subject 30581,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1659,Subject 30581,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1659,Subject 30586,On Trial,Subject continuing,Visit 4 (Month 15),2025-11-08,Visit Level,Form 6,2.0,Study 22,
Study 22,IND,Site 1659,Subject 30587,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1659,Subject 30587,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1660,Subject 30598,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1660,Subject 30598,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1661,Subject 30606,On Trial,Subject continuing,Visit 6 (Month 27),2025-11-03,Visit Level,Form 9,7.0,Study 22,
Study 22,IND,Site 1661,Subject 30616,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,IND,Site 1662,Subject 30634,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1662,Subject 30634,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1662,Subject 30638,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1662,Subject 30638,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1667,Subject 30717,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1667,Subject 30717,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1667,Subject 30729,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,IND,Site 1667,Subject 30734,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1667,Subject 30734,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1668,Subject 30747,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1668,Subject 30747,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,IND,Site 1672,Subject 30788,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,IND,Site 1672,Subject 30788,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ISR,Site 861,Subject 8134,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ISR,Site 861,Subject 8134,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ISR,Site 861,Subject 8141,On Trial,Subject continuing,Visit 4 (Month 15),2025-11-09,Visit Level,Form 4,1.0,Study 22,
Study 22,ISR,Site 784,Subject 8168,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ISR,Site 784,Subject 8168,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ISR,Site 784,Subject 33153,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-22,Visit Level,Form 10,19.0,Study 22,
Study 22,ISR,Site 784,Subject 33153,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-22,Visit Level,Form 6,19.0,Study 22,
Study 22,ISR,Site 785,Subject 8178,On Trial,Subject continuing,Visit 5 (Month 21),2025-09-09,Visit Level,Form 9,62.0,Study 22,
Study 22,ISR,Site 785,Subject 8179,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ISR,Site 785,Subject 8179,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ISR,Site 863,Subject 8223,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,ISR,Site 863,Subject 8223,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,ISR,Site 781,Subject 8249,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ISR,Site 781,Subject 8249,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1746,Subject 33179,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1746,Subject 33179,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 518,Subject 33182,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 518,Subject 33182,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 518,Subject 33192,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 518,Subject 33192,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1747,Subject 33200,Discontinued,,End of Study (EOS),,Visit Level,Form 24,,Study 22,
Study 22,ITA,Site 1748,Subject 33208,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1748,Subject 33208,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1748,Subject 33209,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1748,Subject 33209,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1748,Subject 33210,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1748,Subject 33210,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1748,Subject 33217,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1748,Subject 33217,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 465,Subject 33218,Discontinued,Subject discontinued from study at this visit,Visit 3 (Month 9),,Visit Level,Form 20,,Study 22,
Study 22,ITA,Site 465,Subject 33219,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 465,Subject 33219,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1749,Subject 33223,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1749,Subject 33223,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1749,Subject 33224,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1749,Subject 33224,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1749,Subject 33226,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1749,Subject 33226,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 580,Subject 3963,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 580,Subject 3963,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 581,Subject 3966,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-05,Visit Level,Form 10,5.0,Study 22,
Study 22,ITA,Site 581,Subject 3966,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-05,Visit Level,Form 4,5.0,Study 22,
Study 22,ITA,Site 1750,Subject 33295,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1750,Subject 33295,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1750,Subject 33297,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1750,Subject 33297,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 866,Subject 8278,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 866,Subject 8278,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,Adverse Event,,Summary Page,Form 21,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,Disposition,,Summary Page,Form 7,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,End of Study (EOS),,Visit Level,Form 10,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,End of Study (EOS),,Visit Level,Form 4,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,End of Study (EOS),,Visit Level,Form 6,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,End of Study (EOS),,Visit Level,Form 24,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,,End of Study (EOS),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 866,Subject 33312,Discontinued,Subject discontinued from study at this visit,Visit 4 (Month 15),,Visit Level,Form 20,,Study 22,
Study 22,ITA,Site 1752,Subject 33335,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1752,Subject 33335,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1753,Subject 33367,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1753,Subject 33367,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1753,Subject 33386,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1753,Subject 33386,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1754,Subject 33392,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1754,Subject 33392,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1754,Subject 33394,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1754,Subject 33394,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1755,Subject 33417,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1755,Subject 33417,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1756,Subject 33429,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1756,Subject 33429,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1759,Subject 33465,On Trial,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,ITA,Site 1759,Subject 33465,On Trial,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,ITA,Site 1759,Subject 33465,On Trial,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,ITA,Site 1759,Subject 33465,On Trial,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,ITA,Site 1759,Subject 33465,On Trial,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,ITA,Site 1759,Subject 33465,On Trial,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,ITA,Site 1759,Subject 33465,On Trial,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,ITA,Site 1759,Subject 33465,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1759,Subject 33465,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1759,Subject 33470,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1759,Subject 33470,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1761,Subject 33495,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1761,Subject 33495,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1762,Subject 33497,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1762,Subject 33497,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1762,Subject 33498,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1762,Subject 33498,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1762,Subject 33509,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1762,Subject 33509,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1763,Subject 33510,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ITA,Site 1763,Subject 33510,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ITA,Site 1764,Subject 33532,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-22,Visit Level,Form 4,19.0,Study 22,
Study 22,LTU,Site 543,Subject 45467,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LTU,Site 543,Subject 45467,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LTU,Site 543,Subject 45470,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LTU,Site 543,Subject 45470,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LTU,Site 543,Subject 45474,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LTU,Site 543,Subject 45474,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LTU,Site 543,Subject 45475,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LTU,Site 543,Subject 45475,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LTU,Site 543,Subject 45547,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-24,Visit Level,Form 9,17.0,Study 22,
Study 22,LTU,Site 544,Subject 3847,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-06,Visit Level,Form 4,35.0,Study 22,
Study 22,LTU,Site 1388,Subject 21841,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,LTU,Site 1388,Subject 21841,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,LTU,Site 1389,Subject 21935,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-27,Visit Level,Form 9,14.0,Study 22,
Study 22,LTU,Site 548,Subject 22068,On Trial,Subject continuing,Visit 4 (Month 15),2025-11-03,Visit Level,Form 10,7.0,Study 22,
Study 22,LTU,Site 548,Subject 22068,On Trial,Subject continuing,Visit 4 (Month 15),2025-11-03,Visit Level,Form 9,7.0,Study 22,
Study 22,LTU,Site 549,Subject 45661,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-17,Visit Level,Form 9,24.0,Study 22,
Study 22,LTU,Site 549,Subject 45662,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LTU,Site 549,Subject 45662,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LTU,Site 549,Subject 45680,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,LTU,Site 549,Subject 45680,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,LTU,Site 549,Subject 45681,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,LTU,Site 549,Subject 45681,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,LTU,Site 550,Subject 45689,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,LTU,Site 550,Subject 45689,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,LVA,Site 1362,Subject 20869,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LVA,Site 1362,Subject 20869,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LVA,Site 1362,Subject 20870,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LVA,Site 1362,Subject 20870,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LVA,Site 1362,Subject 20871,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LVA,Site 1362,Subject 20871,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LVA,Site 1362,Subject 20873,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LVA,Site 1362,Subject 20873,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LVA,Site 1363,Subject 20945,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,LVA,Site 1363,Subject 20945,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,LVA,Site 1363,Subject 45420,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,LVA,Site 1363,Subject 45420,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,LVA,Site 1363,Subject 45421,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,LVA,Site 1363,Subject 45421,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,LVA,Site 1364,Subject 20968,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,LVA,Site 1364,Subject 20968,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1981,Subject 39695,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1981,Subject 39695,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1982,Subject 39758,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1982,Subject 39758,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1984,Subject 39807,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1984,Subject 39807,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1985,Subject 39829,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1985,Subject 39829,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1985,Subject 39841,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-15,Visit Level,Form 9,26.0,Study 22,
Study 22,MEX,Site 1986,Subject 39842,On Trial,,Unplanned visit,,Visit Level,Form 8,,Study 22,
Study 22,MEX,Site 1986,Subject 39842,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1986,Subject 39842,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1986,Subject 39843,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1986,Subject 39843,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1986,Subject 39844,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1986,Subject 39844,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1986,Subject 39846,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1986,Subject 39846,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1986,Subject 39848,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1986,Subject 39848,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1986,Subject 39849,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1986,Subject 39849,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1986,Subject 39850,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1986,Subject 39850,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1986,Subject 39865,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,MEX,Site 1986,Subject 39870,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1986,Subject 39870,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1986,Subject 39889,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1986,Subject 39889,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1987,Subject 39895,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1987,Subject 39895,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1988,Subject 39931,On Trial,,Unplanned visit,,Visit Level,Form 28,,Study 22,
Study 22,MEX,Site 1989,Subject 39948,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1989,Subject 39948,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1992,Subject 40019,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1992,Subject 40019,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1992,Subject 40028,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1992,Subject 40028,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1992,Subject 40029,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1992,Subject 40029,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1992,Subject 40030,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1992,Subject 40030,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1992,Subject 40032,On Trial,,Visit 3 (Month 9),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1992,Subject 40032,On Trial,,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1992,Subject 40033,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1992,Subject 40033,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1994,Subject 40055,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-28,Visit Level,Form 10,13.0,Study 22,
Study 22,MEX,Site 1994,Subject 40055,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-28,Visit Level,Form 4,13.0,Study 22,
Study 22,MEX,Site 1994,Subject 40055,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-28,Visit Level,Form 6,13.0,Study 22,
Study 22,MEX,Site 1994,Subject 40055,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-28,Visit Level,Form 9,13.0,Study 22,
Study 22,MEX,Site 1995,Subject 40079,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1995,Subject 40079,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1995,Subject 40080,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1995,Subject 40080,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1998,Subject 40167,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,MEX,Site 1998,Subject 40167,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,MEX,Site 1998,Subject 40167,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,MEX,Site 1998,Subject 40167,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,MEX,Site 1998,Subject 40167,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,MEX,Site 1998,Subject 40167,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,MEX,Site 1998,Subject 40167,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,MEX,Site 1999,Subject 40176,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1999,Subject 40176,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1999,Subject 40177,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1999,Subject 40177,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1999,Subject 40178,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 1999,Subject 40178,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 1999,Subject 40186,On Trial,,Unplanned visit,2025-01-17,Visit Level,Form 8,297.0,Study 22,
Study 22,MEX,Site 2001,Subject 40195,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 2001,Subject 40195,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 2002,Subject 40213,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-28,Visit Level,Form 4,13.0,Study 22,
Study 22,MEX,Site 2002,Subject 40219,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 2002,Subject 40219,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 2002,Subject 40258,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,MEX,Site 2005,Subject 40345,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MEX,Site 2005,Subject 40345,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MEX,Site 2005,Subject 40353,On Trial,,Unplanned visit,,Visit Level,Form 8,,Study 22,
Study 22,MYS,Site 1673,Subject 30833,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1673,Subject 30833,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1673,Subject 30843,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1673,Subject 30843,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1673,Subject 30845,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1673,Subject 30845,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1674,Subject 30857,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1674,Subject 30857,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1674,Subject 30865,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1674,Subject 30865,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1674,Subject 30868,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1674,Subject 30868,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1676,Subject 30889,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1676,Subject 30889,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1677,Subject 30892,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-28,Visit Level,Form 10,13.0,Study 22,
Study 22,MYS,Site 1681,Subject 30933,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1681,Subject 30933,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1681,Subject 30939,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1681,Subject 30939,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1682,Subject 30944,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1682,Subject 30944,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1683,Subject 30971,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1683,Subject 30971,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1683,Subject 30972,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1683,Subject 30972,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1683,Subject 30973,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1683,Subject 30973,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1683,Subject 30974,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1683,Subject 30974,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,MYS,Site 1683,Subject 30977,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,MYS,Site 1683,Subject 30977,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1771,Subject 33601,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1771,Subject 33601,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1773,Subject 33638,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1773,Subject 33638,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1773,Subject 33642,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1773,Subject 33642,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1773,Subject 33644,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1773,Subject 33644,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1774,Subject 33683,On Trial,Subject continuing,Visit 5 (Month 21),2025-07-21,Visit Level,Form 9,112.0,Study 22,
Study 22,NLD,Site 1774,Subject 33690,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1774,Subject 33690,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1774,Subject 33712,Discontinued,Subject discontinued from study at this visit,Visit 4 (Month 15),,Visit Level,Form 9,,Study 22,
Study 22,NLD,Site 1774,Subject 33726,On Trial,Subject continuing,Visit 4 (Month 15),2025-08-18,Visit Level,Form 4,84.0,Study 22,
Study 22,NLD,Site 1775,Subject 33760,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,NLD,Site 1775,Subject 33760,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,NLD,Site 1775,Subject 33760,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,NLD,Site 1775,Subject 33760,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,NLD,Site 1775,Subject 33760,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,NLD,Site 1775,Subject 33760,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,NLD,Site 1775,Subject 33760,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,NLD,Site 1775,Subject 33760,Discontinued,Subject discontinued from study at this visit,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 583,Subject 33791,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 583,Subject 33791,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 583,Subject 33792,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 583,Subject 33792,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 583,Subject 33795,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 583,Subject 33795,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1778,Subject 33866,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1778,Subject 33866,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1778,Subject 33868,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1778,Subject 33868,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1779,Subject 33879,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1779,Subject 33879,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1780,Subject 33894,On Trial,,eSAE,,Summary Page,Form 22,,Study 22,
Study 22,NLD,Site 1780,Subject 33894,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,NLD,Site 1781,Subject 33921,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1781,Subject 33921,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1783,Subject 33959,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1783,Subject 33959,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1785,Subject 33990,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1785,Subject 33990,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1786,Subject 34013,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1786,Subject 34013,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1786,Subject 34017,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1786,Subject 34017,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1786,Subject 34018,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1786,Subject 34018,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1786,Subject 34021,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1786,Subject 34021,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1786,Subject 34024,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1786,Subject 34024,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,NLD,Site 1786,Subject 34025,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,NLD,Site 1786,Subject 34025,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,PHL,Site 557,Subject 31049,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,PHL,Site 557,Subject 31049,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,PHL,Site 557,Subject 31051,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,PHL,Site 557,Subject 31051,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,PHL,Site 1685,Subject 31057,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,PHL,Site 1685,Subject 31057,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 16,Subject 8365,On Trial,Subject discontinued from treatment at this visit,Visit 5 (Month 21),2025-10-19,Visit Level,Form 9,22.0,Study 22,
Study 22,POL,Site 89,Subject 34126,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 89,Subject 34126,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 17,Subject 8412,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 17,Subject 8412,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 92,Subject 656,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 92,Subject 656,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 355,Subject 2852,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 355,Subject 2852,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 355,Subject 34186,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 355,Subject 34186,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 355,Subject 34187,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 355,Subject 34187,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 355,Subject 34188,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 355,Subject 34188,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 96,Subject 8588,On Trial,Missed visit - subject unavailable,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 96,Subject 8588,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 96,Subject 8588,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 96,Subject 8591,On Trial,Missed visit - subject unavailable,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 96,Subject 34204,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-13,Visit Level,Form 10,28.0,Study 22,
Study 22,POL,Site 96,Subject 34205,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 96,Subject 34205,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 99,Subject 718,On Trial,Subject continuing,Visit 4 (Month 15),2025-04-07,Visit Level,Form 9,217.0,Study 22,
Study 22,POL,Site 99,Subject 720,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 99,Subject 720,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 99,Subject 725,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 99,Subject 725,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 101,Subject 34274,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 101,Subject 34274,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,POL,Site 870,Subject 8693,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,POL,Site 870,Subject 8693,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,PRT,Site 521,Subject 3772,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,PRT,Site 521,Subject 3772,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,PRT,Site 521,Subject 8892,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,PRT,Site 521,Subject 8892,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,PRT,Site 523,Subject 9046,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,PRT,Site 523,Subject 9046,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,PRT,Site 877,Subject 9064,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-04,Visit Level,Form 10,6.0,Study 22,
Study 22,PRT,Site 877,Subject 9064,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-04,Visit Level,Form 4,6.0,Study 22,
Study 22,PRT,Site 877,Subject 9064,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-04,Visit Level,Form 9,6.0,Study 22,
Study 22,PRT,Site 878,Subject 9097,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,PRT,Site 878,Subject 9097,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 524,Subject 34305,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 524,Subject 34305,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 524,Subject 34306,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 524,Subject 34306,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1792,Subject 34376,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1792,Subject 34376,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1794,Subject 34380,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1794,Subject 34380,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1796,Subject 34388,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-05,Visit Level,Form 10,5.0,Study 22,
Study 22,ROU,Site 294,Subject 2424,On Trial,Subject continuing,Visit 4 (Month 15),2025-08-12,Visit Level,Form 4,90.0,Study 22,
Study 22,ROU,Site 1803,Subject 34536,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1803,Subject 34536,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1803,Subject 34538,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1803,Subject 34538,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1803,Subject 34539,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1803,Subject 34539,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1805,Subject 34553,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1805,Subject 34553,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1805,Subject 34555,On Trial,,Disposition,,Summary Page,Form 7,,Study 22,
Study 22,ROU,Site 1805,Subject 34556,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1805,Subject 34556,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1805,Subject 34558,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 10,,Study 22,
Study 22,ROU,Site 1805,Subject 34558,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 4,,Study 22,
Study 22,ROU,Site 1805,Subject 34558,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 6,,Study 22,
Study 22,ROU,Site 1805,Subject 34558,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 20,,Study 22,
Study 22,ROU,Site 1805,Subject 34558,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1805,Subject 34558,On Trial,Subject continuing,Visit 4 (Month 15),,Visit Level,Form 9,,Study 22,
Study 22,ROU,Site 1806,Subject 34571,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1806,Subject 34571,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1807,Subject 34605,On Trial,Subject continuing,Visit 4 (Month 15),2025-09-30,Visit Level,Form 4,41.0,Study 22,
Study 22,ROU,Site 1807,Subject 34609,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1807,Subject 34609,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1814,Subject 34762,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1814,Subject 34762,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1814,Subject 34763,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1814,Subject 34763,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ROU,Site 1814,Subject 34766,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ROU,Site 1814,Subject 34766,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,SGP,Site 59,Subject 31072,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-17,Visit Level,Form 9,24.0,Study 22,
Study 22,SGP,Site 59,Subject 31073,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,SGP,Site 59,Subject 31073,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1816,Subject 34808,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 1816,Subject 34808,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1816,Subject 34809,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-14,Visit Level,Form 10,27.0,Study 22,
Study 22,SVK,Site 1816,Subject 34809,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-14,Visit Level,Form 4,27.0,Study 22,
Study 22,SVK,Site 308,Subject 34835,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 308,Subject 34835,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 308,Subject 34840,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,SVK,Site 308,Subject 34840,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,SVK,Site 308,Subject 34840,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,SVK,Site 308,Subject 34840,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,SVK,Site 308,Subject 34840,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,SVK,Site 308,Subject 34840,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,SVK,Site 308,Subject 34840,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,SVK,Site 309,Subject 34872,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 309,Subject 34872,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1818,Subject 34873,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 1818,Subject 34873,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1818,Subject 34884,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 1818,Subject 34884,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1821,Subject 34956,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,SVK,Site 1821,Subject 34956,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,SVK,Site 1821,Subject 34956,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,SVK,Site 1821,Subject 34956,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,SVK,Site 1821,Subject 34956,Discontinued,,End of Study (EOS),,Visit Level,Form 10,,Study 22,
Study 22,SVK,Site 1821,Subject 34956,Discontinued,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,SVK,Site 1821,Subject 34956,Discontinued,,Non-drug therapies,,Summary Page,Form 18,,Study 22,
Study 22,SVK,Site 1822,Subject 34961,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 1822,Subject 34961,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1824,Subject 34986,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 1824,Subject 34986,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1826,Subject 35023,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 1826,Subject 35023,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1827,Subject 35029,On Trial,,Unplanned visit,2025-09-18,Visit Level,Form 19,53.0,Study 22,
Study 22,SVK,Site 1828,Subject 35043,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 1828,Subject 35043,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1830,Subject 35080,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 1830,Subject 35080,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 1835,Subject 35153,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 1835,Subject 35153,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,SVK,Site 313,Subject 35161,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,SVK,Site 313,Subject 35161,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,SWE,Site 1398,Subject 45705,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,SWE,Site 1398,Subject 45705,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,SWE,Site 1398,Subject 45706,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,SWE,Site 1398,Subject 45706,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,SWE,Site 1398,Subject 45707,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,SWE,Site 1398,Subject 45707,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,SWE,Site 2160,Subject 45773,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,SWE,Site 2160,Subject 45773,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,THA,Site 9,Subject 31353,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,THA,Site 9,Subject 31353,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,THA,Site 9,Subject 31354,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,THA,Site 9,Subject 31354,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,THA,Site 9,Subject 31355,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,THA,Site 9,Subject 31355,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,THA,Site 475,Subject 31370,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-31,Visit Level,Form 9,10.0,Study 22,
Study 22,THA,Site 476,Subject 31387,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,THA,Site 476,Subject 31387,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,THA,Site 478,Subject 31440,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-04,Visit Level,Form 10,6.0,Study 22,
Study 22,THA,Site 478,Subject 31440,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-04,Visit Level,Form 4,6.0,Study 22,
Study 22,THA,Site 478,Subject 31440,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-04,Visit Level,Form 20,6.0,Study 22,
Study 22,THA,Site 462,Subject 31449,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-15,Visit Level,Form 4,26.0,Study 22,
Study 22,THA,Site 462,Subject 31463,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-22,Visit Level,Form 10,19.0,Study 22,
Study 22,THA,Site 1688,Subject 31493,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,THA,Site 1688,Subject 31493,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,TUR,Site 777,Subject 31498,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,TUR,Site 777,Subject 31498,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,TUR,Site 480,Subject 3619,On Trial,Subject continuing,Visit 6 (Month 27),2025-10-27,Visit Level,Form 6,14.0,Study 22,
Study 22,TUR,Site 480,Subject 3620,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,TUR,Site 480,Subject 3620,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,TUR,Site 480,Subject 3621,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,TUR,Site 480,Subject 3621,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,TUR,Site 480,Subject 3622,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,TUR,Site 480,Subject 3622,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,TUR,Site 480,Subject 31525,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,TUR,Site 480,Subject 31525,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,TUR,Site 481,Subject 31535,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,TUR,Site 481,Subject 31535,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,TUR,Site 487,Subject 3649,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,TUR,Site 487,Subject 3649,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,TUR,Site 487,Subject 31564,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,TUR,Site 487,Subject 31564,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,TUR,Site 487,Subject 31573,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,TUR,Site 487,Subject 31573,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,TWN,Site 7,Subject 6176,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,TWN,Site 7,Subject 6176,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,TWN,Site 775,Subject 6236,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,TWN,Site 775,Subject 6236,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,TWN,Site 775,Subject 31251,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-31,Visit Level,Form 10,10.0,Study 22,
Study 22,TWN,Site 775,Subject 31251,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-31,Visit Level,Form 4,10.0,Study 22,
Study 22,TWN,Site 775,Subject 31251,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-31,Visit Level,Form 20,10.0,Study 22,
Study 22,TWN,Site 775,Subject 31251,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-31,Visit Level,Form 9,10.0,Study 22,
Study 22,TWN,Site 471,Subject 31275,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,TWN,Site 471,Subject 31275,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,TWN,Site 474,Subject 3598,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-09,Visit Level,Form 4,32.0,Study 22,
Study 22,TWN,Site 460,Subject 31316,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-27,Visit Level,Form 10,14.0,Study 22,
Study 22,TWN,Site 460,Subject 31316,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-27,Visit Level,Form 4,14.0,Study 22,
Study 22,TWN,Site 460,Subject 31316,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-27,Visit Level,Form 20,14.0,Study 22,
Study 22,USA,Site 177,Subject 40379,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 177,Subject 40379,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 177,Subject 40388,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 177,Subject 40388,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 177,Subject 40398,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 18,Subject 70,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 18,Subject 70,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 18,Subject 74,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 18,Subject 74,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 18,Subject 74,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 18,Subject 74,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 18,Subject 74,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 18,Subject 74,Discontinued,,End of Study (EOS),2025-09-20,Visit Level,Form 10,51.0,Study 22,
Study 22,USA,Site 18,Subject 74,Discontinued,,End of Study (EOS),2025-09-20,Visit Level,Form 9,51.0,Study 22,
Study 22,USA,Site 18,Subject 3459,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 18,Subject 3459,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 19,Subject 40431,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 19,Subject 40431,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 19,Subject 40439,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 19,Subject 40439,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 19,Subject 40457,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),,Visit Level,Form 9,,Study 22,
Study 22,USA,Site 326,Subject 40503,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 326,Subject 40503,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 326,Subject 40504,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 326,Subject 40504,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 179,Subject 1605,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 179,Subject 1605,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 328,Subject 40540,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 328,Subject 40540,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 180,Subject 15024,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 182,Subject 40551,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 182,Subject 40551,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 182,Subject 40554,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 182,Subject 40554,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1022,Subject 15044,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1022,Subject 15044,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 535,Subject 40594,On Trial,Subject discontinued from treatment at this visit,Visit 2 (Month 3),,Visit Level,Form 9,,Study 22,
Study 22,USA,Site 535,Subject 40626,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 535,Subject 40626,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 535,Subject 40627,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 535,Subject 40627,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1024,Subject 15267,Screen Failure,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,USA,Site 2007,Subject 40704,On Trial,Subject continuing,Visit 4 (Month 15),2025-08-21,Visit Level,Form 4,81.0,Study 22,
Study 22,USA,Site 24,Subject 15388,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,USA,Site 330,Subject 15405,On Trial,Subject discontinued from treatment at this visit,Visit 6 (Month 27),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 330,Subject 15405,On Trial,Subject discontinued from treatment at this visit,Visit 6 (Month 27),,Visit Level,Form 4,,Study 22,
Study 22,USA,Site 330,Subject 15405,On Trial,Subject discontinued from treatment at this visit,Visit 6 (Month 27),,Visit Level,Form 20,,Study 22,
Study 22,USA,Site 330,Subject 15405,On Trial,Subject discontinued from treatment at this visit,Visit 6 (Month 27),,Visit Level,Form 9,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Non-drug therapies,,Summary Page,Form 18,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 537,Subject 15499,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 331,Subject 2708,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 331,Subject 2708,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 331,Subject 40741,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 331,Subject 40741,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 331,Subject 40755,On Trial,,Visit 5 (Month 21),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 331,Subject 40755,On Trial,,Visit 5 (Month 21),,Visit Level,Form 6,,Study 22,
Study 22,USA,Site 187,Subject 15526,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 187,Subject 15526,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 187,Subject 15527,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 187,Subject 15527,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 187,Subject 15535,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 187,Subject 15535,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 187,Subject 40757,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-03,Visit Level,Form 10,7.0,Study 22,
Study 22,USA,Site 187,Subject 40757,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-03,Visit Level,Form 20,7.0,Study 22,
Study 22,USA,Site 187,Subject 40759,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 187,Subject 40759,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-23,Visit Level,Form 10,18.0,Study 22,
Study 22,USA,Site 187,Subject 40759,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-23,Visit Level,Form 9,18.0,Study 22,
Study 22,USA,Site 187,Subject 40760,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 187,Subject 40760,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 188,Subject 40786,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 188,Subject 40786,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 188,Subject 40795,On Trial,,Visit 3 (Month 9),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 188,Subject 40795,On Trial,,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 538,Subject 15544,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 538,Subject 15544,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 189,Subject 3831,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 189,Subject 3831,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1027,Subject 15547,On Trial,,eSAE,,Summary Page,Form 22,,Study 22,
Study 22,USA,Site 1027,Subject 15547,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 332,Subject 15567,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 15567,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40816,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 332,Subject 40823,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40823,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40849,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40849,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40850,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40850,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40853,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40853,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40855,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40855,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40856,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40856,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40857,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40857,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40858,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40858,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40864,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40864,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 332,Subject 40908,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 332,Subject 40908,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 333,Subject 40965,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 333,Subject 40965,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 333,Subject 40966,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 333,Subject 40966,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 333,Subject 40967,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 333,Subject 40967,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 333,Subject 40969,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 333,Subject 40969,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 333,Subject 40971,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 333,Subject 40971,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 333,Subject 40984,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 333,Subject 40984,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 333,Subject 40989,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 333,Subject 40989,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 334,Subject 41036,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 334,Subject 41036,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 334,Subject 41037,On Trial,Subject continuing,Visit 6 (Month 27),2025-10-31,Visit Level,Form 4,10.0,Study 22,
Study 22,USA,Site 334,Subject 41039,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 334,Subject 41039,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 335,Subject 2736,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,USA,Site 2008,Subject 41068,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2008,Subject 41068,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2008,Subject 41071,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2008,Subject 41071,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2008,Subject 41077,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2008,Subject 41077,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2008,Subject 41079,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2008,Subject 41079,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2008,Subject 41081,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2008,Subject 41081,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2008,Subject 41082,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2008,Subject 41082,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2008,Subject 41083,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2008,Subject 41083,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 593,Subject 15580,On Trial,Subject continuing,Visit 6 (Month 27),2025-10-27,Visit Level,Form 10,14.0,Study 22,
Study 22,USA,Site 593,Subject 15580,On Trial,Subject continuing,Visit 6 (Month 27),2025-10-27,Visit Level,Form 4,14.0,Study 22,
Study 22,USA,Site 594,Subject 4014,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 594,Subject 4014,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1030,Subject 15601,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1030,Subject 15601,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 336,Subject 2743,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 336,Subject 2743,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2010,Subject 41158,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2010,Subject 41158,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2010,Subject 41185,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2010,Subject 41185,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2012,Subject 41217,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2012,Subject 41217,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2012,Subject 41221,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2012,Subject 41221,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2012,Subject 41246,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2012,Subject 41246,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2012,Subject 41248,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2012,Subject 41248,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 342,Subject 41269,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 342,Subject 41269,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 343,Subject 41379,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 343,Subject 41379,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 343,Subject 41388,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 343,Subject 41388,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1035,Subject 15692,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-16,Visit Level,Form 10,25.0,Study 22,
Study 22,USA,Site 1037,Subject 15716,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1037,Subject 15716,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1042,Subject 15783,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1042,Subject 15783,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2019,Subject 41450,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2019,Subject 41450,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2020,Subject 41498,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2020,Subject 41498,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2021,Subject 41515,On Trial,Subject continuing,Visit 5 (Month 21),2025-09-19,Visit Level,Form 9,52.0,Study 22,
Study 22,USA,Site 2022,Subject 41528,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2022,Subject 41528,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2022,Subject 41530,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2022,Subject 41530,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2023,Subject 41569,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-29,Visit Level,Form 4,12.0,Study 22,
Study 22,USA,Site 1048,Subject 41595,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1048,Subject 41595,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1048,Subject 41609,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),2025-07-24,Visit Level,Form 4,109.0,Study 22,
Study 22,USA,Site 2026,Subject 41687,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2026,Subject 41687,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1052,Subject 15977,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-23,Visit Level,Form 10,18.0,Study 22,
Study 22,USA,Site 1020,Subject 15988,On Trial,Subject continuing,Visit 1,2024-06-04,Visit Level,Form 23,524.0,Study 22,
Study 22,USA,Site 1020,Subject 15988,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),2025-09-04,Visit Level,Form 9,67.0,Study 22,
Study 22,USA,Site 1040,Subject 16079,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1040,Subject 16079,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1040,Subject 16081,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1040,Subject 16081,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1056,Subject 41732,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1056,Subject 41732,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1057,Subject 41744,On Trial,Subject continuing,Visit 4 (Month 15),2025-07-02,Visit Level,Form 9,131.0,Study 22,
Study 22,USA,Site 2029,Subject 41764,On Trial,Subject continuing,Visit 6 (Month 27),2025-10-15,Visit Level,Form 4,26.0,Study 22,
Study 22,USA,Site 2029,Subject 41778,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2029,Subject 41778,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2029,Subject 41784,On Trial,,Unplanned visit,2025-03-04,Visit Level,Form 8,251.0,Study 22,
Study 22,USA,Site 1058,Subject 16114,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-28,Visit Level,Form 6,13.0,Study 22,
Study 22,USA,Site 2034,Subject 41853,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2034,Subject 41853,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2035,Subject 16262,On Trial,Subject discontinued from treatment at this visit,Visit 5 (Month 21),2025-10-28,Visit Level,Form 9,13.0,Study 22,
Study 22,USA,Site 2035,Subject 16265,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2035,Subject 16265,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2035,Subject 16267,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2035,Subject 16267,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2035,Subject 16269,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-27,Visit Level,Form 10,14.0,Study 22,
Study 22,USA,Site 2035,Subject 16270,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2035,Subject 16270,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2037,Subject 41901,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2037,Subject 41901,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2038,Subject 41910,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2038,Subject 41910,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2038,Subject 41912,On Trial,Missed visit - subject unavailable,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2038,Subject 41917,On Trial,Missed visit - subject unavailable,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2038,Subject 41917,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2038,Subject 41917,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2038,Subject 41922,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2038,Subject 41922,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2038,Subject 41923,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2038,Subject 41923,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Adverse Event,,Summary Page,Form 21,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1072,Subject 16348,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1074,Subject 16389,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 2042,Subject 41956,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 2042,Subject 41956,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 2042,Subject 41956,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 2042,Subject 41956,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 2042,Subject 41956,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 2042,Subject 41956,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 2042,Subject 41965,On Trial,,eSAE,,Summary Page,Form 22,,Study 22,
Study 22,USA,Site 2042,Subject 41965,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 2042,Subject 41986,On Trial,Missed visit - subject unavailable,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2042,Subject 41986,On Trial,Missed visit - subject unavailable,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2042,Subject 41986,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2042,Subject 41986,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2042,Subject 42010,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2042,Subject 42010,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2042,Subject 42022,On Trial,Subject continuing,Visit 5 (Month 21),2025-11-06,Visit Level,Form 6,4.0,Study 22,
Study 22,USA,Site 2042,Subject 42040,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2042,Subject 42040,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2042,Subject 42043,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2042,Subject 42043,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2043,Subject 42087,On Trial,,eSAE,,Summary Page,Form 22,,Study 22,
Study 22,USA,Site 2043,Subject 42091,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2043,Subject 42091,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2043,Subject 42092,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2043,Subject 42092,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2046,Subject 42121,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2046,Subject 42121,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2046,Subject 42124,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2046,Subject 42124,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2046,Subject 42129,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2046,Subject 42129,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2046,Subject 42131,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2046,Subject 42131,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2046,Subject 42132,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2046,Subject 42132,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1090,Subject 16611,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1090,Subject 16611,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1090,Subject 16612,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1090,Subject 16612,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2049,Subject 42198,On Trial,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 2049,Subject 42198,On Trial,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,USA,Site 2049,Subject 42198,On Trial,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 2049,Subject 42198,On Trial,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 2049,Subject 42198,On Trial,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 2049,Subject 42198,On Trial,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 2049,Subject 42198,On Trial,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 2049,Subject 42198,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2049,Subject 42198,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1103,Subject 16800,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1103,Subject 16800,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2051,Subject 42220,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2051,Subject 42220,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2051,Subject 42224,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2051,Subject 42224,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1106,Subject 16828,On Trial,Subject continuing,Visit 6 (Month 27),2025-09-17,Visit Level,Form 6,54.0,Study 22,
Study 22,USA,Site 1106,Subject 42244,On Trial,Subject continuing,Visit 6 (Month 27),2025-09-22,Visit Level,Form 10,49.0,Study 22,
Study 22,USA,Site 1106,Subject 42244,On Trial,Subject continuing,Visit 6 (Month 27),2025-09-22,Visit Level,Form 9,49.0,Study 22,
Study 22,USA,Site 1106,Subject 42246,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1106,Subject 42246,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1106,Subject 42249,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 1106,Subject 42249,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 1106,Subject 42249,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 1106,Subject 42249,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 1106,Subject 42249,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 1106,Subject 42251,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1106,Subject 42251,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2052,Subject 42256,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2052,Subject 42256,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2052,Subject 42286,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2052,Subject 42295,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2052,Subject 42295,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1110,Subject 16872,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1110,Subject 16872,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1113,Subject 42346,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1113,Subject 42346,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1113,Subject 42348,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1113,Subject 42348,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1113,Subject 42361,On Trial,Missed visit - subject unavailable,Visit 5 (Month 21),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 1113,Subject 42361,On Trial,Missed visit - subject unavailable,Visit 5 (Month 21),,Visit Level,Form 6,,Study 22,
Study 22,USA,Site 1113,Subject 42379,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1113,Subject 42379,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1113,Subject 42384,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1113,Subject 42384,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1054,Subject 42401,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1054,Subject 42401,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1114,Subject 17060,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1114,Subject 17060,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1114,Subject 17068,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1114,Subject 17068,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2057,Subject 42441,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2057,Subject 42441,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2059,Subject 42451,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2059,Subject 42451,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2059,Subject 42471,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 2059,Subject 42471,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 2059,Subject 42471,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 2059,Subject 42471,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 2059,Subject 42471,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 2059,Subject 42471,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 2059,Subject 42471,Discontinued,,End of Study (EOS),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 2059,Subject 42471,Discontinued,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 2060,Subject 42488,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2060,Subject 42488,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1025,Subject 17144,On Trial,Subject continuing,Visit 4 (Month 15),2025-07-02,Visit Level,Form 4,131.0,Study 22,
Study 22,USA,Site 1025,Subject 17151,On Trial,Subject continuing,Visit 4 (Month 15),2025-08-22,Visit Level,Form 4,80.0,Study 22,
Study 22,USA,Site 1121,Subject 42504,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1121,Subject 42504,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2062,Subject 42553,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2062,Subject 42553,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1123,Subject 42583,Discontinued,,Non-drug therapies,,Summary Page,Form 18,,Study 22,
Study 22,USA,Site 2063,Subject 42593,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2063,Subject 42593,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1125,Subject 17225,On Trial,Subject continuing,Visit 5 (Month 21),2025-08-19,Visit Level,Form 6,83.0,Study 22,
Study 22,USA,Site 2066,Subject 42692,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2066,Subject 42692,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2066,Subject 42693,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-15,Visit Level,Form 10,26.0,Study 22,
Study 22,USA,Site 2066,Subject 42705,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2066,Subject 42705,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2066,Subject 42707,On Trial,,Visit 3 (Month 9),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2066,Subject 42707,On Trial,,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2066,Subject 42710,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2066,Subject 42710,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2066,Subject 42712,On Trial,Subject continuing,Visit 3 (Month 9),,Visit Level,Form 9,,Study 22,
Study 22,USA,Site 2066,Subject 42712,On Trial,Subject continuing,Visit 4 (Month 15),2025-04-01,Visit Level,Form 9,223.0,Study 22,
Study 22,USA,Site 2066,Subject 42716,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2066,Subject 42716,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2066,Subject 42729,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2066,Subject 42729,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2046,Subject 42738,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2046,Subject 42738,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2046,Subject 42740,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2046,Subject 42740,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2075,Subject 42799,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2075,Subject 42799,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2075,Subject 42827,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2075,Subject 42827,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2075,Subject 42846,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 2076,Subject 42871,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2076,Subject 42871,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2076,Subject 42873,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2076,Subject 42873,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2076,Subject 42879,On Trial,,Disposition,,Summary Page,Form 7,,Study 22,
Study 22,USA,Site 1139,Subject 17404,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 1139,Subject 17404,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 4,,Study 22,
Study 22,USA,Site 1139,Subject 17404,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 6,,Study 22,
Study 22,USA,Site 1139,Subject 17404,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 20,,Study 22,
Study 22,USA,Site 1139,Subject 17404,On Trial,Subject continuing,Visit 5 (Month 21),,Visit Level,Form 9,,Study 22,
Study 22,USA,Site 2079,Subject 42919,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2079,Subject 42919,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2072,Subject 42945,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2072,Subject 42945,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2080,Subject 42962,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2080,Subject 42962,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2080,Subject 42963,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2080,Subject 42963,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2080,Subject 42965,On Trial,Missed visit - subject unavailable,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2080,Subject 42965,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2080,Subject 42965,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2080,Subject 42967,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2080,Subject 42967,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2082,Subject 43011,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2082,Subject 43011,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2085,Subject 43065,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2085,Subject 43066,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2085,Subject 43066,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2085,Subject 43067,On Trial,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 2085,Subject 43067,On Trial,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,USA,Site 2085,Subject 43067,On Trial,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 2085,Subject 43067,On Trial,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 2085,Subject 43067,On Trial,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 2085,Subject 43067,On Trial,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 2085,Subject 43067,On Trial,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 2086,Subject 43072,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2086,Subject 43072,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,End of Study (EOS),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,End of Study (EOS),,Visit Level,Form 4,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,End of Study (EOS),,Visit Level,Form 6,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,End of Study (EOS),,Visit Level,Form 24,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,End of Study (EOS),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,,Non-drug therapies,,Summary Page,Form 18,,Study 22,
Study 22,USA,Site 2087,Subject 43101,Discontinued,Subject discontinued from study at this visit,Visit 4 (Month 15),,Visit Level,Form 20,,Study 22,
Study 22,USA,Site 2088,Subject 43110,On Trial,,eSAE,,Summary Page,Form 22,,Study 22,
Study 22,USA,Site 2088,Subject 43123,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2088,Subject 43123,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2088,Subject 43137,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2088,Subject 43137,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2088,Subject 43138,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2088,Subject 43138,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2088,Subject 43144,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2088,Subject 43144,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2088,Subject 43176,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2088,Subject 43176,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1152,Subject 17548,On Trial,Subject continuing,Visit 5 (Month 21),2025-10-17,Visit Level,Form 9,24.0,Study 22,
Study 22,USA,Site 1152,Subject 43203,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1152,Subject 43203,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1153,Subject 17554,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1153,Subject 17554,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1103,Subject 43216,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1103,Subject 43216,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1103,Subject 43217,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1103,Subject 43217,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1103,Subject 43218,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1103,Subject 43218,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2091,Subject 43230,On Trial,Subject continuing,Visit 6 (Month 27),2025-10-21,Visit Level,Form 10,20.0,Study 22,
Study 22,USA,Site 2091,Subject 43234,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2091,Subject 43234,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1155,Subject 17588,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1155,Subject 17588,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1116,Subject 43265,On Trial,,Visit 6 (Month 27),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1116,Subject 43265,On Trial,,Visit 6 (Month 27),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1116,Subject 43271,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1116,Subject 43271,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2094,Subject 43285,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2094,Subject 43285,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2094,Subject 43286,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 2094,Subject 43294,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2094,Subject 43294,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2094,Subject 43301,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2094,Subject 43301,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2094,Subject 43302,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2094,Subject 43302,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2094,Subject 43311,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 2094,Subject 43340,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2094,Subject 43340,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2094,Subject 43343,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2094,Subject 43343,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1179,Subject 43313,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1179,Subject 43313,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2095,Subject 43357,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2095,Subject 43357,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1164,Subject 43401,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1164,Subject 43401,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1164,Subject 43410,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1164,Subject 43410,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1164,Subject 43411,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1164,Subject 43411,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1164,Subject 43413,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1164,Subject 43413,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1164,Subject 43419,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1164,Subject 43419,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1164,Subject 43426,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 1164,Subject 43426,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),,Visit Level,Form 4,,Study 22,
Study 22,USA,Site 1164,Subject 43426,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),,Visit Level,Form 6,,Study 22,
Study 22,USA,Site 1164,Subject 43426,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),,Visit Level,Form 9,,Study 22,
Study 22,USA,Site 1164,Subject 43426,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1164,Subject 43426,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1164,Subject 43427,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2097,Subject 43476,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2097,Subject 43476,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2097,Subject 43477,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2097,Subject 43477,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2097,Subject 43493,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2097,Subject 43493,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2097,Subject 43496,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2097,Subject 43496,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2100,Subject 43528,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 2103,Subject 43551,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2103,Subject 43551,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2108,Subject 43591,On Trial,Subject continuing,Visit 4 (Month 15),2025-07-30,Visit Level,Form 10,103.0,Study 22,
Study 22,USA,Site 2108,Subject 43591,On Trial,Subject continuing,Visit 4 (Month 15),2025-07-30,Visit Level,Form 4,103.0,Study 22,
Study 22,USA,Site 2108,Subject 43593,Discontinued,,Disposition,,Summary Page,Form 7,,Study 22,
Study 22,USA,Site 2108,Subject 43593,Discontinued,,End of Study (EOS),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 2108,Subject 43593,Discontinued,,End of Study (EOS),,Visit Level,Form 4,,Study 22,
Study 22,USA,Site 2108,Subject 43593,Discontinued,,End of Study (EOS),,Visit Level,Form 6,,Study 22,
Study 22,USA,Site 2108,Subject 43593,Discontinued,,End of Study (EOS),,Visit Level,Form 24,,Study 22,
Study 22,USA,Site 2108,Subject 43593,Discontinued,,End of Study (EOS),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2108,Subject 43593,Discontinued,,Non-drug therapies,,Summary Page,Form 18,,Study 22,
Study 22,USA,Site 2108,Subject 43597,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2108,Subject 43597,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2112,Subject 43630,Discontinued,,End of Study (EOS),,Visit Level,Form 4,,Study 22,
Study 22,USA,Site 2112,Subject 43630,Discontinued,,End of Study (EOS),,Visit Level,Form 24,,Study 22,
Study 22,USA,Site 2112,Subject 43636,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 2112,Subject 43637,On Trial,,eSAE,,Summary Page,Form 22,,Study 22,
Study 22,USA,Site 2112,Subject 43637,On Trial,,eSAE,,Summary Page,Form 26,,Study 22,
Study 22,USA,Site 2112,Subject 43639,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2112,Subject 43639,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2114,Subject 43647,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),2025-10-03,Visit Level,Form 20,38.0,Study 22,
Study 22,USA,Site 2114,Subject 43647,On Trial,Subject discontinued from treatment at this visit,Visit 4 (Month 15),2025-10-03,Visit Level,Form 9,38.0,Study 22,
Study 22,USA,Site 2116,Subject 43679,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2116,Subject 43679,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1172,Subject 43690,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1172,Subject 43690,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1172,Subject 43693,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1172,Subject 43693,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1172,Subject 43696,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1172,Subject 43696,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2117,Subject 43743,On Trial,,Visit 3 (Month 9),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2117,Subject 43743,On Trial,,Visit 3 (Month 9),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,End of Study (EOS),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,End of Study (EOS),,Visit Level,Form 4,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,End of Study (EOS),,Visit Level,Form 6,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,End of Study (EOS),,Visit Level,Form 24,,Study 22,
Study 22,USA,Site 2117,Subject 43747,Discontinued,,End of Study (EOS),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2120,Subject 43802,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2120,Subject 43802,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2120,Subject 43806,Screen Failure,Subject discontinued from study at this visit,Screening,2024-08-06,Visit Level,Form 29,461.0,Study 22,
Study 22,USA,Site 2120,Subject 43809,Screen Failure,Subject discontinued from study at this visit,Screening,2024-08-13,Visit Level,Form 30,454.0,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,End of Study (EOS),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,End of Study (EOS),,Visit Level,Form 4,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,End of Study (EOS),,Visit Level,Form 6,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,End of Study (EOS),,Visit Level,Form 24,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,End of Study (EOS),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1175,Subject 17825,Discontinued,,Non-drug therapies,,Summary Page,Form 18,,Study 22,
Study 22,USA,Site 1175,Subject 17826,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1175,Subject 17826,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1175,Subject 43823,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1175,Subject 43823,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1175,Subject 43824,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1175,Subject 43824,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1175,Subject 43825,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1175,Subject 43825,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2122,Subject 43840,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2122,Subject 43840,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1179,Subject 43867,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1179,Subject 43867,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1179,Subject 43868,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1179,Subject 43868,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1179,Subject 43869,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1179,Subject 43869,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1179,Subject 43871,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1179,Subject 43871,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1179,Subject 43873,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1179,Subject 43873,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1179,Subject 43874,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1179,Subject 43874,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2124,Subject 43887,On Trial,Subject continuing,Visit 4 (Month 15),2025-08-22,Visit Level,Form 4,80.0,Study 22,
Study 22,USA,Site 1180,Subject 17850,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),,Visit Level,Form 10,,Study 22,
Study 22,USA,Site 1180,Subject 17850,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),,Visit Level,Form 4,,Study 22,
Study 22,USA,Site 1180,Subject 17850,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),,Visit Level,Form 6,,Study 22,
Study 22,USA,Site 1180,Subject 17850,On Trial,Subject discontinued from treatment at this visit,Visit 3 (Month 9),,Visit Level,Form 9,,Study 22,
Study 22,USA,Site 1180,Subject 17850,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1180,Subject 17850,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1181,Subject 17869,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1181,Subject 17869,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1181,Subject 17870,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1181,Subject 17870,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1184,Subject 17929,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1184,Subject 17929,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2125,Subject 43898,Discontinued,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 2125,Subject 43898,Discontinued,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 2125,Subject 43898,Discontinued,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 2125,Subject 43898,Discontinued,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 2125,Subject 43898,Discontinued,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 2128,Subject 43919,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2128,Subject 43919,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2130,Subject 43945,On Trial,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 2130,Subject 43945,On Trial,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,USA,Site 2130,Subject 43945,On Trial,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 2130,Subject 43945,On Trial,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 2130,Subject 43945,On Trial,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 2130,Subject 43945,On Trial,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 2130,Subject 43945,On Trial,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 2130,Subject 43945,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2130,Subject 43945,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2130,Subject 43952,On Trial,,Clinical Events,,Summary Page,Form 11,,Study 22,
Study 22,USA,Site 2130,Subject 43952,On Trial,,Clinical Events,,Summary Page,Form 12,,Study 22,
Study 22,USA,Site 2130,Subject 43952,On Trial,,Clinical Events,,Summary Page,Form 13,,Study 22,
Study 22,USA,Site 2130,Subject 43952,On Trial,,Clinical Events,,Summary Page,Form 14,,Study 22,
Study 22,USA,Site 2130,Subject 43952,On Trial,,Clinical Events,,Summary Page,Form 15,,Study 22,
Study 22,USA,Site 2130,Subject 43952,On Trial,,Clinical Events,,Summary Page,Form 16,,Study 22,
Study 22,USA,Site 2130,Subject 43952,On Trial,,Clinical Events,,Summary Page,Form 17,,Study 22,
Study 22,USA,Site 2130,Subject 43952,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2130,Subject 43952,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 1189,Subject 43960,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 1189,Subject 43960,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2131,Subject 43974,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2131,Subject 43974,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,USA,Site 2106,Subject 19536,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,USA,Site 2106,Subject 19536,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1692,Subject 31616,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,VNM,Site 1692,Subject 31616,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1692,Subject 31634,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,VNM,Site 1692,Subject 31634,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1692,Subject 31635,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,VNM,Site 1692,Subject 31635,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1692,Subject 31636,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,VNM,Site 1692,Subject 31636,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1692,Subject 31638,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,VNM,Site 1692,Subject 31638,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1692,Subject 31639,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,VNM,Site 1692,Subject 31639,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1692,Subject 31640,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,VNM,Site 1692,Subject 31640,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1692,Subject 31646,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,VNM,Site 1692,Subject 31646,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1693,Subject 31702,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,VNM,Site 1693,Subject 31702,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,VNM,Site 1693,Subject 31757,On Trial,Subject continuing,Visit 4 (Month 15),2025-10-22,Visit Level,Form 10,19.0,Study 22,
Study 22,ZAF,Site 61,Subject 31099,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,ZAF,Site 62,Subject 6104,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ZAF,Site 62,Subject 6104,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ZAF,Site 63,Subject 396,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ZAF,Site 63,Subject 396,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ZAF,Site 64,Subject 434,On Trial,,Visit 4 (Month 15),,Visit Level,Form 1,,Study 22,
Study 22,ZAF,Site 64,Subject 434,On Trial,,Visit 4 (Month 15),,Visit Level,Form 2,,Study 22,
Study 22,ZAF,Site 65,Subject 447,On Trial,,Visit 5 (Month 21),,Visit Level,Form 1,,Study 22,
Study 22,ZAF,Site 65,Subject 447,On Trial,,Visit 5 (Month 21),,Visit Level,Form 2,,Study 22,
Study 22,ZAF,Site 65,Subject 468,On Trial,,Unplanned visit,,Visit Level,Form 28,,Study 22,
Study 22,ZAF,Site 67,Subject 477,On Trial,,Protocol Amendment Log,,Summary Page,Form 5,,Study 22,
Study 22,ZAF,Site 68,Subject 31151,On Trial,,Unplanned visit,2025-11-04,Visit Level,Form 9,6.0,Study 22,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_Day 1,2025-08-18,Visit Level,Form 1,87.0,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_Day 1,2025-08-18,Visit Level,Form 2,87.0,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_Day 1,2025-08-18,Visit Level,Form 3,87.0,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_Day 1,2025-08-18,Visit Level,Form 4,87.0,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_Day 1,2025-08-18,Visit Level,Form 5,87.0,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,,EP1_Day 2,,Visit Level,Form 6,,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_PretreatmentBaseline,2025-08-18,Visit Level,Form 7,87.0,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_PretreatmentBaseline,2025-08-18,Visit Level,Form 8,87.0,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_PretreatmentBaseline,2025-08-18,Visit Level,Form 9,87.0,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_PretreatmentBaseline,2025-08-18,Visit Level,Form 10,87.0,Study 23,
Study 23,CIV,Site 63,Subject 6133,On Trial,Subject continuing,EP1_PretreatmentBaseline,2025-08-18,Visit Level,Form 11,87.0,Study 23,
Study 23,CIV,Site 64,Subject 46879,On Trial,,EP1_Day 1,,Visit Level,Form 6,,Study 23,
Study 23,GHA,Site 1673,Subject 30842,On Trial,Subject continuing,EP2_Day 29,2025-10-22,Visit Level,Form 12,22.0,Study 23,
Study 23,GHA,Site 469,Subject 46642,On Trial,Subject continuing,EP2_Day 29,2025-10-28,Visit Level,Form 7,16.0,Study 23,
Study 23,GHA,Site 469,Subject 46670,On Trial,Subject continuing,EP1_Day 29,2025-10-29,Visit Level,Form 7,15.0,Study 23,
Study 23,GHA,Site 469,Subject 46733,On Trial,Subject continuing,EP1_Day 29,2025-11-06,Visit Level,Form 7,7.0,Study 23,
Study 23,RWA,Site 113,Subject 6271,Completed,Subject continuing,EP2_Day 29,2025-11-03,Visit Level,Form 13,10.0,Study 23,
Study 23,UGA,Site 11,Subject 47449,On Trial,,EP1_Day 1,,Visit Level,Form 6,,Study 23,
Study 24,AUS,Site 28,Subject 107,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,AUS,Site 28,Subject 107,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,AUS,Site 28,Subject 107,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,AUS,Site 28,Subject 108,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,AUS,Site 28,Subject 108,On Trial,Subject continuing,Screening,2025-09-18,Visit Level,Form 5,57.0,Study 24,
Study 24,AUS,Site 28,Subject 108,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,AUS,Site 28,Subject 108,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,AUS,Site 28,Subject 2233,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,AUS,Site 28,Subject 2233,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,AUS,Site 28,Subject 2233,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,AUS,Site 28,Subject 2234,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,AUS,Site 28,Subject 2234,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,AUS,Site 28,Subject 2234,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,AUS,Site 28,Subject 2234,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,AUS,Site 259,Subject 2236,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,AUS,Site 259,Subject 4990,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,AUS,Site 259,Subject 4990,On Trial,Subject continuing,Screening,2025-10-01,Visit Level,Form 8,44.0,Study 24,
Study 24,AUS,Site 259,Subject 4990,On Trial,Subject continuing,Screening,2025-10-01,Visit Level,Form 9,44.0,Study 24,
Study 24,AUS,Site 259,Subject 4990,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,AUS,Site 259,Subject 4990,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,AUS,Site 259,Subject 4990,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,AUS,Site 259,Subject 4990,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,AUS,Site 259,Subject 4991,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CAN,Site 952,Subject 13635,On Trial,Subject continuing,Screening,2025-09-24,Visit Level,Form 11,51.0,Study 24,
Study 24,CAN,Site 952,Subject 13635,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 952,Subject 13637,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 12,23.0,Study 24,
Study 24,CAN,Site 952,Subject 13637,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 13,23.0,Study 24,
Study 24,CAN,Site 952,Subject 13637,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CAN,Site 952,Subject 13637,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CAN,Site 952,Subject 13637,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 952,Subject 13637,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CAN,Site 952,Subject 13638,Screening,,Screening,2025-10-28,Visit Level,Form 14,17.0,Study 24,
Study 24,CAN,Site 952,Subject 13638,Screening,,Screening,2025-10-28,Visit Level,Form 15,17.0,Study 24,
Study 24,CAN,Site 952,Subject 13639,On Trial,Subject continuing,Screening,2025-10-30,Visit Level,Form 12,15.0,Study 24,
Study 24,CAN,Site 952,Subject 13639,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CAN,Site 952,Subject 13639,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CAN,Site 952,Subject 13639,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 952,Subject 13639,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CAN,Site 953,Subject 13651,On Trial,Subject continuing,Screening,2025-08-29,Visit Level,Form 12,77.0,Study 24,
Study 24,CAN,Site 953,Subject 13652,On Trial,Subject continuing,Screening,2025-09-29,Visit Level,Form 12,46.0,Study 24,
Study 24,CAN,Site 953,Subject 13653,On Trial,Subject continuing,Screening,2025-09-29,Visit Level,Form 12,46.0,Study 24,
Study 24,CAN,Site 953,Subject 13655,On Trial,Subject continuing,Screening,2025-10-01,Visit Level,Form 12,44.0,Study 24,
Study 24,CAN,Site 953,Subject 13656,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-28,Visit Level,Form 16,17.0,Study 24,
Study 24,CAN,Site 953,Subject 13656,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 12,39.0,Study 24,
Study 24,CAN,Site 953,Subject 13656,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 17,39.0,Study 24,
Study 24,CAN,Site 953,Subject 47750,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-27,Visit Level,Form 16,18.0,Study 24,
Study 24,CAN,Site 953,Subject 47750,On Trial,Subject continuing,Screening,2025-10-08,Visit Level,Form 12,37.0,Study 24,
Study 24,CAN,Site 953,Subject 47751,On Trial,Subject continuing,Screening,2025-10-09,Visit Level,Form 12,36.0,Study 24,
Study 24,CAN,Site 953,Subject 47751,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CAN,Site 953,Subject 47752,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-20,Visit Level,Form 16,25.0,Study 24,
Study 24,CAN,Site 953,Subject 47752,On Trial,Subject continuing,Screening,2025-10-15,Visit Level,Form 12,30.0,Study 24,
Study 24,CAN,Site 953,Subject 47753,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-29,Visit Level,Form 16,16.0,Study 24,
Study 24,CAN,Site 953,Subject 47753,On Trial,Subject continuing,Screening,2025-10-21,Visit Level,Form 12,24.0,Study 24,
Study 24,CAN,Site 953,Subject 47753,On Trial,Subject continuing,Screening,2025-10-21,Visit Level,Form 17,24.0,Study 24,
Study 24,CAN,Site 953,Subject 47753,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CAN,Site 954,Subject 13658,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CAN,Site 954,Subject 13658,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CAN,Site 954,Subject 13658,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CAN,Site 954,Subject 13658,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CAN,Site 954,Subject 13658,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 954,Subject 13658,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CAN,Site 955,Subject 13668,On Trial,Subject continuing,Screening,2025-08-22,Visit Level,Form 17,84.0,Study 24,
Study 24,CAN,Site 955,Subject 13668,On Trial,Subject continuing,Screening,2025-08-22,Visit Level,Form 16,84.0,Study 24,
Study 24,CAN,Site 955,Subject 38951,On Trial,Subject continuing,Screening,2025-09-18,Visit Level,Form 16,57.0,Study 24,
Study 24,CAN,Site 955,Subject 38952,On Trial,Subject continuing,Screening,2025-09-19,Visit Level,Form 12,56.0,Study 24,
Study 24,CAN,Site 955,Subject 47756,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CAN,Site 955,Subject 47756,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CAN,Site 955,Subject 47756,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CAN,Site 955,Subject 47757,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CAN,Site 955,Subject 47757,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CAN,Site 955,Subject 47757,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CAN,Site 955,Subject 47757,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 955,Subject 47757,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CAN,Site 955,Subject 47759,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CAN,Site 955,Subject 47759,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CAN,Site 955,Subject 47759,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 955,Subject 47759,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CAN,Site 955,Subject 47760,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CAN,Site 955,Subject 47761,Screening,Subject continuing,Screening,2025-10-29,Visit Level,Form 14,16.0,Study 24,
Study 24,CAN,Site 955,Subject 47762,Screening,Subject continuing,Screening,2025-11-13,Visit Level,Form 14,1.0,Study 24,
Study 24,CAN,Site 963,Subject 13826,On Trial,Subject continuing,Cycle 4 Day 1,2025-10-21,Visit Level,Form 16,24.0,Study 24,
Study 24,CAN,Site 963,Subject 13829,On Trial,Subject continuing,Screening,2025-08-14,Visit Level,Form 13,92.0,Study 24,
Study 24,CAN,Site 963,Subject 13829,On Trial,Subject continuing,Screening,2025-08-14,Visit Level,Form 19,92.0,Study 24,
Study 24,CAN,Site 963,Subject 13829,On Trial,Subject continuing,Screening,2025-08-14,Visit Level,Form 20,92.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 21,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 12,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 22,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 23,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 19,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 24,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 8,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 9,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 25,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,Subject continuing,Screening,2025-09-17,Visit Level,Form 16,58.0,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CAN,Site 963,Subject 13835,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CAN,Site 963,Subject 13839,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CAN,Site 963,Subject 13839,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 21,29.0,Study 24,
Study 24,CAN,Site 963,Subject 13839,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 12,29.0,Study 24,
Study 24,CAN,Site 963,Subject 13839,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CAN,Site 963,Subject 13839,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CAN,Site 963,Subject 13839,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 963,Subject 13839,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CAN,Site 963,Subject 13839,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CAN,Site 963,Subject 39017,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 5,29.0,Study 24,
Study 24,CAN,Site 963,Subject 39017,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 963,Subject 39017,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,Subject continuing,Screening,2025-11-04,Visit Level,Form 21,10.0,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,Subject continuing,Screening,2025-11-04,Visit Level,Form 12,10.0,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,Subject continuing,Screening,2025-11-04,Visit Level,Form 11,10.0,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,Subject continuing,Screening,2025-11-04,Visit Level,Form 8,10.0,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,Subject continuing,Screening,2025-11-04,Visit Level,Form 9,10.0,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,Subject continuing,Screening,2025-11-04,Visit Level,Form 25,10.0,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,Subject continuing,Screening,2025-11-04,Visit Level,Form 16,10.0,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CAN,Site 963,Subject 39018,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CHN,Site 503,Subject 3706,Screening,,Screening,2025-10-31,Visit Level,Form 15,14.0,Study 24,
Study 24,CHN,Site 503,Subject 3707,Screening,,Screening,2025-11-03,Visit Level,Form 14,11.0,Study 24,
Study 24,CHN,Site 503,Subject 3707,Screening,,Screening,2025-11-03,Visit Level,Form 15,11.0,Study 24,
Study 24,CHN,Site 503,Subject 3708,Screening,,Screening,2025-11-06,Visit Level,Form 14,8.0,Study 24,
Study 24,CHN,Site 503,Subject 3708,Screening,,Screening,2025-11-06,Visit Level,Form 15,8.0,Study 24,
Study 24,CHN,Site 503,Subject 3709,Screening,,Screening,2025-11-10,Visit Level,Form 14,4.0,Study 24,
Study 24,CHN,Site 503,Subject 3709,Screening,,Screening,2025-11-10,Visit Level,Form 15,4.0,Study 24,
Study 24,CHN,Site 507,Subject 3727,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 507,Subject 3728,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 507,Subject 3728,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 507,Subject 3728,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 507,Subject 3728,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CHN,Site 507,Subject 3728,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CHN,Site 507,Subject 3728,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CHN,Site 420,Subject 6459,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 420,Subject 6459,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 420,Subject 6459,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CHN,Site 420,Subject 6459,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CHN,Site 420,Subject 47696,Screening,,Screening,2025-10-31,Visit Level,Form 14,14.0,Study 24,
Study 24,CHN,Site 420,Subject 47696,Screening,,Screening,2025-10-31,Visit Level,Form 15,14.0,Study 24,
Study 24,CHN,Site 421,Subject 3235,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 421,Subject 3235,On Trial,Subject continuing,Screening,2025-10-24,Visit Level,Form 5,21.0,Study 24,
Study 24,CHN,Site 421,Subject 3235,On Trial,Subject continuing,Screening,2025-10-24,Visit Level,Form 8,21.0,Study 24,
Study 24,CHN,Site 421,Subject 3235,On Trial,Subject continuing,Screening,2025-10-24,Visit Level,Form 9,21.0,Study 24,
Study 24,CHN,Site 421,Subject 3235,On Trial,Subject continuing,Screening,2025-10-24,Visit Level,Form 25,21.0,Study 24,
Study 24,CHN,Site 421,Subject 3235,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 421,Subject 3235,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 421,Subject 3235,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CHN,Site 421,Subject 3235,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,Subject continuing,Screening,2025-10-21,Visit Level,Form 5,24.0,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,Subject continuing,Screening,2025-10-21,Visit Level,Form 8,24.0,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,Subject continuing,Screening,2025-10-21,Visit Level,Form 9,24.0,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,Subject continuing,Screening,2025-10-21,Visit Level,Form 25,24.0,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CHN,Site 421,Subject 3236,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CHN,Site 423,Subject 3247,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 423,Subject 6489,On Trial,Subject continuing,Screening,2025-10-20,Visit Level,Form 25,25.0,Study 24,
Study 24,CHN,Site 423,Subject 6490,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 423,Subject 6490,On Trial,Subject continuing,Screening,2025-10-24,Visit Level,Form 9,21.0,Study 24,
Study 24,CHN,Site 423,Subject 6490,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 423,Subject 6490,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 423,Subject 6490,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 423,Subject 6490,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CHN,Site 423,Subject 6490,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CHN,Site 423,Subject 6490,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CHN,Site 423,Subject 6491,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 423,Subject 6491,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 423,Subject 6491,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 423,Subject 6491,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CHN,Site 423,Subject 6491,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CHN,Site 425,Subject 3256,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 425,Subject 3256,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 425,Subject 3256,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 425,Subject 3256,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CHN,Site 2183,Subject 47702,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 2183,Subject 47702,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 2184,Subject 47703,On Trial,Subject continuing,Screening,2025-09-23,Visit Level,Form 12,52.0,Study 24,
Study 24,CHN,Site 2184,Subject 47707,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 2184,Subject 47707,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CHN,Site 2184,Subject 47708,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 2184,Subject 47709,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 2184,Subject 47712,Screening,Subject continuing,Screening,2025-11-06,Visit Level,Form 14,8.0,Study 24,
Study 24,CHN,Site 426,Subject 3257,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 426,Subject 47713,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 426,Subject 47714,On Trial,Subject continuing,Screening,2025-10-29,Visit Level,Form 5,16.0,Study 24,
Study 24,CHN,Site 426,Subject 47714,On Trial,Subject continuing,Screening,2025-10-29,Visit Level,Form 16,16.0,Study 24,
Study 24,CHN,Site 426,Subject 47714,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 426,Subject 47714,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CHN,Site 426,Subject 47714,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CHN,Site 426,Subject 47715,Screening,Subject continuing,Screening,2025-11-03,Visit Level,Form 14,11.0,Study 24,
Study 24,CHN,Site 2185,Subject 47717,On Trial,Subject continuing,Screening,2025-09-04,Visit Level,Form 9,71.0,Study 24,
Study 24,CHN,Site 2185,Subject 47718,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 2185,Subject 47720,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 2185,Subject 47720,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 2185,Subject 47720,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 2185,Subject 47720,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 2185,Subject 47720,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CHN,Site 2185,Subject 47721,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,CHN,Site 2185,Subject 47721,On Trial,Subject continuing,Screening,2025-10-30,Visit Level,Form 9,15.0,Study 24,
Study 24,CHN,Site 2185,Subject 47721,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,CHN,Site 2185,Subject 47721,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,CHN,Site 2185,Subject 47721,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 2185,Subject 47721,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,CHN,Site 2185,Subject 47721,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,CHN,Site 2185,Subject 47721,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,CHN,Site 2186,Subject 47726,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,CHN,Site 2186,Subject 47727,On Trial,Subject continuing,Screening,2025-09-25,Visit Level,Form 16,50.0,Study 24,
Study 24,DEU,Site 520,Subject 3767,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 520,Subject 3767,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 12,39.0,Study 24,
Study 24,DEU,Site 520,Subject 3767,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 23,39.0,Study 24,
Study 24,DEU,Site 520,Subject 3767,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 19,39.0,Study 24,
Study 24,DEU,Site 520,Subject 3767,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 520,Subject 3767,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 520,Subject 3767,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 520,Subject 3767,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 520,Subject 3768,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 520,Subject 3768,On Trial,Subject continuing,Screening,2025-10-23,Visit Level,Form 12,22.0,Study 24,
Study 24,DEU,Site 520,Subject 3768,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 520,Subject 3768,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 520,Subject 3768,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 520,Subject 3768,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 520,Subject 3769,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 520,Subject 3769,On Trial,Subject continuing,Screening,2025-10-20,Visit Level,Form 12,25.0,Study 24,
Study 24,DEU,Site 520,Subject 3769,On Trial,Subject continuing,Screening,2025-10-20,Visit Level,Form 17,25.0,Study 24,
Study 24,DEU,Site 520,Subject 8868,Screening,Subject continuing,Screening,2025-11-10,Visit Level,Form 14,4.0,Study 24,
Study 24,DEU,Site 521,Subject 3773,On Trial,Subject continuing,Screening,2025-10-01,Visit Level,Form 12,44.0,Study 24,
Study 24,DEU,Site 521,Subject 8892,On Trial,Subject continuing,Screening,2025-10-08,Visit Level,Form 12,37.0,Study 24,
Study 24,DEU,Site 521,Subject 8893,On Trial,Subject continuing,Screening,2025-10-27,Visit Level,Form 12,18.0,Study 24,
Study 24,DEU,Site 521,Subject 8893,On Trial,Subject continuing,Screening,2025-10-27,Visit Level,Form 9,18.0,Study 24,
Study 24,DEU,Site 522,Subject 3774,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 522,Subject 3774,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 522,Subject 3774,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,DEU,Site 522,Subject 3774,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 522,Subject 8927,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 522,Subject 8927,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 522,Subject 8927,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 522,Subject 8928,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 522,Subject 8928,On Trial,Subject continuing,Screening,2025-09-26,Visit Level,Form 17,49.0,Study 24,
Study 24,DEU,Site 522,Subject 8928,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 522,Subject 8928,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 875,Subject 8977,On Trial,Subject continuing,Screening,2025-09-22,Visit Level,Form 20,53.0,Study 24,
Study 24,DEU,Site 875,Subject 8978,On Trial,Subject continuing,Screening,2025-09-22,Visit Level,Form 21,53.0,Study 24,
Study 24,DEU,Site 875,Subject 8980,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 875,Subject 8981,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-13,Visit Level,Form 26,32.0,Study 24,
Study 24,DEU,Site 875,Subject 8982,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-23,Visit Level,Form 26,22.0,Study 24,
Study 24,DEU,Site 875,Subject 8982,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 875,Subject 8982,On Trial,Subject continuing,Screening,2025-10-09,Visit Level,Form 21,36.0,Study 24,
Study 24,DEU,Site 875,Subject 8983,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 875,Subject 8983,On Trial,Subject continuing,Screening,2025-10-14,Visit Level,Form 21,31.0,Study 24,
Study 24,DEU,Site 875,Subject 8983,On Trial,Subject continuing,Screening,2025-10-14,Visit Level,Form 12,31.0,Study 24,
Study 24,DEU,Site 875,Subject 8985,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 875,Subject 8986,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 875,Subject 8986,On Trial,Subject continuing,Screening,2025-10-29,Visit Level,Form 21,16.0,Study 24,
Study 24,DEU,Site 875,Subject 8986,On Trial,Subject continuing,Screening,2025-10-29,Visit Level,Form 17,16.0,Study 24,
Study 24,DEU,Site 876,Subject 8989,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 876,Subject 8989,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 876,Subject 8990,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 876,Subject 8990,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 876,Subject 8991,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 9,29.0,Study 24,
Study 24,DEU,Site 876,Subject 8991,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 876,Subject 8991,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 876,Subject 8993,On Trial,Subject continuing,Screening,2025-10-23,Visit Level,Form 9,22.0,Study 24,
Study 24,DEU,Site 876,Subject 8993,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 876,Subject 8993,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 876,Subject 8993,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,DEU,Site 876,Subject 8993,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 879,Subject 9113,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 879,Subject 9113,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 880,Subject 9117,On Trial,Subject continuing,Screening,2025-09-29,Visit Level,Form 12,46.0,Study 24,
Study 24,DEU,Site 880,Subject 9117,On Trial,Subject continuing,Screening,2025-09-29,Visit Level,Form 22,46.0,Study 24,
Study 24,DEU,Site 880,Subject 9117,On Trial,Subject continuing,Screening,2025-09-29,Visit Level,Form 17,46.0,Study 24,
Study 24,DEU,Site 880,Subject 9117,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 880,Subject 9117,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 21,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 12,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 5,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 22,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 13,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 23,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 17,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 19,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 24,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 8,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 9,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 25,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 16,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 880,Subject 9118,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,,Concomitant Medication,,Summary Page,Form 27,,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,Subject discontinued from study at this visit,End of Treatment,2025-10-29,Visit Level,Form 16,16.0,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,,Non-drug therapies,,Summary Page,Form 28,,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 12,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 24,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 8,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 9,45.0,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 880,Subject 9119,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 880,Subject 9120,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 12,38.0,Study 24,
Study 24,DEU,Site 880,Subject 9120,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 880,Subject 9120,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 880,Subject 9120,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 880,Subject 9123,Enrolled,Subject continuing,Screening,2025-10-27,Visit Level,Form 5,18.0,Study 24,
Study 24,DEU,Site 880,Subject 9123,Enrolled,Subject continuing,Screening,2025-10-27,Visit Level,Form 29,18.0,Study 24,
Study 24,DEU,Site 880,Subject 9124,Enrolled,Subject continuing,Screening,2025-10-27,Visit Level,Form 5,18.0,Study 24,
Study 24,DEU,Site 880,Subject 9124,Enrolled,Subject continuing,Screening,2025-10-27,Visit Level,Form 29,18.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-28,Visit Level,Form 16,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 21,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 12,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 5,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 22,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 23,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 17,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 19,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 24,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 8,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 9,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 25,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 16,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,Subject continuing,Screening,2025-10-28,Visit Level,Form 20,17.0,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 880,Subject 9125,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 883,Subject 9190,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-16,Visit Level,Form 16,59.0,Study 24,
Study 24,DEU,Site 883,Subject 9190,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 883,Subject 9190,On Trial,Subject continuing,Screening,2025-09-08,Visit Level,Form 12,67.0,Study 24,
Study 24,DEU,Site 883,Subject 9190,On Trial,Subject continuing,Screening,2025-09-08,Visit Level,Form 16,67.0,Study 24,
Study 24,DEU,Site 883,Subject 9190,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 883,Subject 9190,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 883,Subject 9191,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 883,Subject 9191,On Trial,Subject continuing,Screening,2025-09-29,Visit Level,Form 12,46.0,Study 24,
Study 24,DEU,Site 883,Subject 9191,On Trial,Subject continuing,Screening,2025-09-29,Visit Level,Form 16,46.0,Study 24,
Study 24,DEU,Site 883,Subject 9191,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 883,Subject 9191,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 883,Subject 9192,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-07,Visit Level,Form 16,38.0,Study 24,
Study 24,DEU,Site 883,Subject 9192,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 883,Subject 9192,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 12,45.0,Study 24,
Study 24,DEU,Site 883,Subject 9192,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 16,45.0,Study 24,
Study 24,DEU,Site 883,Subject 9192,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 883,Subject 9192,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 887,Subject 9280,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 887,Subject 9280,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 887,Subject 9281,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 887,Subject 9281,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9287,Discontinued,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9287,Discontinued,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9288,On Trial,,Antineoplastic Therapy,,Summary Page,Form 30,,Study 24,
Study 24,DEU,Site 888,Subject 9288,On Trial,,Non-drug therapies,,Summary Page,Form 28,,Study 24,
Study 24,DEU,Site 888,Subject 9288,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9288,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9289,Screen Failure,,Adverse Event,,Summary Page,Form 31,,Study 24,
Study 24,DEU,Site 888,Subject 9290,Enrolled,Subject continuing,Screening,2025-08-07,Visit Level,Form 5,99.0,Study 24,
Study 24,DEU,Site 888,Subject 9291,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-03,Visit Level,Form 26,72.0,Study 24,
Study 24,DEU,Site 888,Subject 9291,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9291,On Trial,Subject continuing,Screening,2025-08-27,Visit Level,Form 22,79.0,Study 24,
Study 24,DEU,Site 888,Subject 9291,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9291,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9291,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,Subject continuing,Screening,2025-08-11,Visit Level,Form 12,95.0,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,Subject continuing,Screening,2025-08-11,Visit Level,Form 5,95.0,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,Subject continuing,Screening,2025-08-11,Visit Level,Form 22,95.0,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,Subject continuing,Screening,2025-08-11,Visit Level,Form 24,95.0,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,Subject continuing,Screening,2025-08-11,Visit Level,Form 8,95.0,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,Subject continuing,Screening,2025-08-11,Visit Level,Form 9,95.0,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,Subject continuing,Screening,2025-08-11,Visit Level,Form 25,95.0,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9292,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 888,Subject 9293,On Trial,,Adverse Event,,Summary Page,Form 31,,Study 24,
Study 24,DEU,Site 888,Subject 9293,On Trial,,Concomitant Medication,,Summary Page,Form 27,,Study 24,
Study 24,DEU,Site 888,Subject 9293,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9293,On Trial,,Medical History,,Summary Page,Form 32,,Study 24,
Study 24,DEU,Site 888,Subject 9293,On Trial,,Non-drug therapies,,Summary Page,Form 28,,Study 24,
Study 24,DEU,Site 888,Subject 9293,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9293,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9293,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9294,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9294,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9294,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9294,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9295,Enrolled,Subject continuing,Screening,2025-08-18,Visit Level,Form 5,88.0,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,Subject continuing,Screening,2025-08-27,Visit Level,Form 12,79.0,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,Subject continuing,Screening,2025-08-27,Visit Level,Form 5,79.0,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,Subject continuing,Screening,2025-08-27,Visit Level,Form 24,79.0,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,Subject continuing,Screening,2025-08-27,Visit Level,Form 8,79.0,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,Subject continuing,Screening,2025-08-27,Visit Level,Form 9,79.0,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,Subject continuing,Screening,2025-08-27,Visit Level,Form 25,79.0,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9296,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 888,Subject 9297,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-23,Visit Level,Form 26,52.0,Study 24,
Study 24,DEU,Site 888,Subject 9297,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9297,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9297,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9297,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9298,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-18,Visit Level,Form 26,57.0,Study 24,
Study 24,DEU,Site 888,Subject 9298,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9298,On Trial,Subject continuing,Screening,2025-09-04,Visit Level,Form 26,71.0,Study 24,
Study 24,DEU,Site 888,Subject 9298,On Trial,Subject continuing,Screening,2025-09-04,Visit Level,Form 23,71.0,Study 24,
Study 24,DEU,Site 888,Subject 9298,On Trial,Subject continuing,Screening,2025-09-04,Visit Level,Form 17,71.0,Study 24,
Study 24,DEU,Site 888,Subject 9298,On Trial,Subject continuing,Screening,2025-09-04,Visit Level,Form 19,71.0,Study 24,
Study 24,DEU,Site 888,Subject 9298,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9298,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9299,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9299,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9299,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9299,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,DEU,Site 888,Subject 9299,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9299,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9300,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-12,Visit Level,Form 26,63.0,Study 24,
Study 24,DEU,Site 888,Subject 9300,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9300,On Trial,Subject continuing,Screening,2025-09-02,Visit Level,Form 26,73.0,Study 24,
Study 24,DEU,Site 888,Subject 9300,On Trial,Subject continuing,Screening,2025-09-02,Visit Level,Form 24,73.0,Study 24,
Study 24,DEU,Site 888,Subject 9300,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9300,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9300,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9301,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9301,On Trial,Subject continuing,Screening,2025-09-15,Visit Level,Form 22,60.0,Study 24,
Study 24,DEU,Site 888,Subject 9301,On Trial,Subject continuing,Screening,2025-09-15,Visit Level,Form 23,60.0,Study 24,
Study 24,DEU,Site 888,Subject 9301,On Trial,Subject continuing,Screening,2025-09-15,Visit Level,Form 17,60.0,Study 24,
Study 24,DEU,Site 888,Subject 9301,On Trial,Subject continuing,Screening,2025-09-15,Visit Level,Form 19,60.0,Study 24,
Study 24,DEU,Site 888,Subject 9301,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9301,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,DEU,Site 888,Subject 9301,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9301,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,Subject continuing,Screening,2025-09-16,Visit Level,Form 21,59.0,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,Subject continuing,Screening,2025-09-16,Visit Level,Form 12,59.0,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,Subject continuing,Screening,2025-09-16,Visit Level,Form 5,59.0,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,Subject continuing,Screening,2025-09-16,Visit Level,Form 17,59.0,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,Subject continuing,Screening,2025-09-16,Visit Level,Form 24,59.0,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,Subject continuing,Screening,2025-09-16,Visit Level,Form 8,59.0,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,Subject continuing,Screening,2025-09-16,Visit Level,Form 9,59.0,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,Subject continuing,Screening,2025-09-16,Visit Level,Form 25,59.0,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,Subject continuing,Screening,2025-09-16,Visit Level,Form 16,59.0,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9302,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9303,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9303,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9303,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9303,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,DEU,Site 888,Subject 9303,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9303,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 21,45.0,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 12,45.0,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 5,45.0,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 24,45.0,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 8,45.0,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 9,45.0,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 25,45.0,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,Subject continuing,Screening,2025-09-30,Visit Level,Form 16,45.0,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9304,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-16,Visit Level,Form 26,29.0,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 21,38.0,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 12,38.0,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 5,38.0,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 24,38.0,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 8,38.0,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 9,38.0,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 25,38.0,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 16,38.0,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9305,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-16,Visit Level,Form 16,29.0,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,Subject continuing,Screening,2025-10-14,Visit Level,Form 21,31.0,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,Subject continuing,Screening,2025-10-14,Visit Level,Form 12,31.0,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,Subject continuing,Screening,2025-10-14,Visit Level,Form 8,31.0,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,Subject continuing,Screening,2025-10-14,Visit Level,Form 9,31.0,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,Subject continuing,Screening,2025-10-14,Visit Level,Form 25,31.0,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,Subject continuing,Screening,2025-10-14,Visit Level,Form 16,31.0,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9306,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,Subject continuing,Screening,2025-10-17,Visit Level,Form 12,28.0,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,Subject continuing,Screening,2025-10-17,Visit Level,Form 5,28.0,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,Subject continuing,Screening,2025-10-17,Visit Level,Form 24,28.0,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,Subject continuing,Screening,2025-10-17,Visit Level,Form 8,28.0,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,Subject continuing,Screening,2025-10-17,Visit Level,Form 9,28.0,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,Subject continuing,Screening,2025-10-17,Visit Level,Form 25,28.0,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 888,Subject 9307,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 281,Subject 2364,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 281,Subject 2365,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 281,Subject 2365,On Trial,Subject continuing,Screening,2025-09-29,Visit Level,Form 12,46.0,Study 24,
Study 24,DEU,Site 281,Subject 9328,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 281,Subject 9329,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 281,Subject 9329,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 12,39.0,Study 24,
Study 24,DEU,Site 281,Subject 9332,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 281,Subject 9335,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 281,Subject 9335,On Trial,Subject continuing,Screening,2025-10-08,Visit Level,Form 17,37.0,Study 24,
Study 24,DEU,Site 281,Subject 9336,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 281,Subject 9339,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 2187,Subject 47737,On Trial,Subject continuing,Screening,2025-09-04,Visit Level,Form 12,71.0,Study 24,
Study 24,DEU,Site 2187,Subject 47737,On Trial,Subject continuing,Screening,2025-09-04,Visit Level,Form 17,71.0,Study 24,
Study 24,DEU,Site 2187,Subject 47739,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 12,43.0,Study 24,
Study 24,DEU,Site 2187,Subject 47739,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 2187,Subject 47739,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 2187,Subject 47739,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,DEU,Site 2187,Subject 47739,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 2187,Subject 47739,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,Subject continuing,Screening,2025-10-15,Visit Level,Form 21,30.0,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,Subject continuing,Screening,2025-10-15,Visit Level,Form 12,30.0,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,Subject continuing,Screening,2025-10-15,Visit Level,Form 16,30.0,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,Subject continuing,Screening,2025-10-15,Visit Level,Form 20,30.0,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 2187,Subject 47740,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,DEU,Site 2187,Subject 47741,Enrolled,,Adverse Event,,Summary Page,Form 31,,Study 24,
Study 24,DEU,Site 2187,Subject 47741,Enrolled,,Concomitant Medication,,Summary Page,Form 27,,Study 24,
Study 24,DEU,Site 2187,Subject 47741,Enrolled,,Medical History,,Summary Page,Form 32,,Study 24,
Study 24,DEU,Site 904,Subject 9600,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-27,Visit Level,Form 16,18.0,Study 24,
Study 24,DEU,Site 904,Subject 9600,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 904,Subject 9600,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 12,23.0,Study 24,
Study 24,DEU,Site 904,Subject 9600,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 904,Subject 9600,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 904,Subject 9600,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 286,Subject 2386,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 286,Subject 2386,On Trial,Subject continuing,Screening,2025-07-23,Visit Level,Form 17,114.0,Study 24,
Study 24,DEU,Site 286,Subject 2386,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 286,Subject 2386,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 286,Subject 2388,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 286,Subject 2388,On Trial,Subject continuing,Screening,2025-09-03,Visit Level,Form 19,72.0,Study 24,
Study 24,DEU,Site 286,Subject 2388,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 286,Subject 2388,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 286,Subject 2389,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 286,Subject 2389,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 286,Subject 2389,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,DEU,Site 286,Subject 2389,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,DEU,Site 286,Subject 2390,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 286,Subject 2390,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 286,Subject 2390,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,DEU,Site 286,Subject 9776,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,DEU,Site 286,Subject 9776,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 12,39.0,Study 24,
Study 24,DEU,Site 286,Subject 9776,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 9,39.0,Study 24,
Study 24,DEU,Site 286,Subject 9776,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,DEU,Site 286,Subject 9776,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,HKG,Site 10,Subject 18,On Trial,,Antineoplastic Therapy,,Summary Page,Form 30,,Study 24,
Study 24,HKG,Site 10,Subject 852,On Trial,Subject continuing,Cycle 1 Day 1,2025-08-20,Visit Level,Form 16,86.0,Study 24,
Study 24,HKG,Site 10,Subject 852,On Trial,Subject continuing,Screening,2025-07-28,Visit Level,Form 13,109.0,Study 24,
Study 24,HKG,Site 10,Subject 852,On Trial,Subject continuing,Screening,2025-07-28,Visit Level,Form 8,109.0,Study 24,
Study 24,HKG,Site 10,Subject 852,On Trial,Subject continuing,Screening,2025-07-28,Visit Level,Form 9,109.0,Study 24,
Study 24,HKG,Site 110,Subject 893,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,HKG,Site 110,Subject 893,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,HKG,Site 110,Subject 893,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,HKG,Site 110,Subject 893,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,HKG,Site 110,Subject 893,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,IND,Site 597,Subject 4019,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,IND,Site 597,Subject 4019,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,IND,Site 597,Subject 4019,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,IND,Site 597,Subject 4019,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,IND,Site 597,Subject 4019,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,IND,Site 597,Subject 4019,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,IND,Site 597,Subject 4019,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,IND,Site 597,Subject 30317,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,IND,Site 597,Subject 30317,On Trial,Subject continuing,Screening,2025-11-06,Visit Level,Form 5,8.0,Study 24,
Study 24,IND,Site 597,Subject 30317,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,IND,Site 597,Subject 30317,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,IND,Site 597,Subject 30317,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,IND,Site 597,Subject 30317,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,IND,Site 597,Subject 30318,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,IND,Site 597,Subject 30318,On Trial,Subject continuing,Screening,2025-11-06,Visit Level,Form 12,8.0,Study 24,
Study 24,IND,Site 597,Subject 30318,On Trial,Subject continuing,Screening,2025-11-06,Visit Level,Form 5,8.0,Study 24,
Study 24,IND,Site 597,Subject 30318,On Trial,Subject continuing,Screening,2025-11-06,Visit Level,Form 17,8.0,Study 24,
Study 24,IND,Site 597,Subject 30318,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,IND,Site 597,Subject 30318,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,IND,Site 597,Subject 30318,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,IND,Site 597,Subject 30318,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,IND,Site 1646,Subject 30346,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,IND,Site 1646,Subject 30346,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,IND,Site 1646,Subject 30347,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,IND,Site 1646,Subject 30347,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,IND,Site 1646,Subject 30347,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,IND,Site 2163,Subject 47571,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,IND,Site 2163,Subject 47571,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,IND,Site 2163,Subject 47571,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,IND,Site 2163,Subject 47572,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,IND,Site 2163,Subject 47572,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,IND,Site 2163,Subject 47572,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,IND,Site 2163,Subject 47572,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,IND,Site 2163,Subject 47572,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,IND,Site 1648,Subject 30396,Enrolled,Subject continuing,Screening,2025-11-03,Visit Level,Form 5,11.0,Study 24,
Study 24,IND,Site 1648,Subject 30398,On Trial,Subject continuing,Screening,2025-11-03,Visit Level,Form 12,11.0,Study 24,
Study 24,IND,Site 1648,Subject 30398,On Trial,Subject continuing,Screening,2025-11-03,Visit Level,Form 5,11.0,Study 24,
Study 24,IND,Site 1648,Subject 30398,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,IND,Site 1648,Subject 30398,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,IND,Site 1648,Subject 30398,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,IND,Site 1648,Subject 30398,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,IND,Site 1648,Subject 30398,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,IND,Site 1648,Subject 30398,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,IND,Site 1648,Subject 30399,On Trial,Subject continuing,Screening,2025-11-05,Visit Level,Form 5,9.0,Study 24,
Study 24,IND,Site 1648,Subject 30399,On Trial,Subject continuing,Screening,2025-11-05,Visit Level,Form 13,9.0,Study 24,
Study 24,IND,Site 1648,Subject 30399,On Trial,Subject continuing,Screening,2025-11-05,Visit Level,Form 24,9.0,Study 24,
Study 24,ISR,Site 2188,Subject 47744,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 2188,Subject 47745,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 2188,Subject 47745,On Trial,Subject continuing,Screening,2025-08-12,Visit Level,Form 17,94.0,Study 24,
Study 24,ISR,Site 2188,Subject 47746,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-30,Visit Level,Form 16,45.0,Study 24,
Study 24,ISR,Site 2188,Subject 47746,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 524,Subject 3778,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 524,Subject 3778,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,ISR,Site 524,Subject 3778,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,ISR,Site 524,Subject 3778,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,ISR,Site 524,Subject 3778,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,ISR,Site 525,Subject 3782,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 525,Subject 3782,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,ISR,Site 525,Subject 3782,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,ISR,Site 525,Subject 3782,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,ISR,Site 525,Subject 47748,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 525,Subject 47748,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,ISR,Site 525,Subject 47748,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,ISR,Site 525,Subject 47749,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 525,Subject 47749,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,ISR,Site 525,Subject 47749,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,ISR,Site 1791,Subject 34337,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-18,Visit Level,Form 16,57.0,Study 24,
Study 24,ISR,Site 1791,Subject 34337,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 1791,Subject 34337,On Trial,Subject continuing,Screening,2025-09-14,Visit Level,Form 23,61.0,Study 24,
Study 24,ISR,Site 1791,Subject 34337,On Trial,Subject continuing,Screening,2025-09-14,Visit Level,Form 17,61.0,Study 24,
Study 24,ISR,Site 1791,Subject 34337,On Trial,Subject continuing,Screening,2025-09-14,Visit Level,Form 19,61.0,Study 24,
Study 24,ISR,Site 1791,Subject 34337,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,ISR,Site 1791,Subject 34337,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,ISR,Site 1791,Subject 34337,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,ISR,Site 1791,Subject 34338,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 1791,Subject 34338,On Trial,Subject continuing,Screening,2025-09-14,Visit Level,Form 12,61.0,Study 24,
Study 24,ISR,Site 1791,Subject 34338,On Trial,Subject continuing,Screening,2025-09-14,Visit Level,Form 23,61.0,Study 24,
Study 24,ISR,Site 1791,Subject 34338,On Trial,Subject continuing,Screening,2025-09-14,Visit Level,Form 17,61.0,Study 24,
Study 24,ISR,Site 1791,Subject 34338,On Trial,Subject continuing,Screening,2025-09-14,Visit Level,Form 19,61.0,Study 24,
Study 24,ISR,Site 1791,Subject 34338,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,ISR,Site 1791,Subject 34338,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,ISR,Site 1791,Subject 34339,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-17,Visit Level,Form 16,58.0,Study 24,
Study 24,ISR,Site 1791,Subject 34339,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,ISR,Site 1791,Subject 34339,On Trial,Subject continuing,Screening,2025-09-11,Visit Level,Form 23,64.0,Study 24,
Study 24,ISR,Site 1791,Subject 34339,On Trial,Subject continuing,Screening,2025-09-11,Visit Level,Form 17,64.0,Study 24,
Study 24,ISR,Site 1791,Subject 34339,On Trial,Subject continuing,Screening,2025-09-11,Visit Level,Form 19,64.0,Study 24,
Study 24,ISR,Site 1791,Subject 34339,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,ISR,Site 1791,Subject 34339,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,ISR,Site 1791,Subject 34339,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,KOR,Site 48,Subject 208,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 209,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 210,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 212,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 213,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 214,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 216,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 218,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 219,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 220,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 221,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 222,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 223,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 48,Subject 224,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 50,Subject 274,On Trial,Subject continuing,Screening,2025-07-03,Visit Level,Form 12,134.0,Study 24,
Study 24,KOR,Site 50,Subject 285,On Trial,Subject continuing,Screening,2025-09-11,Visit Level,Form 20,64.0,Study 24,
Study 24,KOR,Site 50,Subject 287,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 50,Subject 288,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 50,Subject 288,On Trial,Subject continuing,Screening,2025-10-17,Visit Level,Form 12,28.0,Study 24,
Study 24,KOR,Site 52,Subject 47588,On Trial,Subject continuing,Screening,2025-08-07,Visit Level,Form 9,99.0,Study 24,
Study 24,KOR,Site 52,Subject 47592,On Trial,Subject continuing,Screening,2025-08-13,Visit Level,Form 22,93.0,Study 24,
Study 24,KOR,Site 52,Subject 47596,On Trial,Subject continuing,Cycle 1 Day 15,2025-09-30,Visit Level,Form 22,45.0,Study 24,
Study 24,KOR,Site 52,Subject 47596,On Trial,Subject continuing,Screening,2025-08-26,Visit Level,Form 22,80.0,Study 24,
Study 24,KOR,Site 52,Subject 47597,On Trial,Subject continuing,Screening,2025-09-08,Visit Level,Form 12,67.0,Study 24,
Study 24,KOR,Site 52,Subject 47597,On Trial,Subject continuing,Screening,2025-09-08,Visit Level,Form 22,67.0,Study 24,
Study 24,KOR,Site 52,Subject 47600,On Trial,Subject continuing,Screening,2025-09-04,Visit Level,Form 12,71.0,Study 24,
Study 24,KOR,Site 52,Subject 47600,On Trial,Subject continuing,Screening,2025-09-04,Visit Level,Form 22,71.0,Study 24,
Study 24,KOR,Site 53,Subject 315,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 53,Subject 316,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 53,Subject 317,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 53,Subject 318,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 53,Subject 319,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 53,Subject 320,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 53,Subject 321,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 53,Subject 322,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 2165,Subject 47608,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,KOR,Site 2165,Subject 47608,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,KOR,Site 2165,Subject 47608,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,KOR,Site 2165,Subject 47610,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,KOR,Site 2165,Subject 47610,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,KOR,Site 2165,Subject 47610,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,KOR,Site 2165,Subject 47611,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,KOR,Site 2165,Subject 47611,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,KOR,Site 2165,Subject 47611,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,KOR,Site 2165,Subject 47613,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,KOR,Site 2165,Subject 47613,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,KOR,Site 2165,Subject 47613,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,KOR,Site 2166,Subject 47616,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,KOR,Site 2166,Subject 47616,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,KOR,Site 2166,Subject 47617,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,KOR,Site 2166,Subject 47617,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,KOR,Site 2166,Subject 47618,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,KOR,Site 2166,Subject 47618,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,KOR,Site 2166,Subject 47619,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,KOR,Site 2166,Subject 47619,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,KOR,Site 2169,Subject 47649,Screening,Subject discontinued from study at this visit,Screening,2025-08-29,Visit Level,Form 12,77.0,Study 24,
Study 24,KOR,Site 2169,Subject 47649,Screening,Subject discontinued from study at this visit,Screening,2025-08-29,Visit Level,Form 11,77.0,Study 24,
Study 24,KOR,Site 2169,Subject 47650,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,PRT,Site 349,Subject 2829,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,PRT,Site 1846,Subject 35377,Screening,Subject continuing,Screening,2025-10-30,Visit Level,Form 14,15.0,Study 24,
Study 24,PRT,Site 1846,Subject 35378,Screening,,Screening,2025-11-04,Visit Level,Form 14,10.0,Study 24,
Study 24,PRT,Site 1846,Subject 35378,Screening,,Screening,2025-11-04,Visit Level,Form 15,10.0,Study 24,
Study 24,PRT,Site 530,Subject 3799,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,PRT,Site 530,Subject 3799,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 5,38.0,Study 24,
Study 24,PRT,Site 530,Subject 3799,On Trial,Subject continuing,Screening,2025-10-07,Visit Level,Form 17,38.0,Study 24,
Study 24,PRT,Site 530,Subject 3799,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,PRT,Site 530,Subject 3799,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,PRT,Site 530,Subject 35413,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,PRT,Site 530,Subject 35413,On Trial,Subject continuing,Screening,2025-10-09,Visit Level,Form 5,36.0,Study 24,
Study 24,PRT,Site 530,Subject 35413,On Trial,Subject continuing,Screening,2025-10-09,Visit Level,Form 17,36.0,Study 24,
Study 24,PRT,Site 530,Subject 35413,On Trial,Subject continuing,Screening,2025-10-09,Visit Level,Form 8,36.0,Study 24,
Study 24,PRT,Site 530,Subject 35413,On Trial,Subject continuing,Screening,2025-10-09,Visit Level,Form 9,36.0,Study 24,
Study 24,PRT,Site 530,Subject 35413,On Trial,Subject continuing,Screening,2025-10-09,Visit Level,Form 25,36.0,Study 24,
Study 24,PRT,Site 530,Subject 35413,On Trial,Subject continuing,Screening,2025-10-09,Visit Level,Form 16,36.0,Study 24,
Study 24,PRT,Site 530,Subject 35413,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,PRT,Site 530,Subject 35413,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 21,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 12,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 5,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 23,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 17,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 19,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 24,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 11,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 8,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,Subject continuing,Screening,2025-10-16,Visit Level,Form 16,29.0,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,PRT,Site 530,Subject 35414,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 12,23.0,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 5,23.0,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 8,23.0,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 9,23.0,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 25,23.0,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 16,23.0,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,PRT,Site 530,Subject 35415,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,PRT,Site 530,Subject 35416,Screening,Subject continuing,Screening,2025-10-31,Visit Level,Form 29,14.0,Study 24,
Study 24,PRT,Site 530,Subject 35416,Screening,Subject continuing,Screening,2025-10-31,Visit Level,Form 14,14.0,Study 24,
Study 24,TUR,Site 5,Subject 11,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 5,Subject 11,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 5,Subject 11,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,TUR,Site 5,Subject 3566,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-23,Visit Level,Form 23,52.0,Study 24,
Study 24,TUR,Site 5,Subject 3566,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-23,Visit Level,Form 17,52.0,Study 24,
Study 24,TUR,Site 5,Subject 3566,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-23,Visit Level,Form 19,52.0,Study 24,
Study 24,TUR,Site 5,Subject 3566,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 5,Subject 3566,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 5,Subject 3566,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 5,Subject 3566,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 21,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 12,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 5,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 22,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 13,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 23,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 17,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 19,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 8,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 9,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 25,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 16,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 20,43.0,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,TUR,Site 5,Subject 3567,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,TUR,Site 6,Subject 12,On Trial,Subject continuing,Cycle 2 Day 1,2025-08-04,Visit Level,Form 17,102.0,Study 24,
Study 24,TUR,Site 6,Subject 12,On Trial,Subject continuing,Cycle 3 Day 1,2025-09-09,Visit Level,Form 17,66.0,Study 24,
Study 24,TUR,Site 6,Subject 13,On Trial,Subject continuing,Cycle 3 Day 1,2025-09-10,Visit Level,Form 17,65.0,Study 24,
Study 24,TUR,Site 6,Subject 13,On Trial,Subject continuing,Cycle 4 Day 1,2025-10-10,Visit Level,Form 17,35.0,Study 24,
Study 24,TUR,Site 6,Subject 13,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 6,Subject 31074,On Trial,Subject continuing,Cycle 2 Day 1,2025-10-02,Visit Level,Form 17,43.0,Study 24,
Study 24,TUR,Site 6,Subject 31074,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2170,Subject 47651,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2170,Subject 47652,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2170,Subject 47653,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2170,Subject 47654,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2171,Subject 47655,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2171,Subject 47655,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,TUR,Site 2171,Subject 47656,On Trial,Subject continuing,Cycle 4 Day 1,2025-10-22,Visit Level,Form 16,23.0,Study 24,
Study 24,TUR,Site 2171,Subject 47656,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2171,Subject 47657,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2171,Subject 47657,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 2171,Subject 47657,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 2171,Subject 47657,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,TUR,Site 2171,Subject 47657,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,TUR,Site 2171,Subject 47657,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,TUR,Site 2171,Subject 47657,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,TUR,Site 2172,Subject 47659,On Trial,,Antineoplastic Therapy,,Summary Page,Form 30,,Study 24,
Study 24,TUR,Site 2172,Subject 47659,On Trial,,Medical History,,Summary Page,Form 32,,Study 24,
Study 24,TUR,Site 2172,Subject 47659,On Trial,,Non-drug therapies,,Summary Page,Form 28,,Study 24,
Study 24,TUR,Site 2172,Subject 47660,On Trial,,Unplanned visit,2025-11-14,Visit Level,Form 23,0.0,Study 24,
Study 24,TUR,Site 2172,Subject 47660,On Trial,,Unplanned visit,2025-11-14,Visit Level,Form 19,0.0,Study 24,
Study 24,TUR,Site 2173,Subject 47667,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2174,Subject 47668,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2174,Subject 47668,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 2174,Subject 47668,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,TUR,Site 2174,Subject 47668,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,TUR,Site 2174,Subject 47669,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2174,Subject 47669,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 2174,Subject 47669,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,TUR,Site 2174,Subject 47669,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,TUR,Site 2175,Subject 47670,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2175,Subject 47670,On Trial,Subject continuing,Screening,2025-10-27,Visit Level,Form 13,18.0,Study 24,
Study 24,TUR,Site 2175,Subject 47670,On Trial,Subject continuing,Screening,2025-10-27,Visit Level,Form 20,18.0,Study 24,
Study 24,TUR,Site 2175,Subject 47670,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 2175,Subject 47670,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 2175,Subject 47670,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,TUR,Site 2175,Subject 47670,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,TUR,Site 2175,Subject 47670,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,TUR,Site 2175,Subject 47670,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,TUR,Site 2175,Subject 47671,Screening,Subject continuing,Screening,2025-11-05,Visit Level,Form 14,9.0,Study 24,
Study 24,TUR,Site 2176,Subject 47673,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2176,Subject 47674,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2176,Subject 47675,On Trial,,Adverse Event,,Summary Page,Form 31,,Study 24,
Study 24,TUR,Site 2176,Subject 47675,On Trial,Subject continuing,Screening,2025-09-08,Visit Level,Form 21,67.0,Study 24,
Study 24,TUR,Site 2176,Subject 47675,On Trial,Subject continuing,Screening,2025-09-08,Visit Level,Form 12,67.0,Study 24,
Study 24,TUR,Site 2176,Subject 47675,On Trial,Subject continuing,Screening,2025-09-08,Visit Level,Form 22,67.0,Study 24,
Study 24,TUR,Site 2176,Subject 47675,On Trial,Subject continuing,Screening,2025-09-08,Visit Level,Form 16,67.0,Study 24,
Study 24,TUR,Site 2176,Subject 47675,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 2176,Subject 47675,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 2177,Subject 47677,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2177,Subject 47678,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2177,Subject 47679,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2177,Subject 47680,Screening,,Screening,2025-10-27,Visit Level,Form 14,18.0,Study 24,
Study 24,TUR,Site 2177,Subject 47680,Screening,,Screening,2025-10-27,Visit Level,Form 15,18.0,Study 24,
Study 24,TUR,Site 2178,Subject 47681,On Trial,Subject continuing,Cycle 1 Day 1,2025-08-05,Visit Level,Form 16,101.0,Study 24,
Study 24,TUR,Site 2178,Subject 47681,On Trial,,Non-drug therapies,,Summary Page,Form 28,,Study 24,
Study 24,TUR,Site 2178,Subject 47681,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 2178,Subject 47681,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,TUR,Site 2178,Subject 47682,On Trial,Subject continuing,Cycle 1 Day 1,2025-08-07,Visit Level,Form 16,99.0,Study 24,
Study 24,TUR,Site 2178,Subject 47682,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2178,Subject 47682,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 2178,Subject 47682,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 2178,Subject 47683,On Trial,Subject continuing,Cycle 1 Day 1,2025-10-08,Visit Level,Form 16,37.0,Study 24,
Study 24,TUR,Site 2178,Subject 47683,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2178,Subject 47683,On Trial,Subject continuing,Screening,2025-10-01,Visit Level,Form 16,44.0,Study 24,
Study 24,TUR,Site 2178,Subject 47683,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 2178,Subject 47683,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 2179,Subject 47684,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2179,Subject 47685,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2179,Subject 47687,Screening,Subject continuing,Screening,2025-11-07,Visit Level,Form 14,7.0,Study 24,
Study 24,TUR,Site 2181,Subject 47690,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2181,Subject 47691,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2181,Subject 47692,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-04,Visit Level,Form 16,10.0,Study 24,
Study 24,TUR,Site 2181,Subject 47692,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2181,Subject 47692,On Trial,Subject continuing,Screening,2025-10-31,Visit Level,Form 23,14.0,Study 24,
Study 24,TUR,Site 2181,Subject 47692,On Trial,Subject continuing,Screening,2025-10-31,Visit Level,Form 17,14.0,Study 24,
Study 24,TUR,Site 2181,Subject 47692,On Trial,Subject continuing,Screening,2025-10-31,Visit Level,Form 19,14.0,Study 24,
Study 24,TUR,Site 2181,Subject 47692,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,TUR,Site 2181,Subject 47692,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,TUR,Site 2181,Subject 47692,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,TUR,Site 2181,Subject 47692,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,TUR,Site 558,Subject 3890,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2182,Subject 47693,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2182,Subject 47694,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2182,Subject 47695,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TUR,Site 2182,Subject 47695,On Trial,Subject continuing,Screening,2025-10-13,Visit Level,Form 17,32.0,Study 24,
Study 24,TWN,Site 1673,Subject 30791,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 469,Subject 3565,Enrolled,Subject continuing,Screening,2025-10-27,Visit Level,Form 11,18.0,Study 24,
Study 24,TWN,Site 469,Subject 4744,Enrolled,Subject continuing,Screening,2025-10-28,Visit Level,Form 11,17.0,Study 24,
Study 24,TWN,Site 1674,Subject 30856,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1674,Subject 30857,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1674,Subject 30859,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1674,Subject 30860,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1674,Subject 30861,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1674,Subject 30862,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1674,Subject 30863,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1674,Subject 30864,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1674,Subject 30864,On Trial,Subject continuing,Screening,2025-09-12,Visit Level,Form 11,63.0,Study 24,
Study 24,TWN,Site 1675,Subject 30871,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1675,Subject 30873,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,TWN,Site 1675,Subject 30874,On Trial,Subject continuing,Screening,2025-10-08,Visit Level,Form 12,37.0,Study 24,
Study 24,TWN,Site 1675,Subject 30874,On Trial,Subject continuing,Screening,2025-10-08,Visit Level,Form 13,37.0,Study 24,
Study 24,TWN,Site 1675,Subject 30874,On Trial,Subject continuing,Screening,2025-10-08,Visit Level,Form 20,37.0,Study 24,
Study 24,TWN,Site 1675,Subject 30874,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,TWN,Site 1675,Subject 30875,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 1018,Subject 14934,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 1018,Subject 14934,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,USA,Site 1018,Subject 14935,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 1018,Subject 14935,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,USA,Site 178,Subject 1600,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 178,Subject 1600,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 178,Subject 1600,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 178,Subject 3393,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 178,Subject 3393,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 178,Subject 3393,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,USA,Site 178,Subject 3394,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 178,Subject 3394,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 178,Subject 3394,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 178,Subject 3394,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,USA,Site 178,Subject 40402,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 178,Subject 40402,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 178,Subject 40402,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 178,Subject 40402,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,USA,Site 178,Subject 40403,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 178,Subject 40403,On Trial,Subject continuing,Screening,2025-10-30,Visit Level,Form 17,15.0,Study 24,
Study 24,USA,Site 178,Subject 40403,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 178,Subject 40403,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 178,Subject 40403,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,USA,Site 178,Subject 40403,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,USA,Site 326,Subject 2652,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 326,Subject 2652,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 326,Subject 2652,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 326,Subject 2652,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,USA,Site 326,Subject 2654,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 326,Subject 2654,On Trial,Subject continuing,Screening,2025-09-09,Visit Level,Form 12,66.0,Study 24,
Study 24,USA,Site 326,Subject 2654,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 326,Subject 2654,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 327,Subject 2664,On Trial,Subject continuing,Cycle 5 Day 1,2025-09-17,Visit Level,Form 17,58.0,Study 24,
Study 24,USA,Site 536,Subject 3821,Screen Failure,Subject continuing,Screening,2025-07-30,Visit Level,Form 12,107.0,Study 24,
Study 24,USA,Site 536,Subject 3822,Discontinued,Subject continuing,Cycle 1 Day 1,2025-09-05,Visit Level,Form 16,70.0,Study 24,
Study 24,USA,Site 536,Subject 3822,Discontinued,Subject continuing,Screening,2025-08-08,Visit Level,Form 12,98.0,Study 24,
Study 24,USA,Site 536,Subject 3822,Discontinued,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 536,Subject 3822,Discontinued,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,USA,Site 536,Subject 3823,On Trial,Subject continuing,Cycle 1 Day 1,2025-09-18,Visit Level,Form 16,57.0,Study 24,
Study 24,USA,Site 536,Subject 3823,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 536,Subject 3823,On Trial,Subject continuing,Screening,2025-09-08,Visit Level,Form 12,67.0,Study 24,
Study 24,USA,Site 536,Subject 3823,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 536,Subject 3823,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 536,Subject 3823,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,USA,Site 536,Subject 3823,On Trial,,Study Treatment,,Summary Page,Form 7,,Study 24,
Study 24,USA,Site 536,Subject 40721,Screening,Subject continuing,Screening,2025-11-05,Visit Level,Form 29,9.0,Study 24,
Study 24,USA,Site 536,Subject 40721,Screening,Subject continuing,Screening,2025-11-05,Visit Level,Form 14,9.0,Study 24,
Study 24,USA,Site 536,Subject 40722,Screen Failure,Subject discontinued from study at this visit,Screening,2025-11-06,Visit Level,Form 29,8.0,Study 24,
Study 24,USA,Site 338,Subject 2749,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 338,Subject 2749,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 338,Subject 2749,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 338,Subject 2749,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,USA,Site 1034,Subject 15652,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 1034,Subject 15654,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 1034,Subject 15656,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 1034,Subject 15656,On Trial,Subject continuing,Screening,2025-08-18,Visit Level,Form 12,88.0,Study 24,
Study 24,USA,Site 1034,Subject 15657,On Trial,,Non-drug therapies,,Summary Page,Form 28,,Study 24,
Study 24,USA,Site 1034,Subject 15658,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 2015,Subject 41301,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 2015,Subject 41302,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 2015,Subject 41303,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 2015,Subject 41303,On Trial,Subject continuing,Screening,2025-09-29,Visit Level,Form 12,46.0,Study 24,
Study 24,USA,Site 2015,Subject 41304,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 2015,Subject 41304,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 5,43.0,Study 24,
Study 24,USA,Site 2015,Subject 41304,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 8,43.0,Study 24,
Study 24,USA,Site 2015,Subject 41304,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 9,43.0,Study 24,
Study 24,USA,Site 2015,Subject 41304,On Trial,Subject continuing,Screening,2025-10-02,Visit Level,Form 25,43.0,Study 24,
Study 24,USA,Site 2015,Subject 41305,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 2015,Subject 41305,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 5,23.0,Study 24,
Study 24,USA,Site 2015,Subject 41305,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 8,23.0,Study 24,
Study 24,USA,Site 2015,Subject 41305,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 9,23.0,Study 24,
Study 24,USA,Site 2015,Subject 41305,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 25,23.0,Study 24,
Study 24,USA,Site 1037,Subject 15713,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 1037,Subject 15713,On Trial,Subject continuing,Screening,2025-10-14,Visit Level,Form 22,31.0,Study 24,
Study 24,USA,Site 1037,Subject 15713,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 1037,Subject 15713,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 21,39.0,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 12,39.0,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 22,39.0,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 8,39.0,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 9,39.0,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 25,39.0,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,Subject continuing,Screening,2025-10-06,Visit Level,Form 16,39.0,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,USA,Site 1042,Subject 15782,On Trial,,Study Treatment,,Summary Page,Form 10,,Study 24,
Study 24,USA,Site 2030,Subject 41801,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 2030,Subject 41801,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 2030,Subject 41802,On Trial,Subject continuing,Screening,2025-07-16,Visit Level,Form 12,121.0,Study 24,
Study 24,USA,Site 2030,Subject 41802,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 2030,Subject 41802,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,USA,Site 2030,Subject 41803,On Trial,,Antineoplastic Therapy,,Summary Page,Form 30,,Study 24,
Study 24,USA,Site 2030,Subject 41803,On Trial,,Non-drug therapies,,Summary Page,Form 28,,Study 24,
Study 24,USA,Site 2030,Subject 41803,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 2030,Subject 41803,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 2030,Subject 41803,On Trial,,Study Treatment,,Summary Page,Form 18,,Study 24,
Study 24,USA,Site 2030,Subject 41804,On Trial,,Study Treatment,,Summary Page,Form 2,,Study 24,
Study 24,USA,Site 2030,Subject 41804,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,USA,Site 2030,Subject 41805,On Trial,,Disposition,,Summary Page,Form 1,,Study 24,
Study 24,USA,Site 2030,Subject 41805,On Trial,Subject continuing,Screening,2025-08-12,Visit Level,Form 22,94.0,Study 24,
Study 24,USA,Site 2030,Subject 41805,On Trial,Subject continuing,Screening,2025-08-12,Visit Level,Form 23,94.0,Study 24,
Study 24,USA,Site 2030,Subject 41805,On Trial,Subject continuing,Screening,2025-08-12,Visit Level,Form 19,94.0,Study 24,
Study 24,USA,Site 2030,Subject 41805,On Trial,,Study Treatment,,Summary Page,Form 6,,Study 24,
Study 24,USA,Site 2030,Subject 41805,On Trial,,Study Treatment,,Summary Page,Form 3,,Study 24,
Study 24,USA,Site 2030,Subject 41807,Screening,Subject continuing,Screening,2025-10-10,Visit Level,Form 33,35.0,Study 24,
Study 24,USA,Site 2030,Subject 41808,Screening,Subject continuing,Screening,2025-11-05,Visit Level,Form 14,9.0,Study 24,
Study 2,CHN,Site 4,Subject 10,Survival,,Antineoplastic Medications,,Summary Page,Form1,,Study 2,
Study 2,CHN,Site 4,Subject 10,Survival,,Antineoplastic Radiotherapies,,Summary Page,Form2,,Study 2,
Study 2,CHN,Site 4,Subject 10,Survival,,Antineoplastic Surgeries,,Summary Page,Form3,,Study 2,
Study 2,CHN,Site 4,Subject 106,Follow-Up,,Follow up 5,,Visit Level,Form4,,Study 2,
Study 2,CHN,Site 30,Subject 115,Survival,,Survival,,Summary Page,Form5,,Study 2,
Study 2,CHN,Site 31,Subject 120,Survival,,Survival,,Summary Page,Form5,,Study 2,
Study 2,CHN,Site 33,Subject 122,Follow-Up,,Follow up 5_CO,,Visit Level,Form4,,Study 2,
Study 2,CHN,Site 33,Subject 126,Follow-Up,,Follow up 7,,Visit Level,Form4,,Study 2,
Study 2,CHN,Site 33,Subject 127,Survival,,Survival,,Summary Page,Form5,,Study 2,
Study 2,CHN,Site 33,Subject 130,Survival,,Survival,,Summary Page,Form5,,Study 2,
Study 2,CHN,Site 38,Subject 142,Discontinued,,Survival,,Summary Page,Form5,,Study 2,
Study 2,CHN,Site 40,Subject 157,Follow-Up,,Follow up 5,,Visit Level,Form4,,Study 2,
Study 2,CHN,Site 41,Subject 162,Survival,,Follow up 1,,Visit Level,Form4,,Study 2,
Study 2,CHN,Site 42,Subject 164,Follow-Up,,Follow up 4,,Visit Level,Form4,,Study 2,
Study 2,CHN,Site 42,Subject 165,Survival,,Survival,,Summary Page,Form5,,Study 2,
Study 10,CHN,Site 79,Subject 587,Screening,,Disposition,,Summary Page,Form 1,,Study 10,
Study 10,CHN,Site 79,Subject 587,Screening,,Disposition,,Summary Page,Form 2,,Study 10,
Study 10,CHN,Site 459,Subject 3507,Screening,,Disposition,,Summary Page,Form 1,,Study 10,
Study 10,CHN,Site 459,Subject 3507,Screening,,Disposition,,Summary Page,Form 2,,Study 10,
Study 10,CHN,Site 459,Subject 3507,Screening,Subject continuing,Screening,2025-11-03,Visit Level,Form 4,10.0,Study 10,
Study 10,CHN,Site 459,Subject 3507,Screening,Subject continuing,Screening,2025-11-03,Visit Level,Form 5,10.0,Study 10,
Study 10,CZE,Site 87,Subject 627,Screening,,Concomitant Medication,,Summary Page,Form 6,,Study 10,
Study 10,CZE,Site 87,Subject 627,Screening,,Disposition,,Summary Page,Form 1,,Study 10,
Study 10,CZE,Site 87,Subject 627,Screening,,Disposition,,Summary Page,Form 2,,Study 10,
Study 10,CZE,Site 87,Subject 627,Screening,,Medical History,,Summary Page,Form 7,,Study 10,
Study 10,JPN,Site 462,Subject 3516,Screening,,Disposition,,Summary Page,Form 1,,Study 10,
Study 10,JPN,Site 462,Subject 3516,Screening,,Disposition,,Summary Page,Form 2,,Study 10,
Study 10,JPN,Site 462,Subject 3517,Screening,Subject continuing,Day1,2025-11-06,Visit Level,Form 8,7.0,Study 10,
Study 10,JPN,Site 462,Subject 3517,Screening,,Disposition,,Summary Page,Form 1,,Study 10,
Study 10,JPN,Site 462,Subject 3517,Screening,,Disposition,,Summary Page,Form 2,,Study 10,
Study 10,JPN,Site 463,Subject 3521,Screening,,Disposition,,Summary Page,Form 1,,Study 10,
Study 10,JPN,Site 463,Subject 3521,Screening,,Disposition,,Summary Page,Form 2,,Study 10,
Study 10,JPN,Site 463,Subject 3521,Screening,Subject continuing,Screening,2025-10-29,Visit Level,Form 9,15.0,Study 10,
Study 10,USA,Site 28,Subject 2233,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-01,Visit Level,Form 4,43.0,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,,Concomitant Medication,,Summary Page,Form 6,,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,,Medical History,,Summary Page,Form 7,,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 10,16.0,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 11,16.0,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 4,16.0,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 12,16.0,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 5,16.0,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 13,16.0,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 14,16.0,Study 10,
Study 10,USA,Site 38,Subject 146,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 9,16.0,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,,Concomitant Medication,,Summary Page,Form 6,,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,,Medical History,,Summary Page,Form 7,,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 10,16.0,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 11,16.0,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 4,16.0,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 12,16.0,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 5,16.0,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 13,16.0,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 14,16.0,Study 10,
Study 10,USA,Site 38,Subject 147,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-28,Visit Level,Form 9,16.0,Study 10,
Study 10,USA,Site 40,Subject 159,On Trial,,Concomitant Medication,,Summary Page,Form 6,,Study 10,
Study 10,USA,Site 42,Subject 165,On Trial,,Concomitant Medication,,Summary Page,Form 6,,Study 10,
Study 10,USA,Site 42,Subject 165,On Trial,,Medical History,,Summary Page,Form 7,,Study 10,
Study 11,JPN,Site 454,,On Trial,Subject continuing,Week 68/F16,2025-10-29,Visit Level,Form 2,14.0,Study 11,
Study 11,ARG,Site 526,,On Trial,SUBJECT DISCONTINUED FROM POST TREATMENT FOLLOW UP AT THIS VISIT,Week 76/F24/EOS,2025-11-06,Visit Level,Form 3,6.0,Study 11,
Study 11,USA,Site 186,,On Trial,Subject continuing,Week 64/F12,2025-10-27,Visit Level,Form 3,16.0,Study 11,
Study 11,BEL,Site 63,,On Trial,,Week 72/F20,,Visit Level,Form 5,,Study 11,
Study 11,CZE,Site 7,,Discontinued,,Week 60/F8,,Visit Level,Form 5,,Study 11,
Study 11,CZE,Site 472,,On Trial,,Week 72/F20,,Visit Level,Form 5,,Study 11,
Study 11,FRA,Site 488,,On Trial,,Week 68/F16,,Visit Level,Form 5,,Study 11,
Study 11,DEU,Site 496,,On Trial,,Week 68/F16,,Visit Level,Form 5,,Study 11,
Study 11,DEU,Site 501,,On Trial,,Week 68/F16,,Visit Level,Form 5,,Study 11,
Study 11,ITA,Site 506,,Discontinued,,Week 60/F8,,Visit Level,Form 5,,Study 11,
Study 11,ITA,Site 507,,On Trial,,Week 72/F20,,Visit Level,Form 5,,Study 11,
Study 11,NLD,Site 128,,On Trial,,Week 72/F20,,Visit Level,Form 5,,Study 11,
Study 11,ESP,Site 353,,On Trial,,Week 68/F16,,Visit Level,Form 5,,Study 11,
Study 11,COL,Site 520,,On Trial,,Week 68/F16,,Visit Level,Form 5,,Study 11,
Study 11,ARG,Site 524,,On Trial,,Week 72/F20,,Visit Level,Form 5,,Study 11,
Study 11,MEX,Site 528,,Discontinued,,Week 68/F16,,Visit Level,Form 5,,Study 11,
Study 11,USA,Site 189,,On Trial,,Week 72/F20,,Visit Level,Form 5,,Study 11,
Study 11,IRL,Site 541,,On Trial,,Week 68/F16,,Visit Level,Form 5,,Study 11,
Study 11,ZAF,Site 5,,Discontinued,,Week 76/F24/EOS,,Visit Level,Form 6,,Study 11,
Study 11,ITA,Site 505,,Discontinued,,Week 76/F24/EOS,,Visit Level,Form 6,,Study 11,
Study 11,ITA,Site 507,,On Trial,,Week 76/F24/EOS,,Visit Level,Form 6,,Study 11,
Study 11,CHE,Site 148,,Discontinued,,Week 76/F24/EOS,,Visit Level,Form 6,,Study 11,
Study 11,USA,Site 545,,On Trial,,Week 76/F24/EOS,,Visit Level,Form 6,,Study 11,
Study 11,FRA,Site 492,,Discontinued,,Week 68/F16,,Visit Level,Form 7,,Study 11,
Study 11,FRA,Site 492,,Discontinued,,Week 72/F20,,Visit Level,Form 7,,Study 11,
Study 13,AUS,Site 87,Subject 627,On Trial,,Cycle 4 Day 1,,Visit Level,Form 1,,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-06,Visit Level,Form 2,7.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-06,Visit Level,Form 3,7.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-06,Visit Level,Form 4,7.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Cycle 1 Day 2,2025-11-07,Visit Level,Form 3,6.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Cycle 1 Day 2,2025-11-07,Visit Level,Form 4,6.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,,Cycle 1 Day 8,,Visit Level,Form 1,,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,,Disposition,,Summary Page,Form 5,,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,,Exposure,,Summary Page,Form 6,,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,,Exposure,,Summary Page,Form 7,,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,,Exposure,,Summary Page,Form 8,,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 9,22.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 10,22.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 11,22.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 12,22.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 13,22.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 14,22.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 15,22.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 16,22.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,Subject continuing,Screening,2025-10-22,Visit Level,Form 17,22.0,Study 13,
Study 13,AUS,Site 110,Subject 893,On Trial,,Tumor Assessment Summary,,Summary Page,Form 18,,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-11,Visit Level,Form 2,2.0,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-11,Visit Level,Form 19,2.0,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-11,Visit Level,Form 20,2.0,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-11,Visit Level,Form 21,2.0,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-11,Visit Level,Form 22,2.0,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,Subject continuing,Cycle 1 Day 1,2025-11-11,Visit Level,Form 4,2.0,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,,Cycle 1 Day 2,,Visit Level,Form 1,,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,,Exposure,,Summary Page,Form 6,,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,,Exposure,,Summary Page,Form 7,,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,,Exposure,,Summary Page,Form 8,,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,Subject continuing,Screening,2025-11-04,Visit Level,Form 11,9.0,Study 13,
Study 13,CAN,Site 2,Subject 3,On Trial,,Tumor Assessment Summary,,Summary Page,Form 18,,Study 13,
Study 13,DEU,Site 598,Subject 4020,Screening,,Disposition,,Summary Page,Form 5,,Study 13,
Study 13,DEU,Site 598,Subject 4020,Screening,Subject continuing,Screening,2025-11-12,Visit Level,Form 23,1.0,Study 13,
Study 13,ISR,Site 588,Subject 3983,Discontinued,,Non-drug therapies,,Summary Page,Form 24,,Study 13,
Study 13,ISR,Site 589,Subject 3984,Discontinued,,SAE/ADR,,Summary Page,Form 25,,Study 13,
Study 13,ISR,Site 589,Subject 3984,Discontinued,,SAE/ADR,,Summary Page,Form 26,,Study 13,
Study 13,ISR,Site 589,Subject 3984,Discontinued,,SAE/ADR,,Summary Page,Form 27,,Study 13,
Study 13,ISR,Site 589,Subject 3984,Discontinued,,SAE/ADR,,Summary Page,Form 28,,Study 13,
Study 13,ISR,Site 589,Subject 3984,Discontinued,,SAE/ADR,,Summary Page,Form 29,,Study 13,
Study 13,ISR,Site 589,Subject 3985,Discontinued,,Non-drug therapies,,Summary Page,Form 24,,Study 13,
Study 13,JPN,Site 417,Subject 3229,Discontinued,,Post Antineoplastic therapies,,Summary Page,Form 30,,Study 13,
Study 13,JPN,Site 417,Subject 3229,Discontinued,,Post Antineoplastic therapies,,Summary Page,Form 31,,Study 13,
Study 13,JPN,Site 417,Subject 3229,Discontinued,,Post Antineoplastic therapies,,Summary Page,Form 32,,Study 13,
Study 13,JPN,Site 417,Subject 3229,Discontinued,,Safety F/U,,Visit Level,Form 33,,Study 13,
Study 13,JPN,Site 417,Subject 3229,Discontinued,,Tumor Assessment Summary,,Summary Page,Form 34,,Study 13,
Study 13,KOR,Site 125,Subject 1072,Discontinued,,Post Antineoplastic therapies,,Summary Page,Form 30,,Study 13,
Study 13,KOR,Site 125,Subject 1072,Discontinued,,Post Antineoplastic therapies,,Summary Page,Form 31,,Study 13,
Study 13,KOR,Site 125,Subject 1072,Discontinued,,Post Antineoplastic therapies,,Summary Page,Form 32,,Study 13,
Study 13,KOR,Site 125,Subject 1072,Discontinued,,Safety F/U,,Visit Level,Form 33,,Study 13,
Study 13,SGP,Site 130,Subject 1139,Discontinued,,SAE/ADR,,Summary Page,Form 25,,Study 13,
Study 13,SGP,Site 130,Subject 1139,Discontinued,,SAE/ADR,,Summary Page,Form 26,,Study 13,
Study 13,SGP,Site 130,Subject 1139,Discontinued,,SAE/ADR,,Summary Page,Form 27,,Study 13,
Study 13,SGP,Site 130,Subject 1139,Discontinued,,SAE/ADR,,Summary Page,Form 28,,Study 13,
Study 13,SGP,Site 130,Subject 1139,Discontinued,,SAE/ADR,,Summary Page,Form 35,,Study 13,
Study 13,SGP,Site 130,Subject 1139,Discontinued,,SAE/ADR,,Summary Page,Form 29,,Study 13,
Study 13,SGP,Site 130,Subject 1141,On Trial,,Cycle 2 Day 15,,Visit Level,Form 1,,Study 13,
Study 13,SGP,Site 130,Subject 1141,On Trial,,SAE/ADR,,Summary Page,Form 25,,Study 13,
Study 13,SGP,Site 130,Subject 1141,On Trial,,SAE/ADR,,Summary Page,Form 26,,Study 13,
Study 13,SGP,Site 130,Subject 1141,On Trial,,SAE/ADR,,Summary Page,Form 27,,Study 13,
Study 13,SGP,Site 130,Subject 1141,On Trial,,SAE/ADR,,Summary Page,Form 28,,Study 13,
Study 13,SGP,Site 130,Subject 1141,On Trial,,SAE/ADR,,Summary Page,Form 29,,Study 13,
Study 13,SGP,Site 130,Subject 1141,On Trial,,Tumor Assessment Summary,,Summary Page,Form 36,,Study 13,
Study 13,USA,Site 109,Subject 836,On Trial,,Cycle 2 Day 15,,Visit Level,Form 1,,Study 13,
Study 13,USA,Site 109,Subject 836,On Trial,,Tumor Assessment Summary,,Summary Page,Form 36,,Study 13,
Study 13,USA,Site 468,Subject 3560,Screening,,Disposition,,Summary Page,Form 5,,Study 13,
Study 13,USA,Site 468,Subject 3560,Screening,,Screening,,Visit Level,Form 37,,Study 13,
Study 13,USA,Site 468,Subject 3560,Screening,,Screening,,Visit Level,Form 23,,Study 13,
Study 13,USA,Site 468,Subject 3560,Screening,,Screening,,Visit Level,Form 38,,Study 13,
Study 13,USA,Site 468,Subject 3560,Screening,,Screening,,Visit Level,Form 39,,Study 13,
Study 13,USA,Site 468,Subject 3560,Screening,,Screening,,Visit Level,Form 40,,Study 13,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 1,2025-10-29,Visit Level,Form 1,15.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 1,2025-10-29,Visit Level,Form 2,15.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 1,2025-10-29,Visit Level,Form 3,15.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 1,2025-10-29,Visit Level,Form 4,15.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 1,2025-10-29,Visit Level,Form 5,15.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 1,2025-10-29,Visit Level,Form 6,15.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,,Day 14,,Visit Level,Form 7,,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 2,2025-10-30,Visit Level,Form 8,14.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 2,2025-10-30,Visit Level,Form 9,14.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 2,2025-10-30,Visit Level,Form 10,14.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 2,2025-10-30,Visit Level,Form 11,14.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 2,2025-10-30,Visit Level,Form 12,14.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,Subject continuing,Day 2,2025-10-30,Visit Level,Form 13,14.0,Study 14,
Study 14,CAN,Site 502,Subject 3704,On Trial,,Disposition,,Summary Page,Form 14,,Study 14,
Study 14,CAN,Site 502,Subject 3705,Screening,,Baseline,,Visit Level,Form 15,,Study 14,
Study 14,CAN,Site 502,Subject 3705,Screening,,Baseline,,Visit Level,Form 16,,Study 14,
Study 14,CAN,Site 502,Subject 3705,Screening,,Baseline,,Visit Level,Form 17,,Study 14,
Study 14,CAN,Site 502,Subject 3705,Screening,,Disposition,,Summary Page,Form 14,,Study 14,
Study 16,ARG,Site 678,Subject 4330,On Trial,Subject continuing,Week 68,2025-11-12,Visit Level,From 1,1.0,Study 16,
Study 16,ARG,Site 683,Subject 4353,On Trial,Subject continuing,Week 12,2025-11-05,Visit Level,From 2,8.0,Study 16,
Study 16,AUS,Site 700,Subject 4442,Discontinued,,Unplanned Visit,2025-06-17,Visit Level,From 3,149.0,Study 16,
Study 16,AUS,Site 702,Subject 4451,On Trial,,Unplanned Visit,2025-05-21,Visit Level,From 3,176.0,Study 16,
Study 16,AUS,Site 702,Subject 4451,On Trial,,Unplanned Visit,2025-06-09,Visit Level,From 3,157.0,Study 16,
Study 16,AUS,Site 702,Subject 4452,On Trial,,Adverse Events,,Summary Page,From 4,,Study 16,
Study 16,AUS,Site 702,Subject 4455,On Trial,,Unplanned Visit,2025-11-11,Visit Level,From 3,2.0,Study 16,
Study 16,AUS,Site 702,Subject 4456,On Trial,,Adverse Events,,Summary Page,From 4,,Study 16,
Study 16,BRA,Site 684,Subject 4355,On Trial,,Unplanned Visit,2024-10-21,Visit Level,From 5,388.0,Study 16,
Study 16,BRA,Site 685,Subject 4368,On Trial,Subject continuing,Week 28,2025-11-06,Visit Level,From 1,7.0,Study 16,
Study 16,BRA,Site 686,Subject 4379,On Trial,Subject continuing,Week 20,2025-11-05,Visit Level,From 1,8.0,Study 16,
Study 16,CAN,Site 624,Subject 4181,Follow-Up,,Unplanned Visit,2024-07-05,Visit Level,From 3,496.0,Study 16,
Study 16,CAN,Site 624,Subject 4181,Follow-Up,,Unplanned Visit,2024-07-25,Visit Level,From 3,476.0,Study 16,
Study 16,CHN,Site 736,Subject 4595,On Trial,Subject continuing,Week 24,2025-11-11,Visit Level,From 7,2.0,Study 16,
Study 16,CHN,Site 737,Subject 4598,On Trial,Subject continuing,Week 36,2025-11-07,Visit Level,From 1,6.0,Study 16,
Study 16,CHN,Site 737,Subject 4604,On Trial,Subject continuing,Week 12,2025-10-29,Visit Level,From 8,15.0,Study 16,
Study 16,CHN,Site 741,Subject 4615,On Trial,Subject continuing,Week 26,2025-10-23,Visit Level,From 9,21.0,Study 16,
Study 16,CHN,Site 741,Subject 4616,On Trial,,Disposition,,Summary Page,From 10,,Study 16,
Study 16,CHN,Site 741,Subject 4616,On Trial,Subject continuing,Week 14,2025-10-17,Visit Level,From 9,27.0,Study 16,
Study 16,CHN,Site 742,Subject 4617,On Trial,Subject continuing,Week 42,2025-10-17,Visit Level,From 9,27.0,Study 16,
Study 16,CHN,Site 745,Subject 4634,Discontinued,,Hospitalization,,Summary Page,From 11,,Study 16,
Study 16,CHN,Site 745,Subject 4634,Discontinued,,Procedures,,Summary Page,From 12,,Study 16,
Study 16,CHN,Site 745,Subject 4634,Discontinued,,Survival,,Summary Page,From 13,,Study 16,
Study 16,CHN,Site 747,Subject 4642,On Trial,Subject continuing,Week 26,2025-09-24,Visit Level,From 9,50.0,Study 16,
Study 16,CHN,Site 747,Subject 4642,On Trial,Subject continuing,Week 28,2025-10-09,Visit Level,From 9,35.0,Study 16,
Study 16,CHN,Site 747,Subject 4642,On Trial,Subject continuing,Week 30,2025-10-22,Visit Level,From 9,22.0,Study 16,
Study 16,CHN,Site 747,Subject 4642,On Trial,Subject continuing,Week 32,2025-11-05,Visit Level,From 9,8.0,Study 16,
Study 16,CHN,Site 747,Subject 4643,On Trial,Subject continuing,Week 16,2025-09-23,Visit Level,From 9,51.0,Study 16,
Study 16,CHN,Site 747,Subject 4643,On Trial,Subject continuing,Week 18,2025-10-09,Visit Level,From 9,35.0,Study 16,
Study 16,CHN,Site 747,Subject 4643,On Trial,Subject continuing,Week 20,2025-10-21,Visit Level,From 9,23.0,Study 16,
Study 16,CHN,Site 747,Subject 4643,On Trial,Subject continuing,Week 22,2025-11-04,Visit Level,From 9,9.0,Study 16,
Study 16,CHN,Site 751,Subject 4655,On Trial,Subject continuing,Week 40,2025-10-17,Visit Level,From 8,27.0,Study 16,
Study 16,CHN,Site 751,Subject 4655,On Trial,Subject continuing,Week 40,2025-10-17,Visit Level,From 1,27.0,Study 16,
Study 16,ESP,Site 652,Subject 4252,On Trial,Subject continuing,Week 40,2025-11-04,Visit Level,From 14,9.0,Study 16,
Study 16,ESP,Site 652,Subject 4252,On Trial,Subject continuing,Week 40,2025-11-04,Visit Level,From 15,9.0,Study 16,
Study 16,ESP,Site 652,Subject 4252,On Trial,Subject continuing,Week 40,2025-11-04,Visit Level,From 9,9.0,Study 16,
Study 16,ESP,Site 652,Subject 4252,On Trial,Subject continuing,Week 40,2025-11-04,Visit Level,From 7,9.0,Study 16,
Study 16,FRA,Site 644,Subject 4233,On Trial,Subject continuing,Week 14,2025-08-18,Visit Level,From 9,87.0,Study 16,
Study 16,FRA,Site 644,Subject 4233,On Trial,Subject continuing,Week 16,2025-09-01,Visit Level,From 9,73.0,Study 16,
Study 16,FRA,Site 644,Subject 4233,On Trial,Subject continuing,Week 18,2025-09-15,Visit Level,From 9,59.0,Study 16,
Study 16,FRA,Site 644,Subject 4233,On Trial,Subject continuing,Week 20,2025-09-29,Visit Level,From 9,45.0,Study 16,
Study 16,FRA,Site 644,Subject 4233,On Trial,Subject continuing,Week 22,2025-10-13,Visit Level,From 9,31.0,Study 16,
Study 16,GRC,Site 632,Subject 4204,On Trial,,Unplanned Visit,2025-06-11,Visit Level,From 3,155.0,Study 16,
Study 16,GRC,Site 634,Subject 4207,On Trial,,Unplanned Visit,2025-01-22,Visit Level,From 3,295.0,Study 16,
Study 16,GRC,Site 635,Subject 4208,On Trial,,Unplanned Visit,2025-03-13,Visit Level,From 3,245.0,Study 16,
Study 16,IND,Site 765,Subject 4704,On Trial,,Unplanned Visit,2025-05-19,Visit Level,From 3,178.0,Study 16,
Study 16,IND,Site 765,Subject 4704,On Trial,,Unplanned Visit,2025-06-02,Visit Level,From 3,164.0,Study 16,
Study 16,IND,Site 765,Subject 4707,On Trial,,Unplanned Visit,2025-07-14,Visit Level,From 3,122.0,Study 16,
Study 16,IND,Site 768,Subject 4721,On Trial,Subject continuing,Week 12,2025-11-03,Visit Level,From 8,10.0,Study 16,
Study 16,IND,Site 768,Subject 4721,On Trial,Subject continuing,Week 12,2025-11-03,Visit Level,From 16,10.0,Study 16,
Study 16,IND,Site 768,Subject 4722,On Trial,Subject continuing,Week 12,2025-10-28,Visit Level,From 8,16.0,Study 16,
Study 16,IND,Site 769,Subject 4724,On Trial,Subject continuing,Week 40,2025-11-12,Visit Level,From 17,1.0,Study 16,
Study 16,IND,Site 769,Subject 4724,On Trial,Subject continuing,Week 40,2025-11-12,Visit Level,From 14,1.0,Study 16,
Study 16,IND,Site 769,Subject 4724,On Trial,Subject continuing,Week 40,2025-11-12,Visit Level,From 15,1.0,Study 16,
Study 16,IND,Site 769,Subject 4724,On Trial,Subject continuing,Week 40,2025-11-12,Visit Level,From 7,1.0,Study 16,
Study 16,ISR,Site 771,Subject 4731,On Trial,Subject continuing,Week 32,2025-09-15,Visit Level,From 1,59.0,Study 16,
Study 16,ISR,Site 771,Subject 4733,On Trial,,Unplanned Visit,2025-07-21,Visit Level,From 3,115.0,Study 16,
Study 16,ISR,Site 774,Subject 4742,On Trial,Subject continuing,Week 50,2025-10-29,Visit Level,From 9,15.0,Study 16,
Study 16,ITA,Site 661,Subject 4281,On Trial,Subject continuing,Week 2,2025-05-05,Visit Level,From 2,192.0,Study 16,
Study 16,ITA,Site 661,Subject 4281,On Trial,Subject continuing,Week 2,2025-05-05,Visit Level,From 1,192.0,Study 16,
Study 16,ITA,Site 661,Subject 4281,On Trial,Subject continuing,Week 2,2025-05-05,Visit Level,From 9,192.0,Study 16,
Study 16,ITA,Site 661,Subject 4281,On Trial,Subject continuing,Week 2,2025-05-05,Visit Level,From 16,192.0,Study 16,
Study 16,JPN,Site 703,Subject 4459,On Trial,Subject continuing,Week 42,2025-09-27,Visit Level,From 9,47.0,Study 16,
Study 16,JPN,Site 703,Subject 4459,On Trial,Subject continuing,Week 44,2025-10-11,Visit Level,From 9,33.0,Study 16,
Study 16,JPN,Site 703,Subject 4459,On Trial,Subject continuing,Week 46,2025-10-25,Visit Level,From 9,19.0,Study 16,
Study 16,JPN,Site 703,Subject 4459,On Trial,Subject continuing,Week 48,2025-11-08,Visit Level,From 9,5.0,Study 16,
Study 16,JPN,Site 703,Subject 4462,On Trial,Subject continuing,Week 24,2025-11-07,Visit Level,From 2,6.0,Study 16,
Study 16,JPN,Site 703,Subject 4462,On Trial,Subject continuing,Week 24,2025-11-07,Visit Level,From 16,6.0,Study 16,
Study 16,JPN,Site 703,Subject 4463,On Trial,Subject continuing,Week 14,2025-10-25,Visit Level,From 9,19.0,Study 16,
Study 16,JPN,Site 703,Subject 4463,On Trial,Subject continuing,Week 16,2025-11-09,Visit Level,From 9,4.0,Study 16,
Study 16,JPN,Site 704,Subject 4464,On Trial,Subject continuing,Week 36,2025-10-25,Visit Level,From 9,19.0,Study 16,
Study 16,JPN,Site 706,Subject 4468,On Trial,Subject continuing,Week 26,2025-08-28,Visit Level,From 9,77.0,Study 16,
Study 16,JPN,Site 706,Subject 4468,On Trial,Subject continuing,Week 28,2025-09-11,Visit Level,From 9,63.0,Study 16,
Study 16,JPN,Site 706,Subject 4468,On Trial,Subject continuing,Week 30,2025-09-25,Visit Level,From 9,49.0,Study 16,
Study 16,JPN,Site 706,Subject 4468,On Trial,Subject continuing,Week 32,2025-10-09,Visit Level,From 9,35.0,Study 16,
Study 16,JPN,Site 706,Subject 4468,On Trial,Subject continuing,Week 34,2025-10-22,Visit Level,From 9,22.0,Study 16,
Study 16,JPN,Site 706,Subject 4469,On Trial,Subject continuing,Week 14,2025-09-03,Visit Level,From 9,71.0,Study 16,
Study 16,JPN,Site 706,Subject 4469,On Trial,Subject continuing,Week 16,2025-09-15,Visit Level,From 9,59.0,Study 16,
Study 16,JPN,Site 706,Subject 4469,On Trial,Subject continuing,Week 18,2025-09-30,Visit Level,From 9,44.0,Study 16,
Study 16,JPN,Site 706,Subject 4469,On Trial,Subject continuing,Week 20,2025-10-13,Visit Level,From 9,31.0,Study 16,
Study 16,JPN,Site 706,Subject 4469,On Trial,Subject continuing,Week 22,2025-10-29,Visit Level,From 9,15.0,Study 16,
Study 16,JPN,Site 706,Subject 4470,On Trial,Subject continuing,Week 14,2025-10-10,Visit Level,From 9,34.0,Study 16,
Study 16,JPN,Site 706,Subject 4470,On Trial,Subject continuing,Week 16,2025-10-24,Visit Level,From 9,20.0,Study 16,
Study 16,JPN,Site 708,Subject 4474,On Trial,Subject continuing,Week 26,2025-09-11,Visit Level,From 9,63.0,Study 16,
Study 16,JPN,Site 708,Subject 4474,On Trial,Subject continuing,Week 28,2025-09-25,Visit Level,From 9,49.0,Study 16,
Study 16,JPN,Site 708,Subject 4474,On Trial,Subject continuing,Week 30,2025-10-09,Visit Level,From 9,35.0,Study 16,
Study 16,JPN,Site 708,Subject 4477,On Trial,Subject continuing,Week 14,2025-10-10,Visit Level,From 9,34.0,Study 16,
Study 16,JPN,Site 709,Subject 4480,On Trial,Subject continuing,Week 30,2025-10-08,Visit Level,From 9,36.0,Study 16,
Study 16,JPN,Site 711,Subject 4487,On Trial,,Unplanned Visit,2025-10-24,Visit Level,From 18,20.0,Study 16,
Study 16,JPN,Site 711,Subject 4487,On Trial,,Unplanned Visit,2025-10-24,Visit Level,From 19,20.0,Study 16,
Study 16,JPN,Site 711,Subject 4487,On Trial,,Unplanned Visit,2025-10-24,Visit Level,From 20,20.0,Study 16,
Study 16,JPN,Site 711,Subject 4487,On Trial,,Unplanned Visit,2025-10-24,Visit Level,From 5,20.0,Study 16,
Study 16,JPN,Site 711,Subject 4488,On Trial,Subject continuing,Week 42,2025-10-10,Visit Level,From 9,34.0,Study 16,
Study 16,JPN,Site 711,Subject 4488,On Trial,Subject continuing,Week 44,2025-10-24,Visit Level,From 1,20.0,Study 16,
Study 16,JPN,Site 711,Subject 4488,On Trial,Subject continuing,Week 44,2025-10-24,Visit Level,From 9,20.0,Study 16,
Study 16,JPN,Site 711,Subject 4488,On Trial,Subject continuing,Week 46,2025-11-07,Visit Level,From 9,6.0,Study 16,
Study 16,JPN,Site 712,Subject 4498,On Trial,Subject continuing,Week 18,2025-10-20,Visit Level,From 9,24.0,Study 16,
Study 16,JPN,Site 712,Subject 4499,On Trial,Subject continuing,Week 14,2025-09-29,Visit Level,From 9,45.0,Study 16,
Study 16,JPN,Site 712,Subject 4499,On Trial,Subject continuing,Week 16,2025-10-13,Visit Level,From 9,31.0,Study 16,
Study 16,JPN,Site 712,Subject 4499,On Trial,Subject continuing,Week 18,2025-10-27,Visit Level,From 9,17.0,Study 16,
Study 16,JPN,Site 712,Subject 4499,On Trial,Subject continuing,Week 20,2025-11-10,Visit Level,From 9,3.0,Study 16,
Study 16,JPN,Site 712,Subject 4500,On Trial,Subject continuing,Week 16,2025-11-03,Visit Level,From 1,10.0,Study 16,
Study 16,JPN,Site 712,Subject 4500,On Trial,Subject continuing,Week 16,2025-11-03,Visit Level,From 9,10.0,Study 16,
Study 16,JPN,Site 713,Subject 4501,On Trial,Subject continuing,Week 26,2025-10-22,Visit Level,From 9,22.0,Study 16,
Study 16,JPN,Site 713,Subject 4501,On Trial,Subject continuing,Week 28,2025-11-06,Visit Level,From 1,7.0,Study 16,
Study 16,JPN,Site 713,Subject 4501,On Trial,Subject continuing,Week 28,2025-11-06,Visit Level,From 9,7.0,Study 16,
Study 16,KOR,Site 719,Subject 4515,On Trial,Subject continuing,Week 26,2025-10-29,Visit Level,From 9,15.0,Study 16,
Study 16,KOR,Site 720,Subject 4518,On Trial,Subject continuing,Week 38,2025-10-12,Visit Level,From 9,32.0,Study 16,
Study 16,KOR,Site 720,Subject 4518,On Trial,Subject continuing,Week 40,2025-10-29,Visit Level,From 9,15.0,Study 16,
Study 16,KOR,Site 721,Subject 4521,On Trial,Subject continuing,Week 24,2025-10-27,Visit Level,From 7,17.0,Study 16,
Study 16,KOR,Site 722,Subject 4522,On Trial,,Unplanned Visit,2025-04-28,Visit Level,From 3,199.0,Study 16,
Study 16,KOR,Site 723,Subject 4532,On Trial,,Unplanned Visit,2025-01-08,Visit Level,From 3,309.0,Study 16,
Study 16,MEX,Site 676,Subject 4326,On Trial,Subject continuing,Week 36,2025-11-03,Visit Level,From 16,10.0,Study 16,
Study 16,TUR,Site 757,Subject 4672,On Trial,,Unplanned Visit,2024-09-16,Visit Level,From 3,423.0,Study 16,
Study 16,TUR,Site 757,Subject 4672,On Trial,,Unplanned Visit,2024-09-27,Visit Level,From 3,412.0,Study 16,
Study 16,TUR,Site 760,Subject 4688,On Trial,,Unplanned Visit,2025-06-17,Visit Level,From 3,149.0,Study 16,
Study 16,USA,Site 602,Subject 4092,On Trial,,Unplanned Visit,2025-10-28,Visit Level,From 18,16.0,Study 16,
Study 16,USA,Site 602,Subject 4095,On Trial,Subject continuing,Week 84,2025-10-30,Visit Level,From 9,14.0,Study 16,
Study 16,USA,Site 602,Subject 4101,On Trial,Subject continuing,Week 60,2025-10-30,Visit Level,From 9,14.0,Study 16,
Study 16,USA,Site 602,Subject 4104,On Trial,Subject continuing,Week 22,2025-10-30,Visit Level,From 9,14.0,Study 16,
Study 16,USA,Site 608,Subject 4127,On Trial,Subject continuing,Week 26,2025-09-17,Visit Level,From 9,57.0,Study 16,
Study 16,USA,Site 608,Subject 4127,On Trial,Subject continuing,Week 28,2025-09-29,Visit Level,From 9,45.0,Study 16,
Study 16,USA,Site 608,Subject 4127,On Trial,Subject continuing,Week 30,2025-10-13,Visit Level,From 9,31.0,Study 16,
Study 16,USA,Site 608,Subject 4127,On Trial,Subject continuing,Week 32,2025-10-28,Visit Level,From 9,16.0,Study 16,
Study 16,USA,Site 608,Subject 4127,On Trial,Subject continuing,Week 34,2025-11-10,Visit Level,From 9,3.0,Study 16,
Study 16,USA,Site 610,Subject 4136,On Trial,,Unplanned Visit,2025-05-20,Visit Level,From 5,177.0,Study 16,
Study 16,USA,Site 614,Subject 4153,Completed,,Unplanned Visit,2025-07-11,Visit Level,From 3,125.0,Study 16,
Study 16,USA,Site 618,Subject 4162,On Trial,,Unplanned Visit,2025-04-08,Visit Level,From 3,219.0,Study 16,
Study 16,USA,Site 620,Subject 4165,On Trial,,Unplanned Visit,2025-05-22,Visit Level,From 3,175.0,Study 16,
Study 16,USA,Site 620,Subject 4165,On Trial,,Unplanned Visit,2025-05-27,Visit Level,From 3,170.0,Study 16,
Study 16,USA,Site 620,Subject 4165,On Trial,Subject continuing,Week 16,2025-07-16,Visit Level,From 9,120.0,Study 16,
Study 16,USA,Site 620,Subject 4165,On Trial,Subject continuing,Week 18,2025-07-31,Visit Level,From 9,105.0,Study 16,
Study 16,USA,Site 620,Subject 4165,On Trial,Subject continuing,Week 20,2025-08-15,Visit Level,From 9,90.0,Study 16,
Study 16,USA,Site 620,Subject 4165,On Trial,Subject continuing,Week 24,2025-09-08,Visit Level,From 9,66.0,Study 16,
Study 16,USA,Site 620,Subject 4165,On Trial,Subject continuing,Week 26,2025-09-26,Visit Level,From 9,48.0,Study 16,
Study 16,USA,Site 622,Subject 4174,On Trial,Subject continuing,Week 56,2025-10-30,Visit Level,From 9,14.0,Study 16,
Study 17,CAN,Site 14,Subject 25,Discontinued,,eSAE,,Summary Page,Form 1,,Study 17,
Study 17,CAN,Site 14,Subject 25,Discontinued,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 3,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 4,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 5,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 6,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,END OF TREATMENT,,Visit Level,Form 8,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,END OF TREATMENT,,Visit Level,Form 9,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,eSAE,,Summary Page,Form 1,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,eSAE,,Summary Page,Form 10,,Study 17,
Study 17,CAN,Site 14,Subject 26,Discontinued,,PROCEDURES,,Summary Page,Form 11,,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 12,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 13,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 14,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 15,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 16,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 17,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 18,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 19,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 20,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 21,17.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,,CYCLE 1 DAY 15,,Visit Level,Form 22,,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,,CYCLE 1 DAY 15,,Visit Level,Form 9,,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 2,2025-10-29,Visit Level,Form 17,16.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 2,2025-10-29,Visit Level,Form 19,16.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 3,2025-10-30,Visit Level,Form 17,15.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 3,2025-10-30,Visit Level,Form 19,15.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 4,,Visit Level,Form 9,,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 8,2025-11-03,Visit Level,Form 17,11.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 8,2025-11-03,Visit Level,Form 19,11.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,CYCLE 1 DAY 8,2025-11-03,Visit Level,Form 20,11.0,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,,DISPOSITION,,Summary Page,Form 23,,Study 17,
Study 17,CAN,Site 15,Subject 39,On Trial,Subject continuing,SCREENING,2025-09-18,Visit Level,Form 24,57.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-10-28,Visit Level,Form 25,17.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-10-28,Visit Level,Form 26,17.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-10-28,Visit Level,Form 27,17.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-10-28,Visit Level,Form 28,17.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-10-28,Visit Level,Form 29,17.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,,DISPOSITION,,Summary Page,Form 23,,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,,POST 68GA-NNS309 IMAGING,,Visit Level,Form 30,,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,,POST 68GA-NNS309 IMAGING,,Visit Level,Form 9,,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 31,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 24,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 32,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 33,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 34,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 35,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 36,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 37,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 38,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 20,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 39,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 40,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 41,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 42,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 43,22.0,Study 17,
Study 17,CAN,Site 15,Subject 40,On Trial,Subject continuing,SCREENING,2025-10-23,Visit Level,Form 44,22.0,Study 17,
Study 17,CAN,Site 16,Subject 55,Discontinued,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,CAN,Site 16,Subject 56,Screen Failure,Subject continuing,68GA-NNS309 IMAGING,2025-08-26,Visit Level,Form 25,80.0,Study 17,
Study 17,CHE,Site 776,Subject 4754,Screening,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,CHE,Site 776,Subject 4754,Screening,,eSAE,,Summary Page,Form 1,,Study 17,
Study 17,CHE,Site 776,Subject 4754,Screening,,eSAE,,Summary Page,Form 45,,Study 17,
Study 17,CHE,Site 776,Subject 4754,Screening,,eSAE,,Summary Page,Form 46,,Study 17,
Study 17,CHE,Site 776,Subject 4754,Screening,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,CHE,Site 776,Subject 4754,Screening,Subject continuing,SCREENING,2025-07-11,Visit Level,Form 20,126.0,Study 17,
Study 17,CHE,Site 776,Subject 4755,Screening,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,CHE,Site 776,Subject 4755,Screening,,CONCOMITANT MEDICATION,,Summary Page,Form 47,,Study 17,
Study 17,CHE,Site 776,Subject 4755,Screening,,PROCEDURES,,Summary Page,Form 11,,Study 17,
Study 17,CHE,Site 776,Subject 4755,Screening,Subject continuing,SCREENING,2025-07-18,Visit Level,Form 20,119.0,Study 17,
Study 17,ESP,Site 7,Subject 14,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,ESP,Site 7,Subject 14,On Trial,,CYCLE 2 DAY 15,,Visit Level,Form 22,,Study 17,
Study 17,ESP,Site 7,Subject 14,On Trial,,CYCLE 2 DAY 15,,Visit Level,Form 9,,Study 17,
Study 17,ESP,Site 7,Subject 14,On Trial,,eSAE,,Summary Page,Form 1,,Study 17,
Study 17,ESP,Site 7,Subject 14,On Trial,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,ESP,Site 7,Subject 14,On Trial,Subject continuing,SCREENING,2025-07-25,Visit Level,Form 16,112.0,Study 17,
Study 17,ESP,Site 7,Subject 14,On Trial,,UNPLANNED VISIT,2025-10-23,Visit Level,Form 48,22.0,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-09-03,Visit Level,Form 25,72.0,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,,90 DAYS SAFETY FUP,,Visit Level,Form 49,,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,,90 DAYS SAFETY FUP,,Visit Level,Form 9,,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,Subject continuing,CYCLE 1 DAY 15,2025-09-29,Visit Level,Form 50,46.0,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,Subject continuing,CYCLE 1 DAY 15,2025-09-29,Visit Level,Form 51,46.0,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,,DISEASE PROGRESSION FU 1,,Visit Level,Form 52,,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,,DISEASE PROGRESSION FU 1,,Visit Level,Form 9,,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,Subject moving to safety and disease progression follow up,END OF TREATMENT,2025-10-28,Visit Level,Form 20,17.0,Study 17,
Study 17,ESP,Site 7,Subject 594,On Trial,,PROCEDURES,,Summary Page,Form 11,,Study 17,
Study 17,ESP,Site 775,Subject 4752,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,ESP,Site 775,Subject 4752,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-10-28,Visit Level,Form 18,17.0,Study 17,
Study 17,ESP,Site 775,Subject 4752,On Trial,,CYCLE 1 DAY 22,,Visit Level,Form 22,,Study 17,
Study 17,ESP,Site 775,Subject 4752,On Trial,,CYCLE 1 DAY 22,,Visit Level,Form 9,,Study 17,
Study 17,ESP,Site 775,Subject 4752,On Trial,Subject continuing,SCREENING,2025-09-22,Visit Level,Form 33,53.0,Study 17,
Study 17,FRA,Site 466,Subject 3544,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,FRA,Site 466,Subject 3544,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-09-02,Visit Level,Form 18,73.0,Study 17,
Study 17,FRA,Site 466,Subject 3544,On Trial,,CYCLE 2 DAY 29,,Visit Level,Form 22,,Study 17,
Study 17,FRA,Site 466,Subject 3544,On Trial,,CYCLE 2 DAY 29,,Visit Level,Form 9,,Study 17,
Study 17,FRA,Site 466,Subject 3545,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,FRA,Site 466,Subject 3545,On Trial,,CYCLE 2 DAY 29,,Visit Level,Form 22,,Study 17,
Study 17,FRA,Site 466,Subject 3545,On Trial,,CYCLE 2 DAY 29,,Visit Level,Form 9,,Study 17,
Study 17,FRA,Site 466,Subject 3546,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,FRA,Site 466,Subject 3546,On Trial,Subject continuing,CYCLE 2 DAY 1,2025-10-30,Visit Level,Form 53,15.0,Study 17,
Study 17,FRA,Site 466,Subject 3546,On Trial,,CYCLE 2 DAY 15,,Visit Level,Form 22,,Study 17,
Study 17,FRA,Site 466,Subject 3546,On Trial,,CYCLE 2 DAY 15,,Visit Level,Form 9,,Study 17,
Study 17,FRA,Site 466,Subject 3546,On Trial,,eSAE,,Summary Page,Form 1,,Study 17,
Study 17,FRA,Site 466,Subject 3546,On Trial,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,FRA,Site 466,Subject 3546,On Trial,Subject continuing,SCREENING,2025-08-22,Visit Level,Form 54,84.0,Study 17,
Study 17,FRA,Site 466,Subject 3546,On Trial,Subject continuing,SCREENING,2025-08-22,Visit Level,Form 55,84.0,Study 17,
Study 17,FRA,Site 466,Subject 3546,On Trial,,UNPLANNED VISIT,2025-10-20,Visit Level,Form 35,25.0,Study 17,
Study 17,FRA,Site 466,Subject 3547,Discontinued,,ADVERSE EVENT,,Summary Page,Form 56,,Study 17,
Study 17,FRA,Site 466,Subject 3547,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 3,,Study 17,
Study 17,FRA,Site 466,Subject 3547,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 4,,Study 17,
Study 17,FRA,Site 466,Subject 3547,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 5,,Study 17,
Study 17,FRA,Site 466,Subject 3547,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 6,,Study 17,
Study 17,FRA,Site 466,Subject 3547,Discontinued,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,FRA,Site 466,Subject 3547,Discontinued,,CONCOMITANT MEDICATION,,Summary Page,Form 47,,Study 17,
Study 17,FRA,Site 466,Subject 3547,Discontinued,,MEDICAL HISTORY,,Summary Page,Form 57,,Study 17,
Study 17,FRA,Site 466,Subject 3547,Discontinued,,PROCEDURES,,Summary Page,Form 11,,Study 17,
Study 17,ISR,Site 469,Subject 4745,On Trial,,eSAE,,Summary Page,Form 1,,Study 17,
Study 17,ISR,Site 469,Subject 4745,On Trial,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,ISR,Site 469,Subject 4747,Completed,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,ISR,Site 469,Subject 4749,Discontinued,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,ISR,Site 469,Subject 4749,Discontinued,,eSAE,,Summary Page,Form 1,,Study 17,
Study 17,ISR,Site 469,Subject 4749,Discontinued,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,ISR,Site 469,Subject 4751,Screen Failure,Subject discontinued from study at this visit,SCREENING,2025-09-25,Visit Level,Form 37,50.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,68GA-NNS309 IMAGING,2025-10-14,Visit Level,Form 26,31.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 1,2025-10-29,Visit Level,Form 12,16.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 1,2025-10-29,Visit Level,Form 19,16.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 1,2025-10-29,Visit Level,Form 21,16.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 15,2025-11-10,Visit Level,Form 50,4.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 15,2025-11-10,Visit Level,Form 51,4.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 15,2025-11-10,Visit Level,Form 17,4.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 15,2025-11-10,Visit Level,Form 19,4.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 15,2025-11-10,Visit Level,Form 34,4.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 15,2025-11-10,Visit Level,Form 36,4.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 15,2025-11-10,Visit Level,Form 38,4.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 15,2025-11-10,Visit Level,Form 20,4.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 15,2025-11-10,Visit Level,Form 58,4.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,,CYCLE 1 DAY 22,,Visit Level,Form 22,,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,,CYCLE 1 DAY 22,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 8,2025-11-04,Visit Level,Form 34,10.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 8,2025-11-04,Visit Level,Form 36,10.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 8,2025-11-04,Visit Level,Form 38,10.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,CYCLE 1 DAY 8,2025-11-04,Visit Level,Form 20,10.0,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,POST 68GA-NNS309 IMAGING,,Visit Level,Form 59,,Study 17,
Study 17,USA,Site 177,Subject 1595,Completed,Subject continuing,POST 68GA-NNS309 IMAGING,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 60,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 1,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 61,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 62,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 45,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 46,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 10,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 63,,Study 17,
Study 17,USA,Site 177,Subject 1596,Screen Failure,,eSAE,,Summary Page,Form 64,,Study 17,
Study 17,USA,Site 19,Subject 77,On Trial,,END OF TREATMENT,,Visit Level,Form 8,,Study 17,
Study 17,USA,Site 19,Subject 77,On Trial,,END OF TREATMENT,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 19,Subject 78,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 3,,Study 17,
Study 17,USA,Site 19,Subject 78,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 4,,Study 17,
Study 17,USA,Site 19,Subject 78,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 5,,Study 17,
Study 17,USA,Site 19,Subject 78,Discontinued,,ANTINEOPLASTIC THERAPIES,,Summary Page,Form 6,,Study 17,
Study 17,USA,Site 19,Subject 78,Discontinued,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,USA,Site 19,Subject 79,On Trial,,180 DAYS SAFETY FUP,,Visit Level,Form 49,,Study 17,
Study 17,USA,Site 19,Subject 79,On Trial,,180 DAYS SAFETY FUP,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 19,Subject 79,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,USA,Site 19,Subject 79,On Trial,,CYCLE 2 DAY 15,,Visit Level,Form 22,,Study 17,
Study 17,USA,Site 19,Subject 79,On Trial,,CYCLE 2 DAY 15,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 19,Subject 80,Completed,,90 DAYS SAFETY FUP,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 19,Subject 80,Completed,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,USA,Site 19,Subject 80,Completed,,DISEASE PROGRESSION FU 1,,Visit Level,Form 52,,Study 17,
Study 17,USA,Site 19,Subject 80,Completed,,DISEASE PROGRESSION FU 1,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 19,Subject 81,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,USA,Site 19,Subject 4756,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,USA,Site 19,Subject 4756,On Trial,,CYCLE 1 DAY 22,,Visit Level,Form 22,,Study 17,
Study 17,USA,Site 19,Subject 4756,On Trial,,CYCLE 1 DAY 22,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 19,Subject 4756,On Trial,,DISPOSITION,,Summary Page,Form 23,,Study 17,
Study 17,USA,Site 19,Subject 4756,On Trial,Subject continuing,SCREENING,2025-09-22,Visit Level,Form 24,53.0,Study 17,
Study 17,USA,Site 19,Subject 4757,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,USA,Site 19,Subject 4757,On Trial,,CYCLE 1 DAY 1,,Visit Level,Form 22,,Study 17,
Study 17,USA,Site 19,Subject 4757,On Trial,,CYCLE 1 DAY 1,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 19,Subject 4757,On Trial,,DISPOSITION,,Summary Page,Form 23,,Study 17,
Study 17,USA,Site 19,Subject 4757,On Trial,Subject continuing,SCREENING,2025-10-21,Visit Level,Form 24,24.0,Study 17,
Study 17,USA,Site 325,Subject 2648,Screening,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,USA,Site 325,Subject 2648,Screening,,DISPOSITION,,Summary Page,Form 23,,Study 17,
Study 17,USA,Site 325,Subject 2648,Screening,Subject continuing,SCREENING,2025-09-30,Visit Level,Form 37,45.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-10-22,Visit Level,Form 65,23.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-10-22,Visit Level,Form 66,23.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-10-22,Visit Level,Form 25,23.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,68GA-NNS309 IMAGING,2025-10-22,Visit Level,Form 26,23.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,,BLOOD COMPONENT TRANSFUSION,,Summary Page,Form 7,,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-11-03,Visit Level,Form 12,11.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-11-03,Visit Level,Form 13,11.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-11-03,Visit Level,Form 14,11.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-11-03,Visit Level,Form 15,11.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-11-03,Visit Level,Form 17,11.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-11-03,Visit Level,Form 18,11.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 1,2025-11-03,Visit Level,Form 21,11.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,,CYCLE 1 DAY 15,,Visit Level,Form 22,,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,,CYCLE 1 DAY 15,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 2,2025-11-04,Visit Level,Form 17,10.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 3,2025-11-05,Visit Level,Form 17,9.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 8,2025-11-10,Visit Level,Form 17,4.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 8,2025-11-10,Visit Level,Form 34,4.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 8,2025-11-10,Visit Level,Form 36,4.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 8,2025-11-10,Visit Level,Form 38,4.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 8,2025-11-10,Visit Level,Form 20,4.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,CYCLE 1 DAY 8,2025-11-10,Visit Level,Form 58,4.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,,DISPOSITION,,Summary Page,Form 23,,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,,eSAE,,Summary Page,Form 1,,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,,eSAE,,Summary Page,Form 2,,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,,eSAE,,Summary Page,Form 10,,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,,eSAE,,Summary Page,Form 63,,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,,eSAE,,Summary Page,Form 64,,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,SCREENING,2025-10-17,Visit Level,Form 48,28.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,SCREENING,2025-10-17,Visit Level,Form 33,28.0,Study 17,
Study 17,USA,Site 325,Subject 2649,On Trial,Subject continuing,SCREENING,2025-10-17,Visit Level,Form 39,28.0,Study 17,
Study 17,USA,Site 327,Subject 2664,On Trial,,180 DAYS SAFETY FUP,,Visit Level,Form 49,,Study 17,
Study 17,USA,Site 327,Subject 2664,On Trial,,180 DAYS SAFETY FUP,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 327,Subject 3396,Discontinued,,90 DAYS SAFETY FUP,,Visit Level,Form 49,,Study 17,
Study 17,USA,Site 327,Subject 3396,Discontinued,,90 DAYS SAFETY FUP,,Visit Level,Form 9,,Study 17,
Study 17,USA,Site 327,Subject 4759,On Trial,,CYCLE 1 DAY 8,,Visit Level,Form 22,,Study 17,
Study 17,USA,Site 327,Subject 4759,On Trial,,CYCLE 1 DAY 8,,Visit Level,Form 9,,Study 17,
Study 18,USA,Site 2,Subject 4781,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-14,Visit Level,Form 1,29.0,Study 18,
Study 18,USA,Site 2,Subject 4783,Screening,,Screening,2025-10-14,Visit Level,Form 2,29.0,Study 18,
Study 18,USA,Site 2,Subject 4783,Screening,,Screening,2025-10-14,Visit Level,Form 1,29.0,Study 18,
Study 18,USA,Site 2,Subject 4783,Screening,,Screening,2025-10-14,Visit Level,Form 3,29.0,Study 18,
Study 18,USA,Site 2,Subject 4785,Screening,,Screening,2025-10-14,Visit Level,Form 2,29.0,Study 18,
Study 18,USA,Site 2,Subject 4785,Screening,,Screening,2025-10-14,Visit Level,Form 1,29.0,Study 18,
Study 18,USA,Site 2,Subject 4785,Screening,,Screening,2025-10-14,Visit Level,Form 3,29.0,Study 18,
Study 18,USA,Site 2,Subject 4788,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-20,Visit Level,Form 1,23.0,Study 18,
Study 18,USA,Site 2,Subject 4790,Screen Failure,Subject discontinued from study at this visit,Screening,2025-10-20,Visit Level,Form 1,23.0,Study 18,
Study 18,USA,Site 2,Subject 4791,Screening,,Screening,2025-10-20,Visit Level,Form 2,23.0,Study 18,
Study 18,USA,Site 2,Subject 4791,Screening,,Screening,2025-10-20,Visit Level,Form 1,23.0,Study 18,
Study 18,USA,Site 2,Subject 4791,Screening,,Screening,2025-10-20,Visit Level,Form 3,23.0,Study 18,
Study 18,USA,Site 2,Subject 4795,Screening,,Screening,2025-10-20,Visit Level,Form 2,23.0,Study 18,
Study 18,USA,Site 2,Subject 4795,Screening,,Screening,2025-10-20,Visit Level,Form 1,23.0,Study 18,
Study 18,USA,Site 2,Subject 4795,Screening,,Screening,2025-10-20,Visit Level,Form 3,23.0,Study 18,
,,,,,,,2025-10-07,,,,Study 1,
,,,,,,,,,,,Study 1,
,,,,,,,2025-10-30,,,,Study 1,
,,,,,,,2025-09-16,,,,Study 1,
,,,,,,,2025-10-14,,,,Study 1,
,,,,,,,2025-08-26,,,,Study 1,
,,,,,,,2025-09-24,,,,Study 1,
,,,,,,,2025-10-16,,,,Study 1,
,,,,,,,2025-10-17,,,,Study 1,
,,,,,,,2025-10-08,,,,Study 1,
,,,,,,,2025-04-10,,,,Study 1,
,,,,,,,2025-09-14,,,,Study 1,
,,,,,,,2025-09-23,,,,Study 1,
,,,,,,,2025-09-17,,,,Study 1,
,,,,,,,2025-08-07,,,,Study 1,
,,,,,,,2025-08-19,,,,Study 1,
,,,,,,,2025-09-08,,,,Study 1,
,,,,,,,2025-09-30,,,,Study 1,
,,,,,,,2025-10-21,,,,Study 1,
,,,,,,,2025-07-22,,,,Study 1,
,,,,,,,2025-09-15,,,,Study 1,
,,,,,,,2025-10-22,,,,Study 1,
,,,,,,,2025-09-29,,,,Study 1,
,,,,,,,2025-07-30,,,,Study 1,
,,,,,,,2025-10-01,,,,Study 1,
,,,,,,,2025-09-12,,,,Study 1,
,,,,,,,2025-10-03,,,,Study 1,
,,,,,,,2025-10-24,,,,Study 1,
,,,,,,,2025-11-12,,,,Study 1,
,,,,,,,2025-09-19,,,,Study 1,
Study 4,GBR,Site 158,Subject 1442,,,Antineoplastic - Medication,2025-09-02,Summary Page,Form 1,73.0,Study 4,
Study 4,GBR,Site 158,Subject 1442,,,Antineoplastic-Radiotherapy,2025-09-02,Summary Page,Form 2,73.0,Study 4,
Study 4,GBR,Site 158,Subject 1442,,,Antineoplastic-Radiotherapy,2023-03-09,Summary Page,Form 3,981.0,Study 4,
Study 4,GBR,Site 158,Subject 1442,,,Antineoplastic Surgery,2025-09-02,Summary Page,Form 4,73.0,Study 4,
Study 5,ARG,Site 165,Subject 2590,On Trial,,Screening,2025-09-15,Form 1,,60.0,Study 5,Subject continuing
Study 5,ARG,Site 165,Subject 2590,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ARG,Site 165,Subject 2590,On Trial,,Last Fraction (EOT1),,Form 1,,,Study 5,
Study 5,ARG,Site 165,Subject 2590,On Trial,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,ARG,Site 165,Subject 2591,Screening,,Screening,2025-10-02,Form 1,,43.0,Study 5,
Study 5,ARG,Site 315,Subject 2592,Screening,,Screening,2025-10-30,Form 1,,15.0,Study 5,
Study 5,ARG,Site 315,Subject 2593,Screening,,Screening,,Form 1,,,Study 5,
Study 5,ARG,Site 315,Subject 2594,Screening,,Screening,2025-11-05,Form 1,,9.0,Study 5,
Study 5,ARG,Site 316,Subject 2595,Screen Failure,,Screening,2025-08-01,Form 1,,105.0,Study 5,Subject discontinued from study at this visit
Study 5,ARG,Site 316,Subject 2595,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ARG,Site 316,Subject 2596,Screen Failure,,Screening,2025-08-04,Form 1,,102.0,Study 5,Subject discontinued from study at this visit
Study 5,ARG,Site 316,Subject 2596,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ARG,Site 316,Subject 2597,Screen Failure,,Screening,2025-08-14,Form 1,,92.0,Study 5,Subject discontinued from study at this visit
Study 5,ARG,Site 316,Subject 2597,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ARG,Site 316,Subject 2598,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ARG,Site 316,Subject 2599,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ARG,Site 316,Subject 2600,Screen Failure,,Screening,2025-09-24,Form 1,,51.0,Study 5,Subject discontinued from study at this visit
Study 5,ARG,Site 316,Subject 2600,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 2,Follow-Up,,EOT2/Safety FU (42D),2025-02-07,Form 1,,280.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,AUS,Site 2,Subject 2,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 2,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 2,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 2,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,AUS,Site 2,Subject 3,Follow-Up,,Efficacy FU 2,2025-10-02,Form 1,,43.0,Study 5,SUBJECT CONTINUING
Study 5,AUS,Site 2,Subject 3,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 3,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 3,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 3,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 3,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 3,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,AUS,Site 2,Subject 3,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,AUS,Site 2,Subject 4,Follow-Up,,EOT2/Safety FU (42D),2025-06-25,Form 1,,142.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,AUS,Site 2,Subject 4,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 4,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,AUS,Site 2,Subject 4,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,AUS,Site 28,Subject 107,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,AUS,Site 28,Subject 107,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,AUS,Site 28,Subject 107,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,AUS,Site 28,Subject 107,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,AUS,Site 28,Subject 107,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,AUS,Site 28,Subject 107,Follow-Up,,Long term safety FU 2,,Form 1,,,Study 5,
Study 5,AUS,Site 28,Subject 2235,On Trial,,Cycle 2 Week 3,,Form 1,,,Study 5,
Study 5,AUS,Site 259,Subject 2236,Screening,,Screening,2025-10-31,Form 1,,14.0,Study 5,
Study 5,AUT,Site 14,Subject 25,Follow-Up,,Last Fraction (EOT1),2025-03-28,Form 1,,231.0,Study 5,Subject continuing
Study 5,AUT,Site 14,Subject 25,Follow-Up,,Screening,2025-02-18,Form 1,,269.0,Study 5,Subject continuing
Study 5,AUT,Site 14,Subject 25,Follow-Up,,EOT2/Safety FU (42D),2025-09-23,Form 1,,52.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,AUT,Site 14,Subject 25,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,AUT,Site 14,Subject 25,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,AUT,Site 14,Subject 25,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,AUT,Site 14,Subject 25,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,AUT,Site 14,Subject 25,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,AUT,Site 14,Subject 25,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,AUT,Site 15,Subject 44,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,AUT,Site 15,Subject 45,On Trial,,Cycle 3 Week 3,,Form 1,,,Study 5,
Study 5,AUT,Site 15,Subject 45,On Trial,,Cycle 3 Week 1,2025-11-11,Form 1,,3.0,Study 5,SUBJECT CONTINUING
Study 5,AUT,Site 15,Subject 45,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,AUT,Site 15,Subject 45,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,AUT,Site 15,Subject 45,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,BEL,Site 268,Subject 2298,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,BEL,Site 268,Subject 2299,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,BEL,Site 268,Subject 2299,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,BEL,Site 268,Subject 2299,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,BEL,Site 268,Subject 2299,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,BEL,Site 268,Subject 2299,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,BEL,Site 268,Subject 2299,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,BEL,Site 268,Subject 2304,On Trial,,Cycle 4 Week 1,,Form 1,,,Study 5,
Study 5,BEL,Site 268,Subject 2304,On Trial,,Cycle 3 Week 3,2025-10-23,Form 1,,22.0,Study 5,SUBJECT CONTINUING
Study 5,BEL,Site 268,Subject 2310,Screening,,Screening,2025-11-10,Form 1,,4.0,Study 5,
Study 5,BRA,Site 324,Subject 2638,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,BRA,Site 324,Subject 2640,On Trial,,Cycle 3 Week 1,,Form 1,,,Study 5,
Study 5,BRA,Site 324,Subject 2640,On Trial,,Last Fraction (EOT1),2025-08-25,Form 1,,81.0,Study 5,Subject continuing
Study 5,BRA,Site 324,Subject 2640,On Trial,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,BRA,Site 324,Subject 2641,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,BRA,Site 324,Subject 2642,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,BRA,Site 324,Subject 2645,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,BRA,Site 324,Subject 2646,Screening,,Screening,2025-10-09,Form 1,,36.0,Study 5,
Study 5,BRA,Site 324,Subject 2647,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,CAN,Site 317,Subject 2603,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,CAN,Site 317,Subject 2603,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,CAN,Site 317,Subject 2603,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,CAN,Site 317,Subject 2603,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,CAN,Site 317,Subject 2603,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,CAN,Site 317,Subject 2603,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,CAN,Site 317,Subject 2603,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,CAN,Site 317,Subject 2608,On Trial,,EOT2/Safety FU (42D),,Form 1,,,Study 5,
Study 5,CAN,Site 317,Subject 2608,On Trial,,Last Fraction (EOT1),2025-05-26,Form 1,,172.0,Study 5,Subject continuing
Study 5,CAN,Site 317,Subject 2608,On Trial,,Screening,2025-04-10,Form 1,,218.0,Study 5,Subject continuing
Study 5,CAN,Site 318,Subject 2616,On Trial,,Cycle 4 Week 1,,Form 1,,,Study 5,
Study 5,CAN,Site 318,Subject 2616,On Trial,,Screening,2025-05-12,Form 1,,186.0,Study 5,Subject continuing
Study 5,CAN,Site 320,Subject 2618,On Trial,,EOT2/Safety FU (42D),2025-09-05,Form 1,,70.0,Study 5,SUBJECT MOVING TO SURVIVAL
Study 5,CAN,Site 320,Subject 2618,On Trial,,Survival FU 1,,Form 1,,,Study 5,
Study 5,CAN,Site 320,Subject 2622,On Trial,,Cycle 4 Week 1,,Form 1,,,Study 5,
Study 5,CAN,Site 320,Subject 2622,On Trial,,Last Fraction (EOT1),2025-07-02,Form 1,,135.0,Study 5,Subject continuing
Study 5,CAN,Site 320,Subject 2622,On Trial,,Cycle 3 Week 1,2025-10-08,Form 1,,37.0,Study 5,SUBJECT CONTINUING
Study 5,CAN,Site 320,Subject 2622,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,CAN,Site 320,Subject 2622,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,CAN,Site 320,Subject 2622,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2626,Survival,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2626,Survival,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2626,Survival,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2626,Survival,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2626,Survival,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,CAN,Site 322,Subject 2626,Survival,,Survival FU 2,,Form 1,,,Study 5,
Study 5,CAN,Site 322,Subject 2629,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,CAN,Site 322,Subject 2629,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,SUBJECT CONTINUING
Study 5,CAN,Site 322,Subject 2629,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2629,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2629,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2629,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2629,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,CAN,Site 322,Subject 2630,Follow-Up,,EOT2/Safety FU (42D),2025-07-24,Form 1,,113.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,CAN,Site 322,Subject 2630,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2630,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2630,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2630,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2630,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,CAN,Site 322,Subject 2630,Follow-Up,,Survival FU 1,,Form 1,,,Study 5,
Study 5,CAN,Site 322,Subject 2633,On Trial,,Cycle 4 Week 3,,Form 1,,,Study 5,
Study 5,CAN,Site 322,Subject 2634,On Trial,,Cycle 4 Week 1,,Form 1,,,Study 5,
Study 5,CAN,Site 322,Subject 2634,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2634,On Trial,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,CAN,Site 322,Subject 2635,Screening,,Screening,,Form 1,,,Study 5,
Study 5,CAN,Site 322,Subject 2636,Screening,,Screening,2025-11-04,Form 1,,10.0,Study 5,Subject continuing
Study 5,CAN,Site 322,Subject 2636,Screening,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,CHE,Site 311,Subject 2581,Discontinued,,Efficacy FU 1,,Form 1,,,Study 5,SUBJECT DISCONTINUED FROM STUDY AT THIS VISIT
Study 5,CHE,Site 311,Subject 2581,Discontinued,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,CHE,Site 311,Subject 2581,Discontinued,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,CHE,Site 311,Subject 2581,Discontinued,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,CHE,Site 311,Subject 2581,Discontinued,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,CHE,Site 312,Subject 2582,On Trial,,Cycle 4 Week 1,,Form 1,,,Study 5,
Study 5,CHE,Site 312,Subject 2582,On Trial,,Last Fraction (EOT1),2025-07-10,Form 1,,127.0,Study 5,Subject continuing
Study 5,CHE,Site 312,Subject 2582,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,CHE,Site 312,Subject 2582,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,CHE,Site 312,Subject 2582,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,CHE,Site 312,Subject 2582,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,CHE,Site 313,Subject 2584,Follow-Up,,EOT2/Safety FU (42D),2025-07-23,Form 1,,114.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,CHE,Site 313,Subject 2584,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,CHE,Site 313,Subject 2584,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,CHN,Site 346,Subject 2818,Screening,,Screening,2025-10-27,Form 1,,18.0,Study 5,
Study 5,CHN,Site 346,Subject 2819,Screening,,Screening,2025-10-28,Form 1,,17.0,Study 5,
Study 5,CHN,Site 346,Subject 2820,Screening,,Screening,,Form 1,,,Study 5,
Study 5,CHN,Site 346,Subject 2821,Screening,,Screening,,Form 1,,,Study 5,
Study 5,CHN,Site 348,Subject 2825,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,CHN,Site 348,Subject 2826,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,CHN,Site 348,Subject 2827,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,CHN,Site 348,Subject 2828,Screen Failure,,Screening,2025-10-23,Form 1,,22.0,Study 5,Subject continuing
Study 5,CHN,Site 348,Subject 2828,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,CHN,Site 348,Subject 2828,Screen Failure,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,CZE,Site 271,Subject 2318,On Trial,,EOT2/Safety FU (42D),,Form 1,,,Study 5,
Study 5,CZE,Site 271,Subject 2320,Screen Failure,,Screening,2025-06-16,Form 1,,151.0,Study 5,Subject discontinued from study at this visit
Study 5,CZE,Site 271,Subject 2322,On Trial,,Cycle 3 Week 1,,Form 1,,,Study 5,
Study 5,DEU,Site 280,Subject 2360,Screen Failure,,Screening,2025-09-08,Form 1,,67.0,Study 5,Subject discontinued from study at this visit
Study 5,DEU,Site 280,Subject 2360,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,DEU,Site 280,Subject 2361,Screening,,Screening,2025-10-14,Form 1,,31.0,Study 5,Subject continuing
Study 5,DEU,Site 280,Subject 2362,Screening,,Screening,2025-10-14,Form 1,,31.0,Study 5,Subject continuing
Study 5,DEU,Site 280,Subject 2362,Screening,,Concomitant Medication,,Form 2,,,Study 5,
Study 5,DEU,Site 280,Subject 2362,Screening,,First Fraction (SBRT),,Form 1,,,Study 5,
Study 5,DEU,Site 280,Subject 2362,Screening,,Medical History,,Form 2,,,Study 5,
Study 5,DEU,Site 280,Subject 2362,Screening,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,DEU,Site 280,Subject 2363,Screening,,Screening,2025-11-04,Form 1,,10.0,Study 5,
Study 5,DEU,Site 281,Subject 2365,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,DEU,Site 281,Subject 2365,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,DEU,Site 281,Subject 2365,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,DEU,Site 281,Subject 2365,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,DEU,Site 281,Subject 2365,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,DEU,Site 281,Subject 2365,On Trial,,Concomitant Medication,,Form 2,,,Study 5,
Study 5,DEU,Site 281,Subject 2366,On Trial,,Screening,2025-10-02,Form 1,,43.0,Study 5,Subject continuing
Study 5,DEU,Site 281,Subject 2366,On Trial,,Adverse Event,,Form 2,,,Study 5,
Study 5,DEU,Site 281,Subject 2366,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,DEU,Site 281,Subject 2366,On Trial,,Concomitant Medication,,Form 2,,,Study 5,
Study 5,DEU,Site 281,Subject 2366,On Trial,,Last Fraction (EOT1),,Form 1,,,Study 5,
Study 5,DEU,Site 281,Subject 2366,On Trial,,Medical History,,Form 2,,,Study 5,
Study 5,DEU,Site 281,Subject 2366,On Trial,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2371,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2372,On Trial,,Cycle 4 Week 1,,Form 1,,,Study 5,
Study 5,DEU,Site 282,Subject 2372,On Trial,,Last Fraction (EOT1),2025-07-18,Form 1,,119.0,Study 5,Subject continuing
Study 5,DEU,Site 282,Subject 2372,On Trial,,Cycle 3 Week 1,2025-10-28,Form 1,,17.0,Study 5,SUBJECT CONTINUING
Study 5,DEU,Site 282,Subject 2372,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2372,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2372,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2372,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2372,On Trial,,Gamma Counter Calibration,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2373,On Trial,,Cycle 3 Week 1,,Form 1,,,Study 5,
Study 5,DEU,Site 282,Subject 2373,On Trial,,Last Fraction (EOT1),2025-08-29,Form 1,,77.0,Study 5,Subject continuing
Study 5,DEU,Site 282,Subject 2373,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2373,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2373,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2373,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,DEU,Site 282,Subject 2373,On Trial,,Gamma Counter Calibration,,Form 2,,,Study 5,
Study 5,DEU,Site 283,Subject 2375,Screening,,Screening,2025-11-12,Form 1,,2.0,Study 5,
Study 5,DEU,Site 283,Subject 2376,Screening,,Screening,2025-11-12,Form 1,,2.0,Study 5,
Study 5,ESP,Site 300,Subject 2480,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2480,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2480,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2480,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2480,Follow-Up,,Efficacy FU 4,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2480,Follow-Up,,Long term safety FU 2,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2487,Follow-Up,,Screening,2024-09-30,Form 1,,410.0,Study 5,Subject continuing
Study 5,ESP,Site 300,Subject 2487,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2488,Follow-Up,,EOT2/Safety FU (42D),2025-04-23,Form 1,,205.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,ESP,Site 300,Subject 2488,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2491,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2491,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2491,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2491,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2491,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2491,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2496,Follow-Up,,EOT2/Safety FU (42D),2025-07-17,Form 1,,120.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,ESP,Site 300,Subject 2496,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2498,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2504,On Trial,,EOT2/Safety FU (42D),,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2505,On Trial,,Cycle 4 Week 1,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2505,On Trial,,Last Fraction (EOT1),2025-06-27,Form 1,,140.0,Study 5,Subject continuing
Study 5,ESP,Site 300,Subject 2506,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2507,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2508,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2509,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2510,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2511,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2512,On Trial,,Cycle 1 Week 1,2025-10-22,Form 1,,23.0,Study 5,SUBJECT CONTINUING
Study 5,ESP,Site 300,Subject 2512,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2512,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2512,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2512,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2512,On Trial,,Concomitant Medication,,Form 2,,,Study 5,
Study 5,ESP,Site 300,Subject 2512,On Trial,,Cycle 1 Week 3,,Form 1,,,Study 5,
Study 5,ESP,Site 300,Subject 2512,On Trial,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,ESP,Site 301,Subject 2514,Follow-Up,,EOT2/Safety FU (42D),2025-06-03,Form 1,,164.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,ESP,Site 301,Subject 2514,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ESP,Site 301,Subject 2514,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,ESP,Site 302,Subject 2518,Follow-Up,,Cycle 4 Week 1,2025-09-11,Form 1,,64.0,Study 5,SUBJECT CONTINUING
Study 5,ESP,Site 302,Subject 2518,Follow-Up,,EOT2/Safety FU (42D),2025-10-29,Form 1,,16.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,ESP,Site 302,Subject 2518,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ESP,Site 302,Subject 2518,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,ESP,Site 302,Subject 2518,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ESP,Site 302,Subject 2518,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ESP,Site 302,Subject 2518,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ESP,Site 302,Subject 2518,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,ESP,Site 302,Subject 2518,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,ESP,Site 302,Subject 2520,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 302,Subject 2521,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 302,Subject 2523,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 302,Subject 2525,Screening,,Screening,2025-10-15,Form 1,,30.0,Study 5,
Study 5,ESP,Site 302,Subject 2526,Screening,,Screening,2025-11-07,Form 1,,7.0,Study 5,
Study 5,ESP,Site 303,Subject 2532,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 303,Subject 2533,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 303,Subject 2534,Screen Failure,,Screening,,Form 1,,,Study 5,Subject discontinued from study at this visit
Study 5,ESP,Site 303,Subject 2534,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 303,Subject 2535,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 303,Subject 2536,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 303,Subject 2537,Screening,,Screening,2025-09-26,Form 1,,49.0,Study 5,
Study 5,ESP,Site 303,Subject 2538,Screening,,Screening,,Form 1,,,Study 5,
Study 5,ESP,Site 305,Subject 2543,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 305,Subject 2544,Screen Failure,,Screening,2025-06-23,Form 1,,144.0,Study 5,Subject discontinued from study at this visit
Study 5,ESP,Site 305,Subject 2544,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ESP,Site 305,Subject 2545,Screening,,Screening,2025-10-31,Form 1,,14.0,Study 5,
Study 5,ESP,Site 306,Subject 2549,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,ESP,Site 306,Subject 2549,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,ESP,Site 306,Subject 2551,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,ESP,Site 306,Subject 2551,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,ESP,Site 306,Subject 2553,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,ESP,Site 306,Subject 2555,Follow-Up,,Cycle 2 Week 3,2025-06-18,Form 1,,149.0,Study 5,SUBJECT CONTINUING
Study 5,ESP,Site 306,Subject 2555,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ESP,Site 306,Subject 2555,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,ESP,Site 306,Subject 2555,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ESP,Site 306,Subject 2555,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ESP,Site 306,Subject 2555,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ESP,Site 306,Subject 2555,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,ESP,Site 306,Subject 2555,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,ESP,Site 306,Subject 2558,On Trial,,Cycle 2 Week 3,,Form 1,,,Study 5,
Study 5,ESP,Site 306,Subject 2559,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,ESP,Site 306,Subject 2562,Screening,,Screening,,Form 1,,,Study 5,
Study 5,ESP,Site 307,Subject 2569,Follow-Up,,Last Fraction (EOT1),2025-04-19,Form 1,,209.0,Study 5,Subject continuing
Study 5,ESP,Site 307,Subject 2569,Follow-Up,,EOT2/Safety FU (42D),2025-10-21,Form 1,,24.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,ESP,Site 307,Subject 2569,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ESP,Site 307,Subject 2569,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,ESP,Site 307,Subject 2569,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ESP,Site 307,Subject 2569,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ESP,Site 307,Subject 2569,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ESP,Site 307,Subject 2569,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,ESP,Site 307,Subject 2569,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,ESP,Site 307,Subject 2570,On Trial,,Last Fraction (EOT1),2025-04-29,Form 1,,199.0,Study 5,Subject continuing
Study 5,ESP,Site 307,Subject 2570,On Trial,,EOT2/Safety FU (42D),,Form 1,,,Study 5,
Study 5,ESP,Site 307,Subject 2576,Screening,,Screening,2025-09-29,Form 1,,46.0,Study 5,
Study 5,ESP,Site 307,Subject 2577,Screening,,Screening,2025-10-27,Form 1,,18.0,Study 5,
Study 5,FRA,Site 274,Subject 2336,On Trial,,EOT2/Safety FU (42D),2025-10-15,Form 1,,30.0,Study 5,SUBJECT MOVING TO SURVIVAL
Study 5,FRA,Site 274,Subject 2336,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,FRA,Site 274,Subject 2336,On Trial,,Survival FU 1,,Form 1,,,Study 5,
Study 5,FRA,Site 277,Subject 2339,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,Subject continuing
Study 5,FRA,Site 277,Subject 2339,Follow-Up,,EOT2/Safety FU (42D),2025-03-25,Form 1,,234.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,FRA,Site 277,Subject 2339,Follow-Up,,Long term safety FU 2,,Form 1,,,Study 5,
Study 5,FRA,Site 277,Subject 2344,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,FRA,Site 277,Subject 2345,On Trial,,Screening,2025-04-16,Form 1,,212.0,Study 5,Subject continuing
Study 5,FRA,Site 277,Subject 2345,On Trial,,Cycle 4 Week 1,2025-10-15,Form 1,,30.0,Study 5,SUBJECT CONTINUING
Study 5,FRA,Site 277,Subject 2345,On Trial,,Cycle 4 Week 3,,Form 1,,,Study 5,
Study 5,FRA,Site 277,Subject 2346,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,FRA,Site 277,Subject 2347,On Trial,,Cycle 2 Week 3,,Form 1,,,Study 5,
Study 5,FRA,Site 277,Subject 2347,On Trial,,Last Fraction (EOT1),2025-08-06,Form 1,,100.0,Study 5,Subject continuing
Study 5,FRA,Site 277,Subject 2348,On Trial,,Cycle 3 Week 1,,Form 1,,,Study 5,
Study 5,FRA,Site 277,Subject 2348,On Trial,,Last Fraction (EOT1),2025-08-13,Form 1,,93.0,Study 5,Subject continuing
Study 5,FRA,Site 277,Subject 2349,Screening,,Screening,,Form 1,,,Study 5,
Study 5,GBR,Site 308,Subject 2578,Screening,,Screening,,Form 1,,,Study 5,Subject discontinued from study at this visit
Study 5,GBR,Site 309,Subject 2579,Follow-Up,,Adverse Event,,Form 2,,,Study 5,
Study 5,GBR,Site 309,Subject 2579,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,GBR,Site 309,Subject 2579,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,GBR,Site 309,Subject 2579,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,GBR,Site 309,Subject 2579,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,GBR,Site 309,Subject 2579,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,GBR,Site 310,Subject 2580,Screening,,Screening,2025-10-16,Form 1,,29.0,Study 5,Subject continuing
Study 5,GBR,Site 310,Subject 2580,Screening,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,GBR,Site 310,Subject 2580,Screening,,Concomitant Medication,,Form 2,,,Study 5,
Study 5,GBR,Site 310,Subject 2580,Screening,,First Fraction (SBRT),,Form 1,,,Study 5,
Study 5,GBR,Site 310,Subject 2580,Screening,,Medical History,,Form 2,,,Study 5,
Study 5,GBR,Site 310,Subject 2580,Screening,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,HUN,Site 284,Subject 2380,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,HUN,Site 284,Subject 2380,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,HUN,Site 284,Subject 2380,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,HUN,Site 284,Subject 2380,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,HUN,Site 284,Subject 2380,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,HUN,Site 284,Subject 2380,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,HUN,Site 284,Subject 2380,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,ISR,Site 287,Subject 2397,On Trial,,Last Fraction (EOT1),2025-03-16,Form 1,,243.0,Study 5,Subject continuing
Study 5,ISR,Site 287,Subject 2397,On Trial,,EOT2/Safety FU (42D),2025-09-30,Form 1,,45.0,Study 5,SUBJECT MOVING TO SURVIVAL
Study 5,ISR,Site 287,Subject 2397,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ISR,Site 287,Subject 2397,On Trial,,Survival FU 1,,Form 1,,,Study 5,
Study 5,ISR,Site 288,Subject 2398,On Trial,,Last Fraction (EOT1),2025-06-03,Form 1,,164.0,Study 5,Subject continuing
Study 5,ISR,Site 288,Subject 2398,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ISR,Site 288,Subject 2398,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ISR,Site 288,Subject 2398,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ISR,Site 288,Subject 2398,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ISR,Site 288,Subject 2398,On Trial,,Cycle 4 Week 3,,Form 1,,,Study 5,
Study 5,ISR,Site 289,Subject 2404,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ISR,Site 290,Subject 2406,Follow-Up,,EOT2/Safety FU (42D),2025-01-27,Form 1,,291.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,ISR,Site 290,Subject 2406,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ISR,Site 290,Subject 2406,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,ISR,Site 290,Subject 2406,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ISR,Site 290,Subject 2406,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ISR,Site 290,Subject 2406,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,ISR,Site 290,Subject 2409,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ISR,Site 290,Subject 2410,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ISR,Site 290,Subject 2411,Screening,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ISR,Site 290,Subject 2412,Screening,,Screening,2025-10-22,Form 1,,23.0,Study 5,Subject continuing
Study 5,ISR,Site 290,Subject 2412,Screening,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ITA,Site 292,Subject 2419,Follow-Up,,Last Fraction (EOT1),2025-04-16,Form 1,,212.0,Study 5,Subject continuing
Study 5,ITA,Site 292,Subject 2419,Follow-Up,,Screening,2025-03-17,Form 1,,242.0,Study 5,Subject continuing
Study 5,ITA,Site 292,Subject 2419,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ITA,Site 292,Subject 2419,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,ITA,Site 292,Subject 2419,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ITA,Site 292,Subject 2419,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ITA,Site 292,Subject 2419,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ITA,Site 292,Subject 2419,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,ITA,Site 292,Subject 2419,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,ITA,Site 294,Subject 2424,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2443,Follow-Up,,EOT2/Safety FU (42D),2025-10-29,Form 1,,16.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,ITA,Site 297,Subject 2443,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2443,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2443,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2443,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2443,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2443,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,ITA,Site 297,Subject 2446,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2453,On Trial,,Cycle 1 Week 1,2025-10-30,Form 1,,15.0,Study 5,SUBJECT CONTINUING
Study 5,ITA,Site 297,Subject 2453,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2453,On Trial,,Cycle 1 Week 3,,Form 1,,,Study 5,
Study 5,ITA,Site 297,Subject 2456,On Trial,,Screening,2025-09-09,Form 1,,66.0,Study 5,Subject continuing
Study 5,ITA,Site 297,Subject 2456,On Trial,,Cycle 1 Week 1,2025-10-30,Form 1,,15.0,Study 5,SUBJECT CONTINUING
Study 5,ITA,Site 297,Subject 2456,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2456,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2456,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2456,On Trial,,Cycle 1 Week 3,,Form 1,,,Study 5,
Study 5,ITA,Site 297,Subject 2456,On Trial,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2457,Screen Failure,,Screening,2025-09-16,Form 1,,59.0,Study 5,Subject discontinued from study at this visit
Study 5,ITA,Site 297,Subject 2459,On Trial,,Screening,2025-09-29,Form 1,,46.0,Study 5,Subject continuing
Study 5,ITA,Site 297,Subject 2459,On Trial,,Adverse Event,,Form 2,,,Study 5,
Study 5,ITA,Site 297,Subject 2459,On Trial,,Cycle 1 Week 1,,Form 1,,,Study 5,
Study 5,ITA,Site 297,Subject 2462,Screening,,Screening,2025-11-03,Form 1,,11.0,Study 5,
Study 5,ITA,Site 297,Subject 2463,Screening,,Screening,2025-11-03,Form 1,,11.0,Study 5,
Study 5,JPN,Site 191,Subject 1678,Screening,,Screening,,Form 1,,,Study 5,Subject continuing
Study 5,JPN,Site 191,Subject 1678,Screening,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,JPN,Site 192,Subject 1690,Follow-Up,,EOT2/Safety FU (42D),2025-04-15,Form 1,,213.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,JPN,Site 192,Subject 1690,Follow-Up,,Survival FU 1,,Form 1,,,Study 5,
Study 5,JPN,Site 192,Subject 2777,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,JPN,Site 192,Subject 2777,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,JPN,Site 25,Subject 1694,Follow-Up,,Efficacy FU 1,2025-10-09,Form 1,,36.0,Study 5,SUBJECT CONTINUING
Study 5,JPN,Site 25,Subject 1694,Follow-Up,,EOT2/Safety FU (42D),2025-06-30,Form 1,,137.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,JPN,Site 25,Subject 1694,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,JPN,Site 25,Subject 1694,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,JPN,Site 25,Subject 1697,On Trial,,Last Fraction (EOT1),2025-10-24,Form 1,,21.0,Study 5,Subject continuing
Study 5,JPN,Site 25,Subject 1697,On Trial,,Screening,2025-09-19,Form 1,,56.0,Study 5,Subject continuing
Study 5,JPN,Site 25,Subject 1697,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,JPN,Site 25,Subject 1697,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,JPN,Site 25,Subject 1697,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,JPN,Site 25,Subject 1697,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,JPN,Site 25,Subject 1697,On Trial,,Cycle 1 Week 3,,Form 1,,,Study 5,
Study 5,JPN,Site 25,Subject 2779,Screen Failure,,Screening,2025-10-10,Form 1,,35.0,Study 5,Subject discontinued from study at this visit
Study 5,JPN,Site 25,Subject 2779,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,JPN,Site 193,Subject 2789,Screen Failure,,Screening,2025-06-27,Form 1,,140.0,Study 5,Subject discontinued from study at this visit
Study 5,JPN,Site 193,Subject 2793,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,JPN,Site 193,Subject 2793,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,JPN,Site 193,Subject 2793,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,JPN,Site 193,Subject 2793,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,JPN,Site 193,Subject 2793,On Trial,,Cycle 1 Week 3,,Form 1,,,Study 5,
Study 5,JPN,Site 345,Subject 2808,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,JPN,Site 196,Subject 1713,Follow-Up,,EOT2/Safety FU (42D),2025-11-05,Form 1,,9.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,JPN,Site 196,Subject 1713,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,JPN,Site 196,Subject 1713,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,JPN,Site 196,Subject 1713,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,JPN,Site 196,Subject 1713,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,JPN,Site 196,Subject 1713,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,JPN,Site 197,Subject 2810,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,JPN,Site 197,Subject 2810,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,JPN,Site 197,Subject 2810,On Trial,,Cycle 4 Week 3,,Form 1,,,Study 5,
Study 5,JPN,Site 198,Subject 1724,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,JPN,Site 198,Subject 1725,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,JPN,Site 198,Subject 1725,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,JPN,Site 198,Subject 1725,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,JPN,Site 198,Subject 1725,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,JPN,Site 198,Subject 1725,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,JPN,Site 198,Subject 1725,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,JPN,Site 200,Subject 2813,On Trial,,Screening,2025-09-29,Form 1,,46.0,Study 5,Subject continuing
Study 5,JPN,Site 200,Subject 2813,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,JPN,Site 200,Subject 2813,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,JPN,Site 200,Subject 2813,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,JPN,Site 200,Subject 2813,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,JPN,Site 200,Subject 2813,On Trial,,Cycle 1 Week 1,,Form 1,,,Study 5,
Study 5,JPN,Site 200,Subject 2813,On Trial,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,MYS,Site 266,Subject 2291,On Trial,,Cycle 3 Week 3,,Form 1,,,Study 5,
Study 5,MYS,Site 266,Subject 2291,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,MYS,Site 267,Subject 2294,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,NLD,Site 314,Subject 2585,On Trial,,Cycle 3 Week 3,,Form 1,,,Study 5,
Study 5,NLD,Site 314,Subject 2585,On Trial,,Last Fraction (EOT1),2025-07-10,Form 1,,127.0,Study 5,Subject continuing
Study 5,NLD,Site 314,Subject 2585,On Trial,,Screening,2025-05-23,Form 1,,175.0,Study 5,Subject continuing
Study 5,NLD,Site 314,Subject 2585,On Trial,,Cycle 2 Week 3,2025-10-02,Form 1,,43.0,Study 5,SUBJECT CONTINUING
Study 5,NLD,Site 314,Subject 2585,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2242,Follow-Up,,Long term safety FU 2,,Form 1,,,Study 5,
Study 5,SGP,Site 261,Subject 2242,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2242,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2242,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,SGP,Site 261,Subject 2243,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2243,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2243,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2243,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2243,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2243,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,SGP,Site 261,Subject 2243,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,SGP,Site 261,Subject 2245,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,SUBJECT CONTINUING
Study 5,SGP,Site 261,Subject 2245,Follow-Up,,EOT2/Safety FU (42D),2025-10-22,Form 1,,23.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,SGP,Site 261,Subject 2245,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2245,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2245,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2245,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2245,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2245,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,SGP,Site 261,Subject 2245,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,SGP,Site 261,Subject 2246,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2246,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2246,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2246,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2246,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2246,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,SGP,Site 261,Subject 2251,Enrolled,,Screening,2025-10-08,Form 1,,37.0,Study 5,Subject continuing
Study 5,SGP,Site 261,Subject 2251,Enrolled,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,SGP,Site 261,Subject 2251,Enrolled,,First Fraction (SBRT),,Form 1,,,Study 5,
Study 5,SVK,Site 298,Subject 2464,Follow-Up,,EOT2/Safety FU (42D),2025-08-19,Form 1,,87.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,SVK,Site 298,Subject 2464,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,SVK,Site 298,Subject 2464,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,SVK,Site 299,Subject 2472,On Trial,,Cycle 3 Week 3,,Form 1,,,Study 5,
Study 5,SVK,Site 299,Subject 2472,On Trial,,Cycle 3 Week 1,,Form 1,,,Study 5,SUBJECT CONTINUING
Study 5,SVK,Site 299,Subject 2476,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,TWN,Site 262,Subject 2257,Discontinued,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,TWN,Site 262,Subject 2257,Discontinued,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,TWN,Site 262,Subject 2257,Discontinued,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,TWN,Site 262,Subject 2257,Discontinued,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,TWN,Site 262,Subject 2257,Discontinued,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,TWN,Site 263,Subject 2262,Follow-Up,,EOT2/Safety FU (42D),2025-07-16,Form 1,,121.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,TWN,Site 263,Subject 2262,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,TWN,Site 263,Subject 2269,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,TWN,Site 263,Subject 2269,On Trial,,Screening,2025-08-20,Form 1,,86.0,Study 5,Subject continuing
Study 5,TWN,Site 263,Subject 2269,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,TWN,Site 263,Subject 2269,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,TWN,Site 263,Subject 2269,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,TWN,Site 263,Subject 2269,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,TWN,Site 265,Subject 2286,Screening,,Screening,2025-10-22,Form 1,,23.0,Study 5,
Study 5,USA,Site 18,Subject 68,Screening,,Screening,2025-09-25,Form 1,,50.0,Study 5,
Study 5,USA,Site 19,Subject 78,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,USA,Site 19,Subject 78,On Trial,,Last Fraction (EOT1),2025-09-26,Form 1,,49.0,Study 5,Subject continuing
Study 5,USA,Site 19,Subject 78,On Trial,,Screening,2025-09-10,Form 1,,65.0,Study 5,Subject continuing
Study 5,USA,Site 19,Subject 78,On Trial,,Cycle 1 Week 1,2025-10-15,Form 1,,30.0,Study 5,SUBJECT CONTINUING
Study 5,USA,Site 19,Subject 78,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 19,Subject 78,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 19,Subject 78,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 19,Subject 78,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 19,Subject 78,On Trial,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2654,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2654,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,USA,Site 326,Subject 2655,Follow-Up,,Efficacy FU 2,2025-09-24,Form 1,,51.0,Study 5,SUBJECT CONTINUING
Study 5,USA,Site 326,Subject 2655,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,USA,Site 326,Subject 2655,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 326,Subject 2656,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2656,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2656,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2656,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2656,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 326,Subject 2657,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2657,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2657,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2657,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 326,Subject 2657,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 326,Subject 2663,Screen Failure,,Adverse Event,,Form 2,,,Study 5,
Study 5,USA,Site 179,Subject 1605,Follow-Up,,Efficacy FU 1,2025-08-29,Form 1,,77.0,Study 5,SUBJECT CONTINUING
Study 5,USA,Site 179,Subject 1605,Follow-Up,,EOT2/Safety FU (42D),2025-05-16,Form 1,,182.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,USA,Site 179,Subject 1605,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 179,Subject 1605,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 179,Subject 1605,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,USA,Site 179,Subject 1606,Follow-Up,,Efficacy FU 1,2025-10-23,Form 1,,22.0,Study 5,SUBJECT CONTINUING
Study 5,USA,Site 179,Subject 1606,Follow-Up,,EOT2/Safety FU (42D),2025-07-10,Form 1,,127.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,USA,Site 179,Subject 1606,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 179,Subject 1606,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,USA,Site 179,Subject 1606,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 179,Subject 1606,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 179,Subject 1606,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 179,Subject 1606,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,USA,Site 179,Subject 1606,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 179,Subject 1607,On Trial,,Cycle 3 Week 3,,Form 1,,,Study 5,
Study 5,USA,Site 327,Subject 2664,Screen Failure,,Screening,2025-05-12,Form 1,,186.0,Study 5,Subject discontinued from study at this visit
Study 5,USA,Site 327,Subject 2666,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,USA,Site 327,Subject 2666,On Trial,,Last Fraction (EOT1),2025-09-19,Form 1,,56.0,Study 5,Subject continuing
Study 5,USA,Site 327,Subject 2666,On Trial,,Screening,2025-07-22,Form 1,,115.0,Study 5,Subject continuing
Study 5,USA,Site 328,Subject 2668,On Trial,,Last Fraction (EOT1),2025-06-20,Form 1,,147.0,Study 5,Subject continuing
Study 5,USA,Site 328,Subject 2668,On Trial,,Screening,2025-05-02,Form 1,,196.0,Study 5,Subject continuing
Study 5,USA,Site 328,Subject 2668,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 328,Subject 2668,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 328,Subject 2668,On Trial,,Cycle 4 Week 3,,Form 1,,,Study 5,
Study 5,USA,Site 181,Subject 2674,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 181,Subject 2674,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,USA,Site 181,Subject 2674,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 181,Subject 2674,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 181,Subject 2674,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 181,Subject 2674,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 181,Subject 2674,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 181,Subject 2681,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,USA,Site 181,Subject 2681,On Trial,,Last Fraction (EOT1),2025-10-13,Form 1,,32.0,Study 5,Subject continuing
Study 5,USA,Site 181,Subject 2681,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 181,Subject 2681,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 181,Subject 2681,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2685,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2685,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2685,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2685,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2685,Follow-Up,,Efficacy FU 3,,Form 1,,,Study 5,
Study 5,USA,Site 329,Subject 2685,Follow-Up,,Long term safety FU 2,,Form 1,,,Study 5,
Study 5,USA,Site 329,Subject 2686,Follow-Up,,Survival FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 329,Subject 2690,Survival,,Survival FU 2,,Form 1,,,Study 5,
Study 5,USA,Site 329,Subject 2694,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2694,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2694,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2694,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2694,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 329,Subject 2694,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 329,Subject 2695,Follow-Up,,Last Fraction (EOT1),2025-05-07,Form 1,,191.0,Study 5,Subject continuing
Study 5,USA,Site 329,Subject 2695,Follow-Up,,EOT2/Safety FU (42D),2025-11-06,Form 1,,8.0,Study 5,SUBJECT MOVING TO POST TREATMENT FOLLOW UP
Study 5,USA,Site 329,Subject 2695,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2695,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2695,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2695,Follow-Up,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2695,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 329,Subject 2695,Follow-Up,,Efficacy FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 329,Subject 2695,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 329,Subject 2698,On Trial,,EOT2/Safety FU (42D),,Form 1,,,Study 5,
Study 5,USA,Site 329,Subject 2698,On Trial,,Last Fraction (EOT1),2025-05-07,Form 1,,191.0,Study 5,Subject continuing
Study 5,USA,Site 329,Subject 2698,On Trial,,Screening,2025-03-20,Form 1,,239.0,Study 5,Subject continuing
Study 5,USA,Site 329,Subject 2700,Screening,,Screening,,Form 1,,,Study 5,
Study 5,USA,Site 187,Subject 2712,Screen Failure,,Screening,2025-07-21,Form 1,,116.0,Study 5,Subject discontinued from study at this visit
Study 5,USA,Site 187,Subject 2713,Screening,,Screening,2025-10-14,Form 1,,31.0,Study 5,
Study 5,USA,Site 333,Subject 2721,Follow-Up,,Efficacy FU 1,2025-07-07,Form 1,,130.0,Study 5,SUBJECT CONTINUING
Study 5,USA,Site 333,Subject 2721,Follow-Up,,Efficacy FU 2,,Form 1,,,Study 5,
Study 5,USA,Site 333,Subject 2721,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,
Study 5,USA,Site 333,Subject 2724,On Trial,,Cycle 4 Week 1,,Form 1,,,Study 5,
Study 5,USA,Site 333,Subject 2724,On Trial,,Last Fraction (EOT1),2025-07-02,Form 1,,135.0,Study 5,Subject continuing
Study 5,USA,Site 333,Subject 2724,On Trial,,Screening,2025-05-20,Form 1,,178.0,Study 5,Subject continuing
Study 5,USA,Site 333,Subject 2724,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 333,Subject 2724,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 333,Subject 2724,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 333,Subject 2728,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,USA,Site 333,Subject 2728,On Trial,,Last Fraction (EOT1),2025-09-26,Form 1,,49.0,Study 5,Subject continuing
Study 5,USA,Site 333,Subject 2728,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 333,Subject 2728,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 333,Subject 2728,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 335,Subject 2731,Follow-Up,,Long term safety FU 1,,Form 1,,,Study 5,Subject continuing
Study 5,USA,Site 335,Subject 2731,Follow-Up,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 335,Subject 2731,Follow-Up,,Antineoplastic - CM,,Form 2,,,Study 5,
Study 5,USA,Site 335,Subject 2731,Follow-Up,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 335,Subject 2731,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 335,Subject 2731,Follow-Up,,Long term safety FU 2,,Form 1,,,Study 5,
Study 5,USA,Site 335,Subject 2733,On Trial,,Cycle 4 Week 3,,Form 1,,,Study 5,
Study 5,USA,Site 335,Subject 2736,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,USA,Site 335,Subject 2736,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 335,Subject 2738,Screening,,Screening,2025-10-28,Form 1,,17.0,Study 5,
Study 5,USA,Site 336,Subject 2740,On Trial,,Cycle 2 Week 3,,Form 1,,,Study 5,
Study 5,USA,Site 336,Subject 2740,On Trial,,Cycle 2 Week 1,2025-10-14,Form 1,,31.0,Study 5,SUBJECT CONTINUING
Study 5,USA,Site 336,Subject 2743,Screening,,Screening,2025-10-02,Form 1,,43.0,Study 5,Subject continuing
Study 5,USA,Site 336,Subject 2743,Screening,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 337,Subject 2745,On Trial,,Antineoplastic ADT,,Form 2,,,Study 5,
Study 5,USA,Site 337,Subject 2745,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 337,Subject 2745,On Trial,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 337,Subject 2745,On Trial,,Antineoplastic Surgery,,Form 2,,,Study 5,
Study 5,USA,Site 337,Subject 2745,On Trial,,Cycle 4 Week 3,,Form 1,,,Study 5,
Study 5,USA,Site 337,Subject 2745,On Trial,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,USA,Site 338,Subject 2751,On Trial,,Cycle 1 Week 3,,Form 1,,,Study 5,
Study 5,USA,Site 338,Subject 2752,On Trial,,Cycle 1 Week 1,2025-10-23,Form 1,,22.0,Study 5,SUBJECT CONTINUING
Study 5,USA,Site 338,Subject 2752,On Trial,,Cycle 1 Week 3,,Form 1,,,Study 5,
Study 5,USA,Site 338,Subject 2756,Screening,,Screening,2025-10-13,Form 1,,32.0,Study 5,Subject continuing
Study 5,USA,Site 338,Subject 2756,Screening,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 338,Subject 2756,Screening,,Concomitant Medication,,Form 2,,,Study 5,
Study 5,USA,Site 338,Subject 2756,Screening,,First Fraction (SBRT),,Form 1,,,Study 5,
Study 5,USA,Site 338,Subject 2756,Screening,,Medical History,,Form 2,,,Study 5,
Study 5,USA,Site 338,Subject 2756,Screening,,Non-drug therapies,,Form 2,,,Study 5,
Study 5,USA,Site 338,Subject 2757,Screening,,Screening,,Form 1,,,Study 5,
Study 5,USA,Site 338,Subject 2758,Screening,,Screening,,Form 1,,,Study 5,
Study 5,USA,Site 338,Subject 2759,Screening,,Screening,,Form 1,,,Study 5,
Study 5,USA,Site 339,Subject 2762,Enrolled,,Screening,2025-10-27,Form 1,,18.0,Study 5,Subject continuing
Study 5,USA,Site 339,Subject 2762,Enrolled,,Adverse Event,,Form 2,,,Study 5,
Study 5,USA,Site 339,Subject 2762,Enrolled,,First Fraction (SBRT),,Form 1,,,Study 5,
Study 5,USA,Site 340,Subject 2763,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 5,
Study 5,USA,Site 340,Subject 2763,On Trial,,Last Fraction (EOT1),2025-09-26,Form 1,,49.0,Study 5,Subject continuing
Study 5,USA,Site 340,Subject 2763,On Trial,,Screening,2025-08-25,Form 1,,81.0,Study 5,Subject continuing
Study 5,USA,Site 340,Subject 2763,On Trial,,Cycle 1 Week 1,2025-10-14,Form 1,,31.0,Study 5,SUBJECT CONTINUING
Study 5,USA,Site 340,Subject 2763,On Trial,,Antineoplastic - RT,,Form 2,,,Study 5,
Study 5,USA,Site 340,Subject 2765,Screening,,Screening,,Form 1,,,Study 5,
Study 5,USA,Site 340,Subject 2766,Screening,,Screening,,Form 1,,,Study 5,
Study 5,USA,Site 340,Subject 2767,Screening,,Screening,,Form 1,,,Study 5,
Study 5,USA,Site 340,Subject 2768,Screening,,Screening,,Form 1,,,Study 5,
Study 5,USA,Site 342,Subject 2770,Screening,,Screening,2025-10-30,Form 1,,15.0,Study 5,
Study 5,USA,Site 343,Subject 2771,Screening,,Screening,2025-11-07,Form 1,,7.0,Study 5,Subject continuing
Study 5,USA,Site 343,Subject 2771,Screening,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 5,USA,Site 343,Subject 2772,Screening,,Screening,2025-11-12,Form 1,,2.0,Study 5,Subject continuing
Study 5,USA,Site 343,Subject 2772,Screening,,Antineoplastic SBRT,,Form 2,,,Study 5,
Study 6,AUS,Site 14,Subject 25,Screen Failure,,Screening,2025-06-05,Form 1,,162.0,Study 6 ,Subject discontinued from study at this visit
Study 6,AUS,Site 14,Subject 26,On Trial,,Cycle 2 Week 8,,Form 1,,,Study 6 ,
Study 6,AUS,Site 14,Subject 27,Follow-Up,,Antineoplastic CM,,Form 2,,,Study 6 ,
Study 6,AUS,Site 14,Subject 27,Follow-Up,,Antineoplastic RT,,Form 2,,,Study 6 ,
Study 6,AUS,Site 14,Subject 27,Follow-Up,,Antineoplastic Surgery,,Form 2,,,Study 6 ,
Study 6,AUS,Site 14,Subject 27,Follow-Up,,Long term follow-up 1,,Form 1,,,Study 6 ,
Study 6,AUS,Site 14,Subject 28,Screen Failure,,Screening,2025-07-24,Form 1,,113.0,Study 6 ,Subject discontinued from study at this visit
Study 6,AUS,Site 14,Subject 29,On Trial,,Cycle 2 Week 1,2025-11-11,Form 1,,3.0,Study 6 ,Subject continuing
Study 6,AUS,Site 14,Subject 29,On Trial,,Cycle 2 Week 3,,Form 1,,,Study 6 ,
Study 6,AUS,Site 14,Subject 30,On Trial,,Cycle 1 Week 8,,Form 1,,,Study 6 ,
Study 6,AUS,Site 14,Subject 31,On Trial,,Cycle 1 Week 8,,Form 1,,,Study 6 ,
Study 6,AUS,Site 14,Subject 32,On Trial,,Cycle 1 Week 1,2025-10-13,Form 1,,32.0,Study 6 ,Subject continuing
Study 6,AUS,Site 14,Subject 32,On Trial,,Cycle 1 Week 7,,Form 1,,,Study 6 ,
Study 6,AUS,Site 14,Subject 33,On Trial,,Cycle 1 Week 1,2025-10-14,Form 1,,31.0,Study 6 ,Subject continuing
Study 6,AUS,Site 14,Subject 33,On Trial,,Cycle 1 Week 7,,Form 1,,,Study 6 ,
Study 6,AUS,Site 14,Subject 34,Screen Failure,,Screening,2025-10-23,Form 1,,22.0,Study 6 ,Subject discontinued from study at this visit
Study 6,AUS,Site 14,Subject 35,Screening,,Disposition,,Form 2,,,Study 6 ,
Study 6,AUS,Site 14,Subject 35,Screening,,Screening,2025-10-28,Form 1,,17.0,Study 6 ,Subject continuing
Study 6,AUS,Site 14,Subject 36,Screening,,Disposition,,Form 2,,,Study 6 ,
Study 6,AUS,Site 14,Subject 36,Screening,,Screening,2025-11-04,Form 1,,10.0,Study 6 ,Subject continuing
Study 6,AUS,Site 15,Subject 39,On Trial,,Cycle 2 Week 8,,Form 1,,,Study 6 ,Subject continuing
Study 6,AUS,Site 15,Subject 39,On Trial,,Cycle 3 Week 1,2025-11-04,Form 1,,10.0,Study 6 ,Subject continuing
Study 6,AUS,Site 15,Subject 39,On Trial,,Cycle 3 Week 5,,Form 1,,,Study 6 ,
Study 6,AUS,Site 15,Subject 39,On Trial,,Screening,2025-06-13,Form 1,,154.0,Study 6 ,Subject continuing
Study 6,AUS,Site 15,Subject 40,On Trial,,Cycle 1 Week 1,2025-08-05,Form 1,,101.0,Study 6 ,Subject continuing
Study 6,AUS,Site 15,Subject 40,On Trial,,Cycle 2 Week 6,,Form 1,,,Study 6 ,
Study 6,AUS,Site 15,Subject 40,On Trial,,Screening,2025-06-27,Form 1,,140.0,Study 6 ,Subject continuing
Study 6,AUS,Site 15,Subject 41,On Trial,,Cycle 1 Week 1,2025-09-16,Form 1,,59.0,Study 6 ,Subject continuing
Study 6,AUS,Site 15,Subject 41,On Trial,,Cycle 1 Week 8,,Form 1,,,Study 6 ,
Study 6,AUS,Site 15,Subject 41,On Trial,,Screening,2025-08-15,Form 1,,91.0,Study 6 ,Subject continuing
Study 6,AUS,Site 15,Subject 42,Screening,,Screening,,Form 1,,,Study 6 ,
Study 6,CHN,Site 165,Subject 1512,Screen Failure,,Screening,2025-04-21,Form 1,,207.0,Study 6 ,Subject discontinued from study at this visit
Study 6,CHN,Site 165,Subject 1513,On Trial,,Cycle 3 Week 1,2025-09-16,Form 1,,59.0,Study 6 ,Subject continuing
Study 6,CHN,Site 165,Subject 1513,On Trial,,Cycle 3 Week 8,,Form 1,,,Study 6 ,Subject continuing
Study 6,CHN,Site 165,Subject 1513,On Trial,,Cycle 4 Week 1,2025-11-14,Form 1,,0.0,Study 6 ,Subject continuing
Study 6,CHN,Site 165,Subject 1513,On Trial,,Cycle 4 Week 5,,Form 1,,,Study 6 ,
Study 6,CHN,Site 165,Subject 1513,On Trial,,Screening,2025-05-06,Form 1,,192.0,Study 6 ,Subject continuing
Study 6,CHN,Site 165,Subject 2586,Discontinued,,Non-drug therapies,,Form 2,,,Study 6 ,
Study 6,CHN,Site 165,Subject 2586,Discontinued,,Screening,2025-07-24,Form 1,,113.0,Study 6 ,Subject continuing
Study 6,CHN,Site 165,Subject 2587,Screening,,Disposition,,Form 2,,,Study 6 ,
Study 6,CHN,Site 165,Subject 2587,Screening,,Screening,2025-10-20,Form 1,,25.0,Study 6 ,Subject continuing
Study 6,CHN,Site 168,Subject 1520,Screen Failure,,Screening,2025-07-29,Form 1,,108.0,Study 6 ,Subject discontinued from study at this visit
Study 6,ISR,Site 62,Subject 383,Screen Failure,,SAE/ADR,,Form 2,,,Study 6 ,
Study 6,JPN,Site 191,Subject 1668,On Trial,,Cycle 1 Week 1,2025-09-16,Form 1,,59.0,Study 6 ,Subject continuing
Study 6,JPN,Site 191,Subject 1668,On Trial,,Cycle 1 Week 8,2025-11-06,Form 1,,8.0,Study 6 ,Subject continuing
Study 6,JPN,Site 191,Subject 1668,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 6 ,Subject continuing
Study 6,JPN,Site 191,Subject 1668,On Trial,,Cycle 2 Week 3,,Form 1,,,Study 6 ,
Study 6,JPN,Site 191,Subject 1668,On Trial,,Disposition,,Form 2,,,Study 6 ,
Study 6,JPN,Site 191,Subject 1668,On Trial,,Screening,2025-08-15,Form 1,,91.0,Study 6 ,Subject continuing
Study 6,JPN,Site 191,Subject 1669,Screen Failure,,Screening,2025-08-29,Form 1,,77.0,Study 6 ,Subject discontinued from study at this visit
Study 6,JPN,Site 352,Subject 2843,On Trial,,Cycle 1 Week 1,2025-10-21,Form 1,,24.0,Study 6 ,Subject continuing
Study 6,JPN,Site 352,Subject 2843,On Trial,,Cycle 1 Week 5,,Form 1,,,Study 6 ,
Study 6,JPN,Site 352,Subject 2843,On Trial,,Disposition,,Form 2,,,Study 6 ,
Study 6,JPN,Site 352,Subject 2843,On Trial,,Screening,2025-09-08,Form 1,,67.0,Study 6 ,Subject continuing
Study 6,JPN,Site 193,Subject 1698,On Trial,,Cycle 1 Week 5,,Form 1,,,Study 6 ,
Study 6,JPN,Site 193,Subject 2780,Screening,,Cycle 1 Week 1,,Form 1,,,Study 6 ,
Study 6,JPN,Site 193,Subject 2780,Screening,,Disposition,,Form 2,,,Study 6 ,
Study 6,JPN,Site 193,Subject 2780,Screening,,Screening,2025-10-15,Form 1,,30.0,Study 6 ,Subject continuing
Study 6,JPN,Site 194,Subject 1699,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 6 ,Subject continuing
Study 6,JPN,Site 194,Subject 1699,On Trial,,Cycle 2 Week 3,,Form 1,,,Study 6 ,
Study 6,JPN,Site 194,Subject 1699,On Trial,,Screening,2025-08-27,Form 1,,79.0,Study 6 ,Subject continuing
Study 6,JPN,Site 194,Subject 1700,Screening,,Cycle 1 Week 1,,Form 1,,,Study 6 ,
Study 6,JPN,Site 194,Subject 1700,Screening,,Disposition,,Form 2,,,Study 6 ,
Study 6,JPN,Site 345,Subject 2803,On Trial,,Cycle 1 Week 1,2025-11-12,Form 1,,2.0,Study 6 ,Subject continuing
Study 6,JPN,Site 345,Subject 2803,On Trial,,Cycle 1 Week 5,,Form 1,,,Study 6 ,
Study 6,JPN,Site 345,Subject 2803,On Trial,,Disposition,,Form 2,,,Study 6 ,
Study 6,JPN,Site 345,Subject 2803,On Trial,,Screening,2025-10-16,Form 1,,29.0,Study 6 ,Subject continuing
Study 6,SGP,Site 349,Subject 2830,Discontinued,,Cycle 1 Week 1,2025-07-08,Form 1,,129.0,Study 6 ,Subject continuing
Study 6,SGP,Site 349,Subject 2830,Discontinued,,SAE/ADR,,Form 2,,,Study 6 ,
Study 6,SGP,Site 349,Subject 2835,On Trial,,Cycle 1 Week 1,2025-10-28,Form 1,,17.0,Study 6 ,Subject continuing
Study 6,SGP,Site 349,Subject 2835,On Trial,,Cycle 1 Week 3,,Form 1,,,Study 6 ,
Study 6,SGP,Site 349,Subject 2835,On Trial,,Screening,2025-09-16,Form 1,,59.0,Study 6 ,Subject continuing
Study 6,TWN,Site 351,Subject 2837,On Trial,,Cycle 1 Week 1,2025-08-19,Form 1,,87.0,Study 6 ,Subject continuing
Study 6,TWN,Site 351,Subject 2837,On Trial,,Cycle 1 Week 8,2025-10-09,Form 1,,36.0,Study 6 ,Subject continuing
Study 6,TWN,Site 351,Subject 2837,On Trial,,Cycle 2 Week 1,2025-10-21,Form 1,,24.0,Study 6 ,Subject continuing
Study 6,TWN,Site 351,Subject 2837,On Trial,,Cycle 2 Week 3,,Form 1,,,Study 6 ,
Study 6,TWN,Site 351,Subject 2837,On Trial,,Disposition,,Form 2,,,Study 6 ,
Study 6,TWN,Site 351,Subject 2837,On Trial,,Screening,2025-07-16,Form 1,,121.0,Study 6 ,Subject continuing
Study 6,TWN,Site 351,Subject 2838,On Trial,,Cycle 1 Week 1,2025-08-19,Form 1,,87.0,Study 6 ,Subject continuing
Study 6,TWN,Site 351,Subject 2838,On Trial,,Cycle 1 Week 5,2025-09-17,Form 1,,58.0,Study 6 ,Subject continuing
Study 6,TWN,Site 351,Subject 2838,On Trial,,Cycle 1 Week 8,2025-10-08,Form 1,,37.0,Study 6 ,Subject continuing
Study 6,TWN,Site 351,Subject 2838,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 6 ,
Study 6,TWN,Site 351,Subject 2838,On Trial,,Disposition,,Form 2,,,Study 6 ,
Study 6,TWN,Site 351,Subject 2838,On Trial,,Screening,2025-07-17,Form 1,,120.0,Study 6 ,Subject continuing
Study 6,TWN,Site 351,Subject 2839,Screen Failure,,Screening,2025-09-16,Form 1,,59.0,Study 6 ,Subject discontinued from study at this visit
Study 6,USA,Site 20,Subject 82,On Trial,,Cycle 2 Week 1,2025-11-12,Form 1,,2.0,Study 6 ,Subject continuing
Study 6,USA,Site 20,Subject 82,On Trial,,Cycle 2 Week 3,,Form 1,,,Study 6 ,
Study 6,USA,Site 20,Subject 1601,On Trial,,Cycle 2 Week 1,,Form 1,,,Study 6 ,
Study 6,USA,Site 20,Subject 1603,Screen Failure,,SAE/ADR,,Form 2,,,Study 6 ,
Study 6,USA,Site 20,Subject 2841,Discontinued,,SAE/ADR,,Form 2,,,Study 6 ,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 1 Week 7,2025-10-28,Visit Level,Form 1,16.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 1 Week 7,2025-10-28,Visit Level,Form 2,16.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 2 Week 1,2025-11-12,Visit Level,Form 3,1.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 2 Week 1,2025-11-12,Visit Level,Form 4,1.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 2 Week 1,2025-11-12,Visit Level,Form 5,1.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 2 Week 1,2025-11-12,Visit Level,Form 6,1.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 2 Week 1,2025-11-12,Visit Level,Form 7,1.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 2 Week 1,2025-11-12,Visit Level,Form 8,1.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 2 Week 1,2025-11-12,Visit Level,Form 9,1.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 2 Week 1,2025-11-12,Visit Level,Form 10,1.0,Study 7,
Study 7,AUS,Site 87,Subject 627,Screening,Subject continuing,Cycle 2 Week 1,2025-11-12,Visit Level,Form 11,1.0,Study 7,
Study 7,AUS,Site 110,Subject 893,Screening,,Adverse Event,,Summary Page,Form 12,,Study 7,
Study 7,AUS,Site 110,Subject 893,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,AUS,Site 110,Subject 893,Screening,Subject discontinued from study at this visit,Screening Visit,,Visit Level,Form 14,,Study 7,
Study 7,AUS,Site 110,Subject 893,Screening,Subject discontinued from study at this visit,Screening Visit,,Visit Level,Form 15,,Study 7,
Study 7,CHN,Site 14,Subject 27,Screening,,Unplanned Visit,2025-09-02,Visit Level,Form 16,72.0,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,Antineoplastic CM,,Summary Page,Form 17,,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,Antineoplastic RT,,Summary Page,Form 18,,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,Antineoplastic RT,,Summary Page,Form 19,,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,Antineoplastic Surgeries,,Summary Page,Form 20,,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,Antineoplastic Surgeries,,Summary Page,Form 21,,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,SAE/ADR,,Summary Page,Form 22,,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,SAE/ADR,,Summary Page,Form 23,,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,SAE/ADR,,Summary Page,Form 24,,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,SAE/ADR,,Summary Page,Form 25,,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,Unplanned Visit,2025-09-22,Visit Level,Form 26,52.0,Study 7,
Study 7,CHN,Site 14,Subject 28,Follow-Up,,Unplanned Visit,2025-09-23,Visit Level,Form 26,51.0,Study 7,
Study 7,CHN,Site 14,Subject 31,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,CHN,Site 14,Subject 32,Screen Failure,,Adverse Event,,Summary Page,Form 12,,Study 7,
Study 7,CHN,Site 14,Subject 34,Enrolled,,Study Drug Administration,,Summary Page,Form 27,,Study 7,
Study 7,CHN,Site 14,Subject 35,Screening,,Screening Visit,2025-11-12,Visit Level,Form 28,1.0,Study 7,
Study 7,CHN,Site 17,Subject 60,Screen Failure,,Adverse Event,,Summary Page,Form 12,,Study 7,
Study 7,CHN,Site 17,Subject 61,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 29,,Study 7,
Study 7,CHN,Site 17,Subject 61,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 16,,Study 7,
Study 7,CHN,Site 17,Subject 61,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 30,,Study 7,
Study 7,CHN,Site 17,Subject 61,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 1,,Study 7,
Study 7,CHN,Site 17,Subject 61,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 31,,Study 7,
Study 7,CHN,Site 17,Subject 61,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 32,,Study 7,
Study 7,CHN,Site 17,Subject 61,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 33,,Study 7,
Study 7,CHN,Site 17,Subject 61,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 34,,Study 7,
Study 7,CHN,Site 17,Subject 62,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,CHN,Site 17,Subject 62,Screening,Subject continuing,Screening Visit,2025-10-31,Visit Level,Form 28,13.0,Study 7,
Study 7,CHN,Site 17,Subject 62,Screening,Subject continuing,Screening Visit,2025-10-31,Visit Level,Form 35,13.0,Study 7,
Study 7,CHN,Site 164,Subject 1498,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,CHN,Site 164,Subject 1498,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 28,22.0,Study 7,
Study 7,CHN,Site 164,Subject 1499,Screening,,Screening Visit,,Visit Level,Form 14,,Study 7,
Study 7,CHN,Site 164,Subject 1499,Screening,,Screening Visit,,Visit Level,Form 28,,Study 7,
Study 7,CHN,Site 164,Subject 1499,Screening,,Screening Visit,,Visit Level,Form 35,,Study 7,
Study 7,CHN,Site 164,Subject 1499,Screening,,Screening Visit,,Visit Level,Form 15,,Study 7,
Study 7,CHN,Site 354,Subject 2850,Screening,Subject continuing,Cycle 1 Week 5,2025-11-10,Visit Level,Form 33,3.0,Study 7,
Study 7,CHN,Site 354,Subject 2851,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,CHN,Site 354,Subject 2851,Screening,Subject continuing,Screening Visit,2025-11-04,Visit Level,Form 28,9.0,Study 7,
Study 7,CHN,Site 93,Subject 674,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,JPN,Site 356,Subject 2853,Screening,Subject continuing,Cycle 1 Week 1,2025-10-15,Visit Level,Form 33,29.0,Study 7,
Study 7,JPN,Site 356,Subject 2853,Screening,Subject continuing,Cycle 1 Week 5,2025-11-10,Visit Level,Form 33,3.0,Study 7,
Study 7,JPN,Site 356,Subject 2853,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,JPN,Site 356,Subject 2853,Screening,Subject continuing,Screening Visit,2025-09-12,Visit Level,Form 36,62.0,Study 7,
Study 7,JPN,Site 356,Subject 2853,Screening,Subject continuing,Screening Visit,2025-09-12,Visit Level,Form 6,62.0,Study 7,
Study 7,JPN,Site 356,Subject 2853,Screening,Subject continuing,Screening Visit,2025-09-12,Visit Level,Form 33,62.0,Study 7,
Study 7,JPN,Site 356,Subject 2853,Screening,,Study Drug Administration,,Summary Page,Form 27,,Study 7,
Study 7,SGP,Site 353,Subject 2844,Screening,,Non-drug Therapies,,Summary Page,Form 37,,Study 7,
Study 7,SGP,Site 353,Subject 2844,Screening,Subject continuing,Screening Visit,2025-09-11,Visit Level,Form 38,63.0,Study 7,
Study 7,SGP,Site 353,Subject 2844,Screening,Subject continuing,Screening Visit,2025-09-11,Visit Level,Form 33,63.0,Study 7,
Study 7,SGP,Site 353,Subject 2844,Screening,,Study Drug Administration,,Summary Page,Form 27,,Study 7,
Study 7,SGP,Site 353,Subject 2845,Screen Failure,,Adverse Event,,Summary Page,Form 12,,Study 7,
Study 7,SGP,Site 12,Subject 22,Screening,Subject continuing,Cycle 1 Week 1,2025-09-18,Visit Level,Form 33,56.0,Study 7,
Study 7,SGP,Site 12,Subject 22,Screening,Subject continuing,Cycle 1 Week 5,2025-10-15,Visit Level,Form 33,29.0,Study 7,
Study 7,SGP,Site 12,Subject 22,Screening,Subject continuing,Screening Visit,2025-08-15,Visit Level,Form 3,90.0,Study 7,
Study 7,SGP,Site 12,Subject 22,Screening,Subject continuing,Screening Visit,2025-08-15,Visit Level,Form 33,90.0,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,,SAE/ADR,,Summary Page,Form 39,,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,,SAE/ADR,,Summary Page,Form 22,,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,,SAE/ADR,,Summary Page,Form 23,,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,,SAE/ADR,,Summary Page,Form 24,,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,,SAE/ADR,,Summary Page,Form 25,,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,Subject continuing,Screening Visit,2025-09-22,Visit Level,Form 40,52.0,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,Subject continuing,Screening Visit,2025-09-22,Visit Level,Form 41,52.0,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,Subject continuing,Screening Visit,2025-09-22,Visit Level,Form 42,52.0,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,Subject continuing,Screening Visit,2025-09-22,Visit Level,Form 6,52.0,Study 7,
Study 7,SGP,Site 12,Subject 2846,Screening,Subject continuing,Screening Visit,2025-09-22,Visit Level,Form 33,52.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 43,22.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 44,22.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 40,22.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 45,22.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 41,22.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 36,22.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 46,22.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 42,22.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 33,22.0,Study 7,
Study 7,SGP,Site 12,Subject 2847,Screening,Subject continuing,Screening Visit,2025-10-22,Visit Level,Form 47,22.0,Study 7,
Study 7,TWN,Site 148,Subject 1393,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 29,,Study 7,
Study 7,TWN,Site 148,Subject 1393,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 33,,Study 7,
Study 7,TWN,Site 148,Subject 1393,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 15,,Study 7,
Study 7,TWN,Site 148,Subject 1393,Screening,Subject continuing,Cycle 1 Week 5,,Visit Level,Form 34,,Study 7,
Study 7,TWN,Site 148,Subject 1394,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,TWN,Site 148,Subject 1394,Screening,Subject continuing,Screening Visit,2025-10-20,Visit Level,Form 6,24.0,Study 7,
Study 7,TWN,Site 95,Subject 682,Screening,,Disposition,,Summary Page,Form 13,,Study 7,
Study 7,TWN,Site 95,Subject 682,Screening,Subject continuing,Screening Visit,2025-10-29,Visit Level,Form 28,15.0,Study 7,
Study 8,ARG,Site 28,Subject 108,Enrolled,Subject continuing,Week 120,2025-10-17,Visit Level,Form 4,27.0,Study 8,
Study 8,ARG,Site 28,Subject 2233,Enrolled,Subject continuing,Week 108,2025-10-02,Visit Level,Form 4,42.0,Study 8,
Study 8,ARG,Site 28,Subject 2235,Enrolled,,Week 96,,Visit Level,Form 4,,Study 8,
Study 8,BGR,Site 110,Subject 893,Enrolled,Subject continuing,Week 96,2025-09-25,Visit Level,Form 5,49.0,Study 8,
Study 8,BGR,Site 88,Subject 634,Enrolled,Subject continuing,Week 96,,Visit Level,Form 6,,Study 8,
Study 8,BGR,Site 88,Subject 634,Enrolled,Subject continuing,Week 96,,Visit Level,Form 5,,Study 8,
Study 8,BGR,Site 88,Subject 634,Enrolled,Subject continuing,Week 96,,Visit Level,Form 4,,Study 8,
Study 8,BGR,Site 88,Subject 634,Enrolled,Subject continuing,Week 96,,Visit Level,Form 7,,Study 8,
Study 8,BGR,Site 88,Subject 634,Enrolled,Subject continuing,Week 96,,Visit Level,Form 8,,Study 8,
Study 8,CHE,Site 428,Subject 3267,Discontinued,,Survival followup week48,,Visit Level,Form 9,,Study 8,
Study 8,DEU,Site 380,Subject 3098,Discontinued,,Healthcare Resource Utilization,,Summary Page,Form 15,,Study 8,
Study 8,DEU,Site 380,Subject 3098,Discontinued,,Non-Drug Therapies / Procedures,,Summary Page,Form 16,,Study 8,
Study 8,DEU,Site 380,Subject 3098,Discontinued,,Post Antineoplastic Medications,,Summary Page,Form 17,,Study 8,
Study 8,DEU,Site 381,Subject 3104,Enrolled,Subject continuing,Week 108,2025-11-04,Visit Level,Form 4,9.0,Study 8,
Study 8,DEU,Site 402,Subject 3177,Discontinued,,Survival followup week72,,Visit Level,Form 9,,Study 8,
Study 8,DEU,Site 402,Subject 3178,Discontinued,,Survival followup week24,,Visit Level,Form 9,,Study 8,
Study 8,DEU,Site 403,Subject 3179,Enrolled,Subject continuing,Week 132,2025-09-17,Visit Level,Form 5,57.0,Study 8,
Study 8,DEU,Site 403,Subject 3179,Enrolled,Subject continuing,Week 132,2025-09-17,Visit Level,Form 8,57.0,Study 8,
Study 8,FRA,Site 364,Subject 2912,Enrolled,Subject continuing,Week 84,2025-10-22,Visit Level,Form 4,22.0,Study 8,
Study 8,FRA,Site 366,Subject 2939,Enrolled,Subject continuing,Week 96,2025-09-22,Visit Level,Form 5,52.0,Study 8,
Study 8,FRA,Site 371,Subject 2987,Enrolled,Subject continuing,Week 96,2025-09-24,Visit Level,Form 6,50.0,Study 8,
Study 8,GBR,Site 431,Subject 3272,Enrolled,Subject continuing,Week 108,2025-10-27,Visit Level,Form 6,17.0,Study 8,
Study 8,GRC,Site 410,Subject 3201,Discontinued,,EOT,,Visit Level,Form 12,,Study 8,
Study 8,GRC,Site 410,Subject 3201,Discontinued,,Healthcare Resource Utilization,,Summary Page,Form 15,,Study 8,
Study 8,GRC,Site 410,Subject 3201,Discontinued,,Post Antineoplastic Medications,,Summary Page,Form 17,,Study 8,
Study 8,GRC,Site 410,Subject 3201,Discontinued,,Unplanned visit,2025-10-14,Visit Level,Form 13,30.0,Study 8,
Study 8,GRC,Site 410,Subject 3201,Discontinued,,Unplanned visit,2025-10-14,Visit Level,Form 14,30.0,Study 8,
Study 8,GRC,Site 410,Subject 3201,Discontinued,,Unplanned visit,2025-10-14,Visit Level,Form 8,30.0,Study 8,
Study 8,HUN,Site 411,Subject 3203,Discontinued,,Healthcare Resource Utilization,,Summary Page,Form 15,,Study 8,
Study 8,HUN,Site 411,Subject 3203,Discontinued,,Post Antineoplastic Medications,,Summary Page,Form 17,,Study 8,
Study 8,IND,Site 449,Subject 3391,Enrolled,Subject continuing,Week 96,2025-10-09,Visit Level,Form 8,35.0,Study 8,
Study 8,MYS,Site 436,Subject 3314,Discontinued,,Survival followup week36,,Visit Level,Form 9,,Study 8,
Study 8,MYS,Site 436,Subject 3314,Discontinued,,Survival followup week48,,Visit Level,Form 9,,Study 8,
Study 8,MYS,Site 436,Subject 3314,Discontinued,,Survival followup week60,,Visit Level,Form 9,,Study 8,
Study 8,MYS,Site 437,Subject 3323,Enrolled,,Unplanned visit,2024-02-02,Visit Level,Form 13,650.0,Study 8,
Study 8,SVK,Site 426,Subject 3257,Enrolled,,Unplanned visit,2025-10-21,Visit Level,Form 13,23.0,Study 8,
Study 8,USA,Site 327,Subject 2666,Enrolled,,30 Days Safety follow-up,,Summary Page,Form 18,,Study 8,
Study 8,USA,Site 327,Subject 2666,Enrolled,,30 Days Safety follow-up,,Summary Page,Form 7,,Study 8,
Study 8,ZAF,Site 317,Subject 2603,Discontinued,,eSAE,,Summary Page,Form 19,,Study 8,
Study 9,BFA,Site 2,Subject 3406,On Trial,,EOS Part B,,Visit Level,Form 1,,Study 9,
Study 9,BFA,Site 2,Subject 3406,On Trial,SUBJECT CONTINUING,Inpatient Treatment/Day 1,2025-10-10,Visit Level,Form 2,33.0,Study 9,
Study 9,BFA,Site 2,Subject 3406,On Trial,SUBJECT CONTINUING,Outpatient FUP 4/Day 16,2025-10-26,Visit Level,Form 3,17.0,Study 9,
Study 9,BFA,Site 2,Subject 3406,On Trial,SUBJECT CONTINUING,Outpatient FUP 4/Day 16,2025-10-26,Visit Level,Form 4,17.0,Study 9,
Study 9,BFA,Site 2,Subject 3406,On Trial,SUBJECT CONTINUING,Outpatient FUP 6/Day 29,2025-11-07,Visit Level,Form 3,5.0,Study 9,
Study 9,BFA,Site 2,Subject 3407,On Trial,,EOS Part B,,Visit Level,Form 1,,Study 9,
Study 9,BFA,Site 2,Subject 3407,On Trial,SUBJECT CONTINUING,Inpatient FUP 1/Day 2,2025-10-11,Visit Level,Form 4,32.0,Study 9,
Study 9,BFA,Site 2,Subject 3407,On Trial,SUBJECT CONTINUING,Inpatient Treatment/Day 1,2025-10-10,Visit Level,Form 2,33.0,Study 9,
Study 9,BFA,Site 2,Subject 3407,On Trial,SUBJECT CONTINUING,Outpatient FUP 1/Day 4,2025-10-13,Visit Level,Form 4,30.0,Study 9,
Study 9,BFA,Site 2,Subject 3407,On Trial,SUBJECT CONTINUING,Outpatient FUP 2/Day 8,2025-10-18,Visit Level,Form 4,25.0,Study 9,
Study 9,BFA,Site 2,Subject 3407,On Trial,SUBJECT CONTINUING,Outpatient FUP 4/Day 16,2025-10-26,Visit Level,Form 4,17.0,Study 9,
Study 9,BFA,Site 2,Subject 3407,On Trial,SUBJECT CONTINUING,Outpatient FUP 6/Day 29,2025-11-07,Visit Level,Form 3,5.0,Study 9,
Study 9,BFA,Site 2,Subject 3407,On Trial,Subject continuing,Screening,2025-10-10,Visit Level,Form 5,33.0,Study 9,
Study 9,BFA,Site 2,Subject 3408,On Trial,,EOS Part B,,Visit Level,Form 1,,Study 9,
Study 9,BFA,Site 2,Subject 3408,On Trial,SUBJECT CONTINUING,Inpatient FUP 1/Day 2,2025-10-13,Visit Level,Form 4,30.0,Study 9,
Study 9,BFA,Site 2,Subject 3408,On Trial,SUBJECT CONTINUING,Inpatient Treatment/Day 1,2025-10-12,Visit Level,Form 2,31.0,Study 9,
Study 9,BFA,Site 2,Subject 3408,On Trial,SUBJECT CONTINUING,Outpatient FUP 1/Day 4,2025-10-15,Visit Level,Form 4,28.0,Study 9,
Study 9,BFA,Site 2,Subject 3408,On Trial,SUBJECT CONTINUING,Outpatient FUP 2/Day 8,2025-10-18,Visit Level,Form 4,25.0,Study 9,
Study 9,BFA,Site 2,Subject 3408,On Trial,SUBJECT CONTINUING,Outpatient FUP 4/Day 16,2025-10-26,Visit Level,Form 3,17.0,Study 9,
Study 9,BFA,Site 2,Subject 3408,On Trial,SUBJECT CONTINUING,Outpatient FUP 6/Day 29,2025-11-10,Visit Level,Form 3,2.0,Study 9,
Study 9,BFA,Site 2,Subject 3408,On Trial,Subject continuing,Screening,2025-10-12,Visit Level,Form 5,31.0,Study 9,
Study 9,BFA,Site 2,Subject 3409,On Trial,,EOS Part B,,Visit Level,Form 1,,Study 9,
Study 9,BFA,Site 2,Subject 3409,On Trial,SUBJECT CONTINUING,Inpatient FUP 1/Day 2,2025-10-13,Visit Level,Form 4,30.0,Study 9,
Study 9,BFA,Site 2,Subject 3409,On Trial,SUBJECT CONTINUING,Inpatient Treatment/Day 1,2025-10-12,Visit Level,Form 2,31.0,Study 9,
Study 9,BFA,Site 2,Subject 3409,On Trial,SUBJECT CONTINUING,Outpatient FUP 1/Day 4,2025-10-15,Visit Level,Form 4,28.0,Study 9,
Study 9,BFA,Site 2,Subject 3409,On Trial,SUBJECT CONTINUING,Outpatient FUP 2/Day 8,2025-10-18,Visit Level,Form 4,25.0,Study 9,
Study 9,BFA,Site 2,Subject 3409,On Trial,SUBJECT CONTINUING,Outpatient FUP 4/Day 16,2025-10-26,Visit Level,Form 3,17.0,Study 9,
Study 9,BFA,Site 2,Subject 3409,On Trial,SUBJECT CONTINUING,Outpatient FUP 6/Day 29,2025-11-10,Visit Level,Form 3,2.0,Study 9,
Study 9,BFA,Site 2,Subject 3409,On Trial,Subject continuing,Screening,2025-10-12,Visit Level,Form 5,31.0,Study 9,
Study 9,BFA,Site 2,Subject 3411,On Trial,SUBJECT CONTINUING,Inpatient FUP 1/Day 2,2025-10-22,Visit Level,Form 4,21.0,Study 9,
Study 9,BFA,Site 2,Subject 3411,On Trial,SUBJECT CONTINUING,Inpatient Treatment/Day 1,2025-10-21,Visit Level,Form 2,22.0,Study 9,
Study 9,BFA,Site 2,Subject 3411,On Trial,SUBJECT CONTINUING,Inpatient Treatment/Day 1,2025-10-21,Visit Level,Form 6,22.0,Study 9,
Study 9,BFA,Site 2,Subject 3411,On Trial,SUBJECT CONTINUING,Outpatient FUP 2/Day 8,2025-10-28,Visit Level,Form 3,15.0,Study 9,
Study 9,BFA,Site 2,Subject 3411,On Trial,,Outpatient FUP 5/Day 22,,Visit Level,Form 7,,Study 9,
Study 9,BFA,Site 2,Subject 3411,On Trial,Subject continuing,Screening,2025-10-21,Visit Level,Form 5,22.0,Study 9,
Study 9,BFA,Site 2,Subject 3412,On Trial,SUBJECT CONTINUING,Inpatient FUP 1/Day 2,2025-10-22,Visit Level,Form 4,21.0,Study 9,
Study 9,BFA,Site 2,Subject 3412,On Trial,SUBJECT CONTINUING,Inpatient Treatment/Day 1,2025-10-21,Visit Level,Form 2,22.0,Study 9,
Study 9,BFA,Site 2,Subject 3412,On Trial,SUBJECT CONTINUING,Inpatient Treatment/Day 1,2025-10-21,Visit Level,Form 6,22.0,Study 9,
Study 9,BFA,Site 2,Subject 3412,On Trial,SUBJECT CONTINUING,Outpatient FUP 2/Day 8,2025-10-28,Visit Level,Form 3,15.0,Study 9,
Study 9,BFA,Site 2,Subject 3412,On Trial,,Outpatient FUP 5/Day 22,,Visit Level,Form 7,,Study 9,
Study 9,BFA,Site 2,Subject 3412,On Trial,Subject continuing,Screening,2025-10-21,Visit Level,Form 5,22.0,Study 9,
